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Mutation and over-expression of Receptor Tyrosine Kinases (RTKs) or the proteins they 
regulate serve as oncogenic drivers in diverse cancers. RTKs catalyze the transfer of phosphate 
from ATP to the hydroxyl group on tyrosine. The proximal stretch of amino acids including this 
post translational modification is then able to be recognized by SH2 and PTB domains. Chapter 1 
details our work to better understand RTK signaling and its link to oncogenesis using protein 
microarrays to systematically and quantitatively measure interactions between virtually every 
SH2 or PTB domain encoded in the human genome and all known sites of tyrosine 
phosphorylation on 40 out of the 53 Receptor Tyrosine Kinases. 
Chapter 2 expands upon this work to study the next layer of binding among SH2 and PTB 
domain-containing adaptor proteins themselves. We found that adaptor proteins, like RTKs, have 
many high affinity bindings sites for other adaptor proteins. In addition, proteins driving 
oncogenesis, including both receptors and adaptor proteins, tend to be highly interconnected via 
a network of SH2 and PTB domain-mediated interactions. Our results suggest that network 
topological properties such as connectivity can be used to prioritize new drug targets in these 
well-studied signaling networks. 
Despite the extensive work presented here on experimentally determining interactions, 
we nevertheless are unable to keep up with the discovery of new sites of tyrosine 




discovered by next generation tumor sequencing approaches. Chapter 3 introduces work in 
progress to build a unified predictive model of SH2 domain interactions via integration of 
diverse data sets of binding as well as crystal structures of domain-peptide interactions. This 
model will enable researchers discovering new phosphorylation events or mutations to be able to 
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1.1 Signal Initiation 
 Phosphotyrosine (pTyr) signaling networks evolved in Metazoans to process extracellular 
cues and elicit cellular responses such as differentiation, proliferation or migration. 
Phosphotyrosine signaling emerges from the dynamic interplay of 4 domain types, the Tyrosine 
Kinase (TK) domain, the Src Homology 2 (SH2) domains, the Phosphotyrosine Binding (PTB) 
domain  and the Tyrosine Phosphatase domain (Lemmon and Schlessinger 2010).  
Canonical phosphotyrosine signaling is initiated when a ligand binds to the extracellular 
domain of its cognate Receptor Tyrosine Kinase (RTK), inducing the receptor’s transition from a 
catalytically inactive to active form. However, there are notable differences among the receptors 
in the organization of their inactive and active forms as well as the mechanism of the transition 
between the two. The current view is that the majority of receptors exist as monomers in their 
inactive form and ligand binding induces dimerization and activation. However, there are 
exceptions to this rule. Insulin and IGF1R receptors exist as preformed dimers and ligand 
binding induces a conformational change that induces activation. EGFR can also exist in inactive 
oligomers of unknown size. Moreover, Eph receptors require the formation of larger oligomers at 
sites of cell-cell contact to be fully activated . 
Ligand-induced dimerization primarily exists on a mechanistic continuum from purely 
ligand mediated to receptor mediated, defined by the composition of the dimerization interface. 
In a purely ligand-mediated mode, a bivalent ligand is able to simultaneously interact with two 
receptors leading to receptor crosslinking with no receptor-receptor contacts made 
extracellularly. An exemplar of this mode is NTRK1, whose ligand, NGF is shown in a crystal 






mechanistic end is EGFR, whose ligand EGF binds to only one receptor molecule, inducing a 
conformational change extracellularly. This exposes a dimerization arm, which is then able to 
interact with another molecule of EGFR (Burgess et al. 2003). Another distinct class of 
mechanism is exemplified by RET, where the ligand GDNF binds the coreceptor GFRα and the 
complex subsequently induces receptor dimerization (Schlee, Carmillo, and Whitty 2006). 
Dimerization relieves cis-autoinhibitory contacts with the kinase domain by trans-
phosphorylation. These autoinhibitory contacts are typically with the activation loop (Nolen, 
Taylor, and Ghosh 2004), but can also be to the juxtamembrane region (Till et al. 2002) or with 
the C-terminus (Niu, Peters, and Kontos 2002). The kinase domain then becomes fully active and 
catalyzes the auto-phosphorylation of intracellular tyrosine residues (Lemmon and Schlessinger 
2010). These phosphotyrosine residues can then be recognized selectively by the approximately 
120 SH2 and 44 PTB domains. Upon recruitment, many adaptor proteins bearing SH2 and PTB 
domains themselves become phosphorylated on tyrosine residues by active receptor or cytosolic 
tyrosine kinases. This second set of phosphorylation events leads to the recruitment of additional 
SH2 and PTB domain-containing proteins. SH2 and PTB domains also undergo rapid binding 
and unbinding.  
Signal termination can occur when tyrosine phosphatase domains hydrolyze the 
phosphate. However, this system is highly dynamic with rapid turnover of the phosphate. 
Phosphotyrosines have half-lives of a few seconds, and thus turn over hundreds of times during 
the course of early signaling events. Once a receptor’s kinase domain is inhibited by a drug, it 
rapidly loses its phosphorylation with half-lives on the order of 15 seconds. This signal ablation 






(Kleiman et al. 2011).  Rapid dynamics allows SH2 and PTB domain binding to be effectively 
non-competitive, allowing for a given site to interact with many adaptors. It also allows adaptors 
to rapidly interact with many neighboring RTKs. 
1.2. SH2 Domains 
1.2.1 Structure 
 SH2 domains correspond to a conserved stretch of approximately 100 residues with a 
characteristic fold composed of two α–helices that flank an anti-parallel β sheet comprising three 
to four β strands. The phosphotyrosine residue binds the more conserved N-terminal region of 
the protein containing an arginine. In a couple of SH2 domains such as those found on the 
proteins Tyk2 and Rin2, however the arginine is mutated leading to an apparent loss of 
phosphotyrosine binding capacity (B. A. Liu et al. 2006). The domain also binds residues 
primarily C-terminal to the phosphotyrosine in the more variable C-terminus. Variation in those 
contact residues allows for sequence selectivity to be achieved between ligand and domain 
(Figure 1.1). A unique class of SH2-like domains is the CBL tyrosine kinase-binding (TKB) 
domain. While sharing little sequence similarity with SH2 domains, the TKB domain possesses a 
highly similar fold and shares the canonical arginine residue that is required for phosphotyrosine 







Figure 1.1: Complex of SH2 domain with peptide. X-ray crystal structure of the SH2 domain 
of LCK is shown in complex with the phosphopeptide EPQyEEIPIYL (PDB ID 1LCJ). The 
peptide takes on an extended conformation within the SH2 domain binding groove. 
 
 Residues outside the canonical binding pocket can also facilitate target recognition. For 
example, a crystal structure of the complex between FGFR1 and PLC-γ showed a secondary 
binding site on the SH2 domain for the kinase domain, which further strengthened the 
interaction. However, most of the binding energy still came from the canonical binding mode 
(Bae et al. 2009). This coupled with the success of peptide-based methods of identifying new 







 SH2 domain–peptide interactions are typically of moderate affinity from 0.1 µM to 5 µM. 
A recent study shows, however, that SH2 domains are not optimized for maximum affinity. 
“Superbinder” SH2 domains can be generated through a triple point mutation resulting in a 
domain with identical ligand selectivity but capable of sub-nanomolar affinity. These 
superbinder domains effectively blocked signaling when expressed in cells, showing that the 
moderate affinity is critical for proper function of the network (Kaneko et al. 2012). Reduced 
affinity can minimize cross target binding as well as increase the dynamics of the network by 
speeding up dissociation. 
1.2.2 Function 
 SH2 domain-containing proteins carry out at least three distinctive functions within cells: 
scaffold, enzymes and transcription factors. 
 The enzymatic class of proteins shares a common property in that their substrates are 
membrane localized. SH2 domain binding to membrane bound targets brings the catalytic 
domains in close proximity to their substrates and thereby facilitates catalytic activity. For 
instance, the vast majority of cytosolic tyrosine kinases (CTKs), such as Src and Abl1, also 
contain SH2 domains. SH2 domain binding relieves auto inhibitory interactions and liberates the 
tyrosine kinase domain to phosphorylate additional substrates. This typically proceeds in a 
processive fashion, generating additional sites of tyrosine phosphorylation on a target, which can 
be further recognized by the SH2 domain. CTKs are also capable of phosphorylating tyrosine 
residues on RTKs, expanding the repertoire of interactions possible on the receptor. Another 
class of enzymatic proteins, such as PLC-γ and PI3K, act upon phosphoinositides, a type of 






these phospholipds, which stabilizes membrane association and increases the lifetime of these 
membrane scaffolds. SH2 domains are also present on proteins such as RASA1 containing G-
protein activating domains (GAPs) or the VAV family of guanine exchange factors (GEFs). 
 Most enzymatic proteins are involved in relaying and amplifying signals downstream of 
RTKs, causing additional rounds of activation. A notable exception is CBL.  CBL contains 
ubiquitin ligase activity allowing for it to poly-ubiquinate receptors interacting with the SH2 
domain. This leads to receptor internalization and subsequent degradation. This is a form of 
negative feedback loop, which serves to attenuate signals downstream of RTKs. Also, tyrosine 
phosphatases such as PTPN11 and PTPN6 become active by engagement of their SH2 domains. 
They catalyze the hydrolysis of phosphotyrosine, which for the most part leads to a decrease in 
signaling.  
However, even these negative regulatory units can often have contradictory signal 
amplification properties. CBL-promoted internalization of catalytically active receptors allows 
them to reach additional intracellular substrates. PTPN11 can dephosphorylate negative 
regulatory sites on proteins such as SRC, which can lead to signal amplification. In fact, PTPN11 
misregulation can lead to amplified ERK signaling and can drive oncogenesis. 
Scaffold proteins contain additional protein interaction domains such as PTB or SH3 
domains. An example is Grb2, which contains one SH2 domain and two SH3 domains. The N-
terminal SH3 domain interacts with a proline-rich region in SOS, which activates Ras, initiating 
the MAPK cascade. The C-terminal SH3 domain is simultaneously capable of binding a proline 






Gab1 is subsequently able to become tyrosine phosphorylated itself, which presents sites of 
recruitment for PI3K (Salcini et al. 1994).  
1.3 PTB Domains 
1.3.1 Structure 
 In contrast to SH2 domains, PTB domains constitute a smaller but more diverse class of 
phosphotyrosine recognition modules. They can be broadly divided into three families, the 
phosphotyrosine-dependent Shc-like and IRS-like class and the phosphorylation-independent 
Dab-like class. They share little sequence homology among themselves and are characterized 
instead by a distinct PH-like fold.  
PTB domains recognize peptides in quite a distinct manner from SH2 domains. In 
contrast to the extended conformation, peptides take on a β-turn conformation in the PTB 
binding pocket (DiNitto and Lambright 2006). Sequence selectivity is achieved by the peptide N-
terminal residues forming an anti-parallel β-strand with the domain. The canonical motif of PTB 
domains is NPXpY, although peptides matching that motif are recognized differently by the 







Figure 1.2: Prototypical PDB-peptide complex. IRS1-PTB Domain interacts with a IL-4 
receptor derived phosphopeptide (PDB: 1IRS). The peptide (pink) takes on a β-turn L-shaped 
conformation within the binding pocket. The interaction is phosphotyrosine-dependent. 
 
Most PTB domains fall within the phosphotyrosine-independent Dab class. In fact, some 
of these domains dissociate from their ligand upon phosphorylation. For instance, the Numb PTB 
domain binds to the sequence NVYYY in E-cadherin, but phosphorylation by Src abrogates 







PTB domain-containing proteins are typically involved in phosphotyrosine signaling as 
scaffolds. Shc recognizes phosphopeptides primarily through its PTB domain primarily, and only 
secondarily its SH2 domain. Upon binding receptor through its PTB domain, Shc becomes 
tyrosine phosphorylated on Tyr427 of SHC1 (or Tyr317 in the p52 SHC1 isoform). This 
provides a binding site for Grb2 and thereby induces activation of the RAS/MAPK kinase 
cascade (Salcini et al. 1994). Similarly, FRS2α and FRS2β mediate many of the signals 
downstream of the FGFR family and NTRK family of receptors (Lemmon and Schlessinger 
2010).  
Dok (downstream of tyrosine kinase) family of proteins play many diverse roles, 
typically as negative regulators of many signaling pathways such as in adaptive and innate 
immunity (Mashima et al. 2013). Tensin family members can serve as tumor suppressors through 
their constitutive interaction with the DLC (deleted in liver cancer) genes. These examples, while 
not exhaustive, are illustrative of the many diverse roles played by PTB domain-containing 
proteins both in normal and disease physiology.  
1.4 Pathways 
Molecular pathways prototypically have a “bow-tie” structure, where many extracellular 
cues bind distinct receptors. Activated receptors are capable of  binding a myriad of adaptors 
which then relay signals to very few conserved processes that integrate the diverse signals. They 
subsequently activate a wide set of effectors to elicit distinct phenotypic responses. There are 
four canonical RTK pathways –PI3K/AKT/mTOR, RAS/MAPK, PLC-γ/ PKC, and STAT – that 







 RTK activation can lead to the recruitment of PI3K either directly through 
phosphorylation sites on the receptor or indirectly through adaptor intermediates such as IRS1 or 
Gab1. PI3K is composed of two subunits, the p85 regulatory subunit containing two SH2 
domains and the p110 catalytic subunit containing a lipid kinase. Engagement of the SH2 
domains on p85 relieves autoinhibitory contacts as well as localizes the protein complex to the 
membrane. This activates the p110 subunit and brings it in close proximity to its primary 
substrate phosphoinositide (4,5) phosphate (PIP2). The enzyme catalyzes phosphotransfer from 
ATP to the 3’ hydroxyl on PIP2, generating the critical secondary messenger PIP3.  
PIP3 is capable of being recognized by the PH domains of 3’-phoshoinositde-dependent 
kinase (PDK1) and protein kinase B (Akt), leading to their translocation to the membrane. This 
brings the two enzymes into close proximity, leading to the phosphorylation of Akt by PDK1 and 
its subsequent activation. Akt is at the center of the “bow-tie” network, and is able to modulate 
cellular phenotype such as modulating protein synthesis via the mTOR complex, inhibiting 
apoptosis by phosphorylation of BAD and inducing cell-cycle entry by phosphorylation of GSK-
3. 
There are multiple mechanisms for signal attenuation of this pathway. For instance, 
inositol phosphatases such as PTEN and SHIP catalyze the dephosphorylation of PIP3. PP2A 
and PHLPP directly dephosphorylate Akt, inactivating the kinase. Akt also engages in negative 
feedback loops primarily at the transcriptional level. It inhibits FOXO-mediated RTK 






treatment with inhibitors targeting this pathway has the unintended effect of upregulating kinase 
signaling (Chandarlapaty et al. 2011). 
1.4.2 RAS/MAPK 
 Activation of the MAPK pathway requires the membrane localization of the guanine 
nucleotide exchange factor son of sevenless (SOS). SOS is constitutively associated with Grb2 
through an interaction mediated by the Grb2 SH3 domain and a proline rich region on SOS. This 
complex can be directly recruited to the membrane by direct binding of the Grb2 SH2 domain to 
an activated RTK. Conversely, the complex can be recruited indirectly through Shc, which 
becomes tyrosine phosphorylated upon recruitment to the membrane, which creates a binding 
site for Grb2 (Salcini et al. 1994). 
 Membrane localized SOS promotes the nucleotide exchange of GDP for GTP on the 
prenylated RAS family of proteins: KRAS, NRAS and HRAS. GTP bound RAS activates RAF, 
which phosphorylates and activates the MAPK kinases, MEK1 and MEK2. MEK can then 
subsequently activate the ERK family of kinases, whose downstream targets include the 
transcription factors CREB and c-Jun (Downward 2003). 
1.4.3 PLC-γ/PKC 
 PLC-γ contains two SH2 domains, which act normally to suppress catalytic function 
(Carpenter and Ji 1999). Like many enzymatic SH2 domain-containing proteins, engagement of 
the SH2 domains by activated receptors liberates the auto-inhibitory conformation and promotes 






leads to the phosphorylation of Tyr771, Tyr783 and Tyr1254 and the activation of the enzyme 
(Kim et al. 1991). 
 PLC-γ catalyzes the hydrolysis of PIP2, generating two secondary messengers 
diacylglycerol (DAG) and inositoyl 1,4,5-triphosphate (IP3). IP3 binding to its endoplasmic 
reticulum (ER)-localized receptor, IP3R, leads to the release of calcium ions from the ER. This 
leads to the activation of calmodulin and related kinases. DAG and calcium also combine to 
activate protein kinase C (PKC), which is a central hub of this pathway and mediates many of the 
physiological responses downstream of PLC-γ (Choi, Ryu, and Suh 2007). 
1.4.4 STAT 
 The signal transducer and activator of transcription (STAT) family of proteins is among 
the simplest of the pathways activated downstream of RTKs. This class of SH2 domain-
containing proteins is unique in also functioning as transcription factors. They are therefore able 
to directly couple receptor activation to changes in gene expression.  
Inactive STATs exist as monomers in the cytosol. Binding by the SH2 domain and 
subsequent tyrosine phosphorylation allows the STAT proteins to dimerize by reciprocal binding 
of the pTyr by the SH2 domain. Active dimers are then able to translocate to the nucleus and 
initiate the transcription of numerous genes (Harrison 2012).  
1.5 Challenges to the Pathway View of Signaling 
 The term pathway implies linearity and modularity in the interacting components 






MAPK signaling pathway being the prototypical example (Lemmon and Schlessinger 2010). 
However, as more data have been collected, this conception has proved increasingly inadequate. 
RTKs share a similar set of interactors and activate many of the same response pathways. 
They do not, however, necessarily elicit the same phenotypes. For example, both EGFR and 
NTRK1 induce MAPK signaling in PC12 cells, but EGFR triggers proliferation whereas NTRK1 
promotes differentiation (Marshall 1995). Both of these phenotypes are dependent on ERK 
activity. However, even the act of overexpressing EGFR in those cells can shift the response 
from proliferation to differentiation. This is thought to be due to the differential recruitment of 
negative and positive feedback mechanisms within the MAPK pathway (Santos, Verveer, and 
Bastiaens 2007). This phenomenon is also observed clinically, where only a subset of RTKs have 
been shown to drive cancer despite sharing many downstream pathways (Santarius et al. 2010). 
Current qualitative representations of signaling networks as linear cascades are inadequate to 
explain the diverse phenotypes that arise downstream of different RTKs (Lemmon and 
Schlessinger 2010).  
Increasing understanding of pathway crosstalk has also undermined the concept of 
pathway modularity. In a purely modular network, the activity of one pathway does not affect the 
activity of another. However, this is clearly not the case. For instance, PLC-γ catalyzes the 
hydrolysis of PIP2 whereas PI3K catalyzes its phosphorylation. Whichever is recruited first to 
the activated receptor will rapidly deplete the substrate for the second (Mayer, Blinov, and Loew 
2009). This is also seen in the clinic where single drug targeting of the MAPK or PI3K pathways 







1.6 Phosphotyrosine Signaling in Disease 
Aberrant signal processing by RTK signaling networks has been causally linked to cancer 
development, maintenance, and progression in many human tissues. Well-studied examples 
include overexpression of ERBB2 in breast cancer (Perren 1991), KIT in testicular germ cell 
tumors (McIntyre et al. 2005), and MET in gastric cancer (Comoglio, Giordano, and Trusolino 
2008). Constitutive activating mutations of RTKs, such as those observed in the RET kinase 
(Mulligan et al. 1993; Hofstra et al. 1994) in multiple endocrine neoplasia type 2 or KIT in 
gastrointestinal stromal tumors (Hirota et al. 1998) are also capable of driving oncogenesis.  
Underscoring the critical role played by RTKs in cancer is the considerable effort 
underway to develop drugs targeting them. There are two classes of drugs in development, 
antibody therapeutics target the extracellular portions of receptors and small molecule tyrosine 
kinase domain inhibitors that bind in the ATP recognition region of the RTKs and interfere with 
its ability to catalyze phosphorylation. Tyrosine kinase inhibitors typically have the drawback of 
being cross-reactive with other targets leading to potential side effects. Antibodies on the other 
hand typically have insufficient efficacy as monotherapies (Lemmon and Schlessinger 2010). 
Both drug classes almost invariably lead to drug resistance caused by tumor mutations that 
abrogate the tumor’s dependence on the targeted RTK or the affinity of the inhibitor to its target 







Table 1.1: Phosphotyrosine signaling components are targeted by clinical drugs. Both 
antibody and small molecule inhibitors of kinases are clinically used to treat cancer. Despite 
considerable effort, SH2 and phosphatases have so far not been effectively drugged (Lemmon 
and Schlessinger 2010).  
 
Small Molecule  Mab  Target  Disease  Year of approval  
Imatinib (Gleevec)  PDGFR, KIT, Abl, Arg  CML, GIST  2001 
Gefitinib (Iressa)  EGFR  Esophageal cancer, Glioma  2003 
Erlotinib (Tarceva)  EGFR  Esophageal cancer, Glioma  2004 





carcinoma  2005 




pancreatic cancer  
2006 
Desatinib (Sprycel)  Abl, Arg, KIT, PDGFR, Src  
Gleevec-resistant 
CML  2007 
Nilotinib (Tasigna)  Abl, Arg, KIT, PDGFR  
Gleevec-resistant 
CML  2007 
Lapatinib (Tykerb)  EGFR, ErbB2  Mammary carcinoma  2007 
Trastuzumab (Herceptin)  ErbB2  Mammary carcinoma  1998 
Cetuximab (Erbitux)  EGFR  
Colorectal cancer, 
Head and neck 
cancer  
2004 
Bevacizumab (Avastin)  VEGF  Lung cancer, Colorectal cancer  2004 








Similarly to RTKs, mutation or overexpression of SH2 domain-containing cytosolic 
proteins such as ABL kinase (Druker et al. 2001) or the PI3K p85 regulatory subunit (Cheung et 
al. 2011) can also drive cancer, in these cases by inducing constitutive enzymatic activity that is 
decoupled from upstream signaling events. Drugs targeting the catalytic activity of Abl are 
already in clinical use (Goldman and Melo 2003) and inhibitors of PI3K are in development 
(Howes et al. 2007). 
Phosphotyrosine signaling abnormalities have also been shown to promote diseases 
outside of cancer. The virally transcribed protein p28sis activates PDGFR in an autocrine loop 
leading to pro-survival signaling. The avian erythroblastosis virus encodes a truncated form of 
EGFR that becomes constitutively active. Bacterial proteins are also capable of becoming 
tyrosine phosphorylated and interacting with SH2 and PTB domain-containing proteins to rewire 
signaling for their advantage (Boettcher et al. 2010; Mehlitz et al. 2010). 
1.7 Qualitative Methods to Study SH2/PTB Domain Interactions 
Systematic methods that have been used to study the binding properties of these 
phosphotyrosine interacting domains can be broadly divided into two classes – display and array. 
Display methods can use phosphopeptide libraries attached to beads, phage or as nucleotide-
peptide hybrids. Binders are then isolated and typically the interacting peptides are identified in 
bulk, giving a frequency distribution of the presence of each amino acid at the individual 
positions of the peptide (Zhou et al. 1993). The positive features of these methods are their 
capacity to encode large libraries and thereby probe a wide range of interactions. The drawback 






light on cellular function. Moreover, the assay is competitive so high affinity non-physiological 
sequences sequester the protein away from more physiologically relevant but weaker binding 
peptides.  
Peptide array methods typically involve direct synthesis on a membrane using the SPOTS 
method (Rodriguez et al. 2004; B. A. Liu et al. 2010). These membranes can then be directly 
probed with labeled domain and detected or the peptides can be cleaved off the membrane and 
arrayed in higher density on another surface (Miller et al. 2008). This method has the advantage 
of being able to assay the domains against the same set of peptides, facilitating systematic 
comparison in the recognition properties of these domains. Also, because these peptides are 
spatially isolated, identifying which peptide interacts with a given domain is operationally 
simpler than in the display methods. The addressable sequence space is lower for this assay; 
however, recent advances in generating high density peptide arrays should minimize this gap 
(Breitling et al. 2009). 
 The drawback to all these methods is that they are non-quantitative. Their signal is 
usually directly proportional to the amount of a given peptide. If one sequence is synthesized 
with a higher yield on a membrane, it will yield a higher signal than a peptide of equal affinity 
but lower synthetic yield. The relationship between spot intensity and affinity is a complicated 
one and can invert when probing at different concentrations. This makes comparisons across 
peptides and domains difficult (Gordus and MacBeath 2006; Jones et al. 2005). 






To overcome many of these challenges, the MacBeath lab has developed quantitative protein 
domain microarrays. In this approach, 134 purified recombinant SH2 and PTB domains were 
printed as microarrays in individual wells of 96-well microtiter plates. The arrays were then 
probed with fluorescently labeled phosphopeptides derived from known sites of tyrosine 
phosphorylation on human proteins. By probing the array with eight different concentrations of 
each peptide, full saturation binding curves were obtained, providing an estimate of the 
equilibrium dissociation constant for each biochemical interaction. One advantage of this method 
is that its quantitative nature allows facile comparison of interaction strength across domains and 
peptides. Nitrocellulose membranes used in peptide arrays have also notably higher background 
fluorescence than the glass surfaces used for domain arrays. On-membrane synthesis also does 
not allow for peptide purification. This can result in signal that can potentially be a result of 
binding to mis-synthesized peptides. 
Previous work focused on nine RTKs: FGFR1, IGF1R, MET, NTRK2, PDGFRβ and the four 
ErbB receptors (Jones et al. 2005; Kaushansky et al. 2008). We have further validated many of 
the measured interactions in a cellular context by testing novel binding partners and by 
comparison with known interactions (Jung et al. 2011; Mehlitz et al. 2010; Boettcher et al. 
2010). This work forms the foundation for the majority of the experimental work detailed in this 
thesis, which describes utilizing this approach to systematically quantify, on a nearly proteome-
wide level, interactions between SH2 or PTB domains and known sites of tyrosine 
phosphorylation on both human RTKs and the adaptor proteins themselves. This represents an 
order of magnitude more interactions than have been tested in any previous publication. 






Previous systematic research on the binding specificity of SH2/PTB domains has been 
performed using phosphorylated peptide libraries. Early studies of this type uncovered consensus 
binding motifs of many SH2 domains (Huang et al. 2008; Rodriguez et al. 2004; Zhou et al. 
1993).  It was hoped that these motifs contained within them sufficient information to predict all 
known interaction sites of that domain. It is now apparent, however, that these motifs are 
simplified views of in vivo selectivity and that specificity is also defined by “anti-motifs” 
representing excluded contacts for SH2 domains (B. A. Liu et al. 2010), SH3 domains (Gorelik, 
Stanger, and Davidson 2011), and probably other modular interaction domains as well. This lack 
of positional independence makes it very difficult to predict accurately whether an SH2 or PTB 
domain will bind to a particular sequence in vivo. 
 Despite the challenges of prediction, the explosion of high throughput mass spectrometric 
studies has led to the discovery of many sites of tyrosine phosphorylation whose functional 
importance is unknown (Guo et al. 2008; Rikova et al. 2007). Moreover, genome-wide tumor 
sequencing efforts are identifying mutations near tyrosine phosphorylation sites that can perturb 
binding. Biochemical studies continue to lag behind in their ability to characterize and ascribe 
functional roles to these data. Development of an accurate predictive model can provide 
biological hypotheses that can be rapidly tested by researchers. Work towards development of 





























Recently, Barabási and colleagues advanced a mathematical argument that network 
driver nodes, the nodes that control information flow in a network, should not be highly 
interconnected (Y.-Y. Liu, Slotine, and Barabási 2011). If this notion is extended to cancer, in 
which signaling networks are substantially altered or rewired, we would expect that proteins 
driving oncogenesis would not be highly interconnected. We sought to determine experimentally 
if there is indeed a link between network connectivity and the propensity of a protein to drive 
cancer. In making this determination, we cannot rely solely on literature-derived interaction 
networks (Jonsson and Bates 2006; Wachi, Yoneda, and Wu 2005) as they are confounded by 
study bias (Hakes, Robertson, and Oliver 2005; Hakes et al. 2008). Specifically, oncogenic 
proteins are more intensively studied than non-oncogenic proteins, potentially resulting in a bias 
in terms of number of binding partners. As a means to collect systematic pTyr-mediated 
interaction data, in vivo methods like the yeast two-hybrid system are not suitable as they do not 
allow for control over post-translational modification events (Phizicky et al. 2003). Systematic 
co-immunoprecipitation coupled with mass spectrometry is also problematic, as many 
interactions mediated by tyrosine phosphorylation are transient, with half lives on the order of 
seconds, and any particular cell type expresses only a subset of the proteome (Mayer, Blinov, 
and Loew 2009).  
To circumvent these limitations, we used protein domain microarrays to systematically 
probe and quantify every possible interaction between human SH2 or PTB domains and sites of 
tyrosine of RTKs. Overall, we found we find a very high degree of connectivity that challenges 
conventional, linear views of receptor-adapter interaction. Moreover, RTKs and adaptor proteins 






that do not. This suggests that these connectivity profiles may provide insight into how networks 
are rewired and may help prioritize new targets for anti-cancer drug discovery. 
RESULTS AND DISCUSSION 
2.2 Data collection 
 We started by compiling a list of known sites of tyrosine phosphorylation on human 
RTKs and on all SH2 and PTB domain-containing proteins listed in the PhosphoSitePlus 
database (Hornbeck et al. 2011). We restricted our studies to experimentally verified sites of 
tyrosine phosphorylation as nonphysiologically relevant sites, when artificially phosphorylated, 
may also bind SH2/PTB domains (Kaushansky, Gordus, Chang, et al. 2008) and thereby 
confound any systems level conclusions drawn from the resulting data. We focused on 40 of the 
53 Uniprot-annotated RTKs that had more than three phosphorylation sites to include only those 
receptors whose biology is sufficiently understood to enable systematic comparison. This 
resulted in a total of 729 unique phosphopeptides that we successfully synthesized, fluorescently 
labeled, and purified using high performance liquid chromatography. We then used each of the 
peptides to probe microarrays comprising virtually every human SH2 and PTB domain. The 
arrays were probed at eight concentrations of each peptide, ranging from 10 nM to 5 µM (see, for 
example, Fig. 2.1A). By repeating this process for each phosphopeptide we were able to generate 
a quantitative interaction map for the receptor (Fig. 2.1B). This process was repeated for all of 
the remaining RTKs to generate, for the first time, a global, systematic, and unbiased view of 
RTK recruitment (Fig. 2.1C). Only interactions with KD < 1 µM are included in these diagrams. 
SH2 domain-mediated interactions of lower affinity have been shown to be physiologically 






interactions exhibit dissociation constants below 1 µM (Ladbury et al. 1995; Piccione et al. 1993; 
Bibbins, Boeuf, and Varmus 1993). The complete list of sub-micromolar interactions is provided 
in Table 2 of the Appendix.
 
Figure 2.1: Determining binding affinity for SH2/PTB domains to phosphopeptides.  (A) 
Example titration of 5 (6)-TAMRA-labeled phosphopeptide corresponding to the sequence 
encompassing KIT-pTyr900. Titrations highlighted in green correspond to previously-identified 
binding partners (Lennartsson et al. 2003). Curves are colored according to affinity (see legend) 
(B) Total connectivity for phosphorylation sites of the oncogenic RTK, KIT. Red circles 
corresponding to phosphorylation sites, blue circles to SH2 domains, and yellow circles to PTB 
domains. Lines are colored according to affinity. (C) Visualization of the binding profile of the 
40 RTKs analyzed in the study. RTKs are sorted in descending order by the total number of links 






As with any assay, one invariably encounters false positives and false negatives. With 
protein domain microarrays, the most frequent source of false positives is nonspecific binding 
between peptide and domain, whereas false negatives likely arise from low surface activity of the 
domains, presumably because some domains denature on the slide surface or are preferentially 
immobilized in a way that blocks access to the binding site. To estimate the stochastic false 
positive rate, we conservatively assumed that domains having the lowest frequency of binding 
were actually inactive in our assay and exhibited no true-positive interactions (any interactions 
identified for these domains are by definition false positives). We observed that domains in the 
bottom 20% of the binding frequency spectrum accounted for 20 interactions out of the 37,490 
titrations performed on the domains, corresponding to a stochastic false positive rate of 5.33x10-
4.  If we extend this rate to all the titrations performed (195,546), we estimate that 104 of the 
2,808 interactions we identified are liable to be stochastic false positives (false discovery rate of 
3.72%).  As there is no reason to believe that false positive errors are observed preferentially 
with phosphopeptides derived from cancer-causing proteins, the primary conclusions of this 
study are not affected. 
Another potential limitation of our approach is that the current list of physiological sites 
of tyrosine phosphorylation in PhosphoSitePlus may be incomplete. This would be particularly 
problematic if non-oncogenic RTKs were less well annotated than oncogenic ones. To 
investigate this possibility, we used phosphotyrosine-directed mass spectrometry (Kaushansky, 
Gordus, Budnik, et al. 2008, 4) to study six non-oncogenic members of the Ephrin class of RTKs 
– EphA2, EphA3, EphA4, EphB2, EphB3 and EphB4. We overexpressed each receptor in 
HEK293T cells, a procedure that induced receptor auto-activation and phosphorylation in all six 






targeted and untargeted µLC-MS/MS. Using this approach, we were able to identify 32 out of the 
38 known sites of intracellular tyrosine phosphorylation (84% sensitivity). Remarkably, we did 
not identify any sites of tyrosine phosphorylation beyond those already reported in the 
PhosphoSitePlus database. This suggests that the many high throughput, pTyr-directed mass 
spectrometric studies that have been used to populate PhosphoSitePlus are not biased against 
non-oncogenic receptors and that the existing list of tyrosine phosphorylation events, at least on 
RTKs, is nearly complete. 
2.3 Oncogenic RTKs are highly connected 
By examining the connectivity profile of the 40 RTKs at various affinity thresholds (Fig. 
2.2 A), we sought to identify whether a link exists between connectivity and oncogenicity. We 
determined whether or not an RTK is an oncogene based on its inclusion in the Sanger Institute’s 
Cancer Gene Census (Santarius et al. 2010) (http://www.sanger.ac.uk/genetics/CGP/Census/), 
which seeks to determine a strict causal (and not merely correlative) relationship between cancer 
development and mutation and/or overexpression of a given gene. Based on these assignments, 
we found that oncogenic RTKs have a significantly higher median connectivity in our interaction 
dataset than non-oncogenic RTKs. At an affinity threshold of 1 µM, for example, the median 
number of binding partners is 21 for non-oncogenic RTKs and 56 for oncogenic receptors, 
corresponding to a ~2.5-fold difference in the number of interactions (Mann-Whitney U-test 
p=2.77x10-5).  Non-oncogenic RTKs also have a median of six phosphorylation sites, whereas 
oncogenic RTKs have nine phosphorylation sites (Mann-Whitney U-test p=0.007), 
corresponding to a 50% increase. This indicates that the primary reason for the increased 






only secondarily an increase in the number of docking sites (Figure 2.2A). For instance, the non-
oncogenic receptor CSF1R, although it has twice as many phosphorylation sites as NTRK3 (8 vs. 
4), has far fewer high-affinity (KD<1 µM) binding partners (6 vs. 58) (Figure 2.2 B). In addition, 
the RTK with the greatest number of phosphorylation sites in our study is the non-oncogenic 
ERBB4 with 16. ERBB4 has only 18 binding partners, however, which places it in the bottom 
25% of the RTKs we studied. 
Many interactions annotated here may be of too low affinity to bind at appreciable levels 
to a receptor that is present at low surface density or at a low level of activation. When a cell 
becomes malignant, however, gene amplification or overexpression may make phosphorylated 
receptors (or adaptors) sufficiently abundant that low affinity interactions are enabled and 
downstream signaling activated. This notion is supported by the observation, in PC12 cells, that 
EGFR mediates proliferation when present at normal levels but differentiation when 
overexpressed (Marshall 1995). These phenomena cannot be captured in qualitative diagrams of 
signaling and highlight the need to think of these interactions as being contextually conditional 








Figure 2.2: Oncogenic RTKs are enriched for binding partners. (A) Cumulative density 
distribution of RTK interactions at different affinity thresholds. Oncogenic RTKs in red have 
significantly more binding partners than non-oncogenic RTKs in grey; median of 56 vs. 21 
interactions with affinity less than 1 µM (Mann-Whitney U-Test p=2.8x10-5). (B) Example of 
connectivity between sites of tyrosine phosphorylation on the non-oncogenic RTK CSF1R and 







2.4 Materials and methods 
A detailed protocol for preparing protein domain microarrays has been described previously 
(Kaushansky et al. 2010). 
2.4.1 Determining interaction affinity 
Following peptide binding, arrays were scanned at multiple PMT voltages on a Tecan LS400 
microarray scanner on both Cy5 and Cy3 channels. Spots with saturated pixels were eliminated. 
The remaining spots were fit to a line that allows for the conversion of all the Cy3 values 
measured at different PMT voltages to the same scale. The fold-over-background value of a 
titration was determined by taking the trimmed mean of the Cy3 values for each domain-peptide 
titration divided by the Cy3 values of the Thioredoxin control spots. The mean Cy3 value of the 
Thioredoxin control spots was then subtracted from the Cy3 value of the domain spot and the 
spots were normalized by the Cy5 value. 
Each domain was printed in quadruplicate in each well and the arrays were probed using eight 
different concentrations of each peptide, ranging from 5 µM down to 10 nM. These 32 data 
points were then fit to the following equation using MATLAB®’s robust fit function with 
bisquare weights: 
Fobs = Fmax[Peptide] / (KD + [Peptide])   Eq. 1 
where Fobs is the mean fluorescence of replicate spots, Fmax is the fluorescence at saturation, 
[Peptide] is the total concentration of phosphopeptide, and KD is the equilibrium dissociation 
constant. Robust fitting procedures are more resistant to the presence of outlier data resulting 






fold-over-background values in the top 10% of the data and R2 values over 0.9 were kept. 
Replicate affinities were then averaged in log space. The MATLAB® code used to perform the 
analysis is supplied in supplementary information. 
2.4.2 Determining oncogene status 
Oncogene status for RTKs was determined using the Sanger Institute Cancer Gene Census 
(Futreal et al. 2004; Santarius et al. 2010). The Sanger list contains only those genes for which a 
strong causal link to cancer has been established.  
2.4.3 Statistical tests for enrichment of binding 
To test against the null hypothesis that the distribution of connectivity is equivalent for both 
Oncogene and non-Oncogene classes, we performed the non-parametric Mann-Whitney U test in 
MATLAB® R2011a (The MathWorks, Inc., Natick, MA). Only those interactions with 
dissociation constants below 1 µM were considered. 
2.4.4 Peptides derived from RTKs 
Table 2.1  RTK Phosphopeptides  (Continued) 
 
Gene pTyr Peptide Sequence Uniprot 
ALK Y1078 MQMELQSPEyKLSKLRT Q9UM73 
ALK Y1092 LRTSTIMTDyNPNYCFA Q9UM73 
ALK Y1096 TIMTDYNPNyCFAGKTS Q9UM73 
ALK Y1131 LGHGAFGEVyEGQVSGM Q9UM73 
ALK Y1278 GDFGMARDIyRASYYRK Q9UM73 
ALK Y1282 MARDIYRASyYRKGGCA Q9UM73 
ALK Y1283 ARDIYRASYyRKGGCAM Q9UM73 
ALK Y1359 PPKNCPGPVyRIMTQCW Q9UM73 
ALK Y1507 KPTSLWNPTyGSWFTEK Q9UM73 







Table 2.1  RTK Phosphopeptides  (Continued) 
 
ALK Y1586 FPCGNVNYGyQQQGLPL Q9UM73 
ALK Y1604 AATAPGAGHyEDTILKS Q9UM73 
AXL Y481 VHRRKKETRyGEVFEPT P30530 
AXL Y698 ADFGLSKKIyNGDYYRQ P30530 
AXL Y702 LSKKIYNGDyYRQGRIA P30530 
AXL Y703 SKKIYNGDYyRQGRIAK P30530 
AXL Y726 AIESLADRVyTSKSDVW P30530 
AXL Y759 QPADCLDGLyALMSRCW P30530 
AXL Y821 PAQEPDEILyVNMDEGG P30530 
AXL Y866 AAEVHPAGRyVLCPSTT P30530 
CSF1R Y546 LYKYKQKPKyQVRWKII P07333 
CSF1R Y561 IIESYEGNSyTFIDPTQ P07333 
CSF1R Y699 GQDPEGGVDyKNIHLEK P07333 
CSF1R Y708 YKNIHLEKKyVRRDSGF P07333 
CSF1R Y723 GFSSQGVDTyVEMRPVS P07333 
CSF1R Y809 ARDIMNDSNyIVKGNAR P07333 
CSF1R Y873 KFYKLVKDGyQMAQPAF P07333 
CSF1R Y923 AQEDRRERDyTNLPSSS P07333 
EGFR Y727 LGSGAFGTVyKGLWIPE P00533 
EGFR Y869 KLLGAEEKEyHAEGGKV P00533 
EGFR Y944 QPPICTIDVyMIMVKCW P00533 
EGFR Y978 SKMARDPQRyLVIQGDE P00533 
EGFR Y998 LPSPTDSNFyRALMDEE P00533 
EGFR Y1016 MDDVVDADEyLIPQQGF P00533 
EGFR Y1069 IKEDSFLQRySSDPTGA P00533 
EGFR Y1092 DDTFLPVPEyINQSVPK P00533 
EGFR Y1125 NPAPSRDPHyQDPHSTA P00533 
EGFR Y1138 HSTAVGNPEyLNTVQPT P00533 
EGFR Y1172 HQISLDNPDyQQDFFPK P00533 
EGFR Y1197 KGSTAENAEyLRVAPQS P00533 
EPHA1 Y599 REDKLWLKPyVDLQAYE P21709 
EPHA1 Y605 LKPYVDLQAyEDPAQGA P21709 
EPHA1 Y781 RLLDDFDGTyETQGGKI P21709 
EPHA2 Y575 RARQSPEDVyFSKSEQL P29317 
EPHA2 Y588 SEQLKPLKTyVDPHTYE P29317 
EPHA2 Y594 LKTYVDPHTyEDPNQAV P29317 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
EPHA2 Y694 YKPMMIITEyMENGALD P29317 
EPHA2 Y735 GMKYLANMNyVHRDLAA P29317 
EPHA2 Y772 VLEDDPEATyTTSGGKI P29317 
EPHA2 Y791 RWTAPEAISyRKFTSAS P29317 
EPHA2 Y921 WLESIKMQQyTEHFMAA P29317 
EPHA2 Y930 YTEHFMAAGyTAIEKVV P29317 
EPHA2 Y960 LPGHQKRIAySLLGLKD P29317 
EPHA3 Y596 HLKLPGLRTyVDPHTYE P29320 
EPHA3 Y602 LRTYVDPHTyEDPTQAV P29320 
EPHA3 Y779 VLEDDPEAAyTTRGGKI P29320 
EPHA3 Y937 CKEIFTGVEySSCDTIA P29320 
EPHA4 Y596 KHLNQGVRTyVDPFTYE P54764 
EPHA4 Y602 VRTYVDPFTyEDPNQAV P54764 
EPHA4 Y779 VLEDDPEAAyTTRGGKI P54764 
EPHA5 Y650 HIKLPGVRTyIDPHTYE P54756 
EPHA5 Y656 VRTYIDPHTyEDPNQAV P54756 
EPHA5 Y833 VLEDDPEAAyTTRGGKI P54756 
EPHA5 Y967 EHSPLGSGAyRSVGEWL P54756 
EPHA7 Y597 ADQEGDEELyFHFKFPG Q15375 
EPHA7 Y608 HFKFPGTKTyIDPETYE Q15375 
EPHA7 Y614 TKTYIDPETyEDPNRAV Q15375 
EPHA7 Y791 VIEDDPEAVyTTTGGKI Q15375 
EPHB1 Y575 KRAYSKEAVySDKLQHY P54762 
EPHB1 Y582 AVYSDKLQHySTGRGSP P54762 
EPHB1 Y594 GRGSPGMKIyIDPFTYE P54762 
EPHB1 Y600 MKIYIDPFTyEDPNEAV P54762 
EPHB1 Y634 IGAGEFGEVyKGRLKLP P54762 
EPHB1 Y778 LQDDTSDPTyTSSLGGK P54762 
EPHB1 Y928 WLSAIKMVQyRDSFLTA P54762 
EPHB2 Y577 RGFERADSEyTDKLQHY P29323 
EPHB2 Y584 SEYTDKLQHyTSGHMTP P29323 
EPHB2 Y596 GHMTPGMKIyIDPFTYE P29323 
EPHB2 Y602 MKIYIDPFTyEDPNEAV P29323 
EPHB2 Y780 LEDDTSDPTyTSALGGK P29323 
EPHB2 Y912 PLLDRTIPDyTSFNTVD P29323 
EPHB3 Y600 SEYTEKLQQyIAPGMKV P54753 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
EPHB3 Y614 MKVYIDPFTyEDPNEAV P54753 
EPHB3 Y754 GMKYLSEMNyVHRDLAA P54753 
EPHB3 Y924 PLLDRTVPDyTTFTTVG P54753 
EPHB4 Y574 KQSNGREAEySDKHGQY P54760 
EPHB4 Y581 AEYSDKHGQyLIGHGTK P54760 
EPHB4 Y596 TKVYIDPFTyEDPNEAV P54760 
EPHB4 Y614 EFAKEIDVSyVKIEEVI P54760 
EPHB4 Y774 LEENSSDPTyTSSLGGK P54760 
EPHB4 Y906 PLLDQRQPHySAFGSVG P54760 
ERBB2 Y735 LGSGAFGTVyKGIWIPD P04626 
ERBB2 Y877 RLLDIDETEyHADGGKV P04626 
ERBB2 Y1005 PASPLDSTFyRSLLEDD P04626 
ERBB2 Y1023 MGDLVDAEEyLVPQQGF P04626 
ERBB2 Y1112 THDPSPLQRySEDPTVP P04626 
ERBB2 Y1127 VPLPSETDGyVAPLTCS P04626 
ERBB2 Y1139 PLTCSPQPEyVNQPDVR P04626 
ERBB2 Y1196 FGGAVENPEyLTPQGGA P04626 
ERBB2 Y1221 AFSPAFDNLyYWDQDPP P04626 
ERBB2 Y1222 FSPAFDNLYyWDQDPPE P04626 
ERBB3 Y1054 QSLLSPSSGyMPMNQGN P21860 
ERBB3 Y1197 TEEEDEDEEyEYMNRRR P21860 
ERBB3 Y1199 EEDEDEEYEyMNRRRRH P21860 
ERBB3 Y1262 GTTPDEDYEyMNRQRDG P21860 
ERBB3 Y1276 RDGGGPGGDyAAMGACP P21860 
ERBB3 Y1289 GACPASEQGyEEMRAFQ P21860 
ERBB3 Y1328 TDSAFDNPDyWHSRLFP P21860 
ERBB4 Y875 RLLEGDEKEyNADGGKM Q15303 
ERBB4 Y1035 QAFNIPPPIyTSRARID Q15303 
ERBB4 Y1056 EIGHSPPPAyTPMSGNQ Q15303 
ERBB4 Y1066 TPMSGNQFVyRDGGFAA Q15303 
ERBB4 Y1081 AAEQGVSVPyRAPTSTI Q15303 
ERBB4 Y1128 VQEDSSTQRySADPTVF Q15303 
ERBB4 Y1150 PRGELDEEGyMTPMRDK Q15303 
ERBB4 Y1162 PMRDKPKQEyLNPVEEN Q15303 
ERBB4 Y1188 DLQALDNPEyHNASNGP Q15303 
ERBB4 Y1202 NGPPKAEDEyVNEPLYL Q15303 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
ERBB4 Y1221 FANTLGKAEyLKNNILS Q15303 
ERBB4 Y1242 AKKAFDNPDyWNHSLPP Q15303 
ERBB4 Y1258 PRSTLQHPDyLQEYSTK Q15303 
ERBB4 Y1262 LQHPDYLQEySTKYFYK Q15303 
ERBB4 Y1266 DYLQEYSTKyFYKQNGR Q15303 
ERBB4 Y1268 LQEYSTKYFyKQNGRIR Q15303 
ERBB4 Y1284 RPIVAENPEyLSEFSLK Q15303 
ERBB4 Y1301 PGTVLPPPPyRHRNTVV Q15303 
FGFR1 Y463 TPMLAGVSEyELPEDPR P11362 
FGFR1 Y585 QARRPPGLEyCYNPSHN P11362 
FGFR1 Y605 RRPPGLEYCyNPSHNPE P11362 
FGFR1 Y653 LARDIHHIDyYKKTTNG P11362 
FGFR1 Y653 SSKDLVSCAyQVARGME P11362 
FGFR1 Y654 ARDIHHIDYyKKTTNGR P11362 
FGFR1 Y730 KPSNCTNELyMMMRDCW P11362 
FGFR1 Y766 IVALTSNQEyLDLSMPL P11362 
FGFR2 Y466 TPMLAGVSEyELPEDPK P21802 
FGFR2 Y586 RARRPPGMEySYDINRV P21802 
FGFR2 Y588 RRPPGMEYSyDINRVPE P21802 
FGFR3 Y577 RARRPPGLDySFDTCKP P22607 
FGFR3 Y599 TFKDLVSCAyQVARGME P22607 
FGFR3 Y647 LARDVHNLDyYKKTTNG P22607 
FGFR3 Y648 ARDVHNLDYyKKTTNGR P22607 
FGFR3 Y724 KPANCTHDLyMIMRECW P22607 
FGFR3 Y760 VLTVTSTDEyLDLSAPF P22607 
FGFR3 Y770 LDLSAPFEQySPGGQDT P22607 
FLT1 Y794 RSSSEIKTDyLSIIMDP P17948 
FLT1 Y1048 CDFGLARDIyKNPDYVR P17948 
FLT1 Y1053 ARDIYKNPDyVRKGDTR P17948 
FLT1 Y1169 ANVQQDGKDyIPINAIL P17948 
FLT1 Y1213 NSGSSDDVRyVNAFKFM P17948 
FLT1 Y1242 PNATSMFDDyQGDSSTL P17948 
FLT1 Y1327 IACCSPPPDyNSVVLYS P17948 
FLT1 Y1333 PPDYNSVVLySTPPI-- P17948 
FLT3 Y572 CHKYKKQFRyESQLQMV P36888 
FLT3 Y589 LDLSAPFEQySPGGQDT P36888 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
FLT3 Y597 EYFYVDFREyEYDLKWE P36888 
FLT3 Y599 FYVDFREYEyDLKWEFP P36888 
FLT3 Y726 IFKEHNFSFyPTFQSHP P36888 
FLT3 Y768 SFHSEDEIEyENQKRLE P36888 
FLT3 Y842 ARDIMSDSNyVVRGNAR P36888 
FLT3 Y955 QLADAEEAMyQNVDGRV P36888 
FLT3 Y969 GRVSECPHTyQNRRPFS P36888 
FLT4 Y830 PAHADIKTGyLSIIMDP P35916 
FLT4 Y833 EVPLEEQCEyLSYDASQ P35916 
FLT4 Y853 LEEQCEYLSyDASQWEF P35916 
FLT4 Y1063 CDFGLARDIyKDPDYVR P35916 
FLT4 Y1068 ARDIYKDPDyVRKGSAR P35916 
FLT4 Y1333 RGARGGQVFyNSEYGEL P35916 
FLT4 Y1337 GGQVFYNSEyGELSEPS P35916 
IGF1R Y973 NSRLGNGVLyASVNPEY P08069 
IGF1R Y980 VLYASVNPEyFSAADVY P08069 
IGF1R Y1161 GDFGMTRDIyETDYYRK P08069 
IGF1R Y1165 MTRDIYETDyYRKGGKG P08069 
IGF1R Y1166 TRDIYETDYyRKGGKGL P08069 
IGF1R Y1280 EPGFREVSFyYSEENKL P08069 
IGF1R Y1281 PGFREVSFYySEENKLP P08069 
IGF1R Y1346 RASFDERQPyAHMNGGR P08069 
INSR Y992 QPDGPLGPLyASSNPEY P06213 
INSR Y999 PLYASSNPEyLSASDVF P06213 
INSR Y1011 ASDVFPCSVyVPDEWEV P06213 
INSR Y1149 AAEIADGMAyLNAKKFV P06213 
INSR Y1185 GDFGMTRDIyETDYYRK P06213 
INSR Y1189 MTRDIYETDyYRKGGKG P06213 
INSR Y1190 TRDIYETDYyRKGGKGL P06213 
INSR Y1355 GSSLGFKRSyEEHIPYT P06213 
INSR Y1361 KRSYEEHIPyTHMNGGK P06213 
KDR Y801 ANGGELKTGyLSIVMDP P35968 
KDR Y951 GARFRQGKDyVGAIPVD P35968 
KDR Y996 EEEEAPEDLyKDFLTLE P35968 
KDR Y1054 CDFGLARDIyKDPDYVR P35968 
KDR Y1059 ARDIYKDPDyVRKGDAR P35968 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
KDR Y1214 EEVCDPKFHyDNTAGIS P35968 
KIT Y553 TYKYLQKPMyEVQWKVV P10721 
KIT Y568 VVEEINGNNyVYIDPTQ P10721 
KIT Y570 EEINGNNYVyIDPTQLP P10721 
KIT Y703 QEDHAEAALyKNLLHSK P10721 
KIT Y721 SSCSDSTNEyMDMKPGV P10721 
KIT Y730 YMDMKPGVSyVVPTKAD P10721 
KIT Y823 ARDIKNDSNyVVKGNAR P10721 
KIT Y900 SPEHAPAEMyDIMKTCW P10721 
KIT Y936 QISESTNHIySNLANCS P10721 
MERTK Y749 ADFGLSKKIySGDYYRQ Q12866 
MERTK Y753 LSKKIYSGDyYRQGRIA Q12866 
MERTK Y754 SKKIYSGDYyRQGRIAK Q12866 
MERTK Y929 HDSKPHEGRyILNGGSE Q12866 
MET Y1003 EMVSNESVDyRATFPED P08581 
MET Y1093 IGRGHFGCVyHGTLLDN P08581 
MET Y1230 ADFGLARDMyDKEYYSV P08581 
MET Y1234 LARDMYDKEyYSVHNKT P08581 
MET Y1235 ARDMYDKEYySVHNKTG P08581 
MET Y1313 QPEYCPDPLyEVMLKCW P08581 
MET Y1349 IFSTFIGEHyVHVNATY P08581 
MET Y1356 EHYVHVNATyVNVKCVA P08581 
MET Y1365 YVNVKCVAPyPSLLSSE P08581 
MST1R Y1017 LPILYSGSDyRSGLALP Q04912 
MST1R Y1238 LARDILDREyYSVQQHR Q04912 
MST1R Y1239 ARDILDREYySVQQHRH Q04912 
MST1R Y1317 QPEYCPDSLyQVMQQCW Q04912 
MST1R Y1353 IVSALLGDHyVQLPATY Q04912 
MST1R Y1360 DHYVQLPATyMNLGPST Q04912 
NTRK1 Y496 QGHIIENPQyFSDACVH P04629 
NTRK1 Y676 GDFGMSRDIySTDYYRV P04629 
NTRK1 Y680 MSRDIYSTDyYRVGGRT P04629 
NTRK1 Y681 SRDIYSTDYyRVGGRTM P04629 
NTRK1 Y757 RPRACPPEVyAIMRGCW P04629 
NTRK1 Y791 QALAQAPPVyLDVLG-- P04629 
NTRK2 Y516 KIPVIENPQyFGITNSQ Q16620 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
NTRK2 Y706 MSRDVYSTDyYRVGGHT Q16620 
NTRK2 Y707 SRDVYSTDYyRVGGHTM Q16620 
NTRK2 Y817 QNLAKASPVyLDILG-- Q16620 
NTRK3 Y516 RIPVIENPQyFRQGHNC Q16288 
NTRK3 Y705 GDFGMSRDVySTDYYRV Q16288 
NTRK3 Y709 MSRDVYSTDyYRVGGHT Q16288 
NTRK3 Y710 SRDVYSTDYyRVGGHTM Q16288 
PDGFRA Y572 ESISPDGHEyIYVDPMQ P16234 
PDGFRA Y574 ISPDGHEYIyVDPMQLP P16234 
PDGFRA Y613 FGKVVEGTAyGLSRSQP P16234 
PDGFRA Y731 ILSFENNGDyMDMKQAD P16234 
PDGFRA Y742 DMKQADTTQyVPMLERK P16234 
PDGFRA Y754 MLERKEVSKySDIQRSL P16234 
PDGFRA Y768 RSLYDRPASyKKKSMLD P16234 
PDGFRA Y849 ARDIMHDSNyVSKGSTF P16234 
PDGFRA Y944 SEPEKRPSFyHLSEIVE P16234 
PDGFRA Y958 IVENLLPGQyKKSYEKI P16234 
PDGFRA Y962 LLPGQYKKSyEKIHLDF P16234 
PDGFRA Y988 RMRVDSDNAyIGVTYKN P16234 
PDGFRA Y1018 EQRLSADSGyIIPLPDI P16234 
PDGFRB Y562 IMLWQKKPRyEIRWKVI P09619 
PDGFRB Y579 ESVSSDGHEyIYVDPMQ P09619 
PDGFRB Y581 VSSDGHEYIyVDPMQLP P09619 
PDGFRB Y740 SLTGESDGGyMDMSKDE P09619 
PDGFRB Y751 DMSKDESVDyVPMLDMK P09619 
PDGFRB Y763 MLDMKGDVKyADIESSN P09619 
PDGFRB Y771 KYADIESSNyMAPYDNY P09619 
PDGFRB Y775 IESSNYMAPyDNYVPSA P09619 
PDGFRB Y778 SNYMAPYDNyVPSAPER P09619 
PDGFRB Y857 ARDIMRDSNyISKGSTF P09619 
PDGFRB Y934 QPAHASDEIyEIMQKCW P09619 
PDGFRB Y970 LLGEGYKKKyQQVDEEF P09619 
PDGFRB Y1009 SPLDTSSVLyTAVQPNE P09619 
PDGFRB Y1021 VQPNEGDNDyIIPLPDP P09619 
RET Y687 RPAQAFPVSySSSGARR P07949 
RET Y752 AFHLKGRAGyTTVAVKM P07949 






Table 2.1  RTK Phosphopeptides  (Continued) 
 
RET Y806 DGPLLLIVEyAKYGSLR P07949 
RET Y826 RESRKVGPGyLGSGGSR P07949 
RET Y864 AWQISQGMQyLAEMKLV P07949 
RET Y900 SDFGLSRDVyEEDSYVK P07949 
RET Y905 SRDVYEEDSyVKRSQGR P07949 
RET Y928 AIESLFDHIyTTQSDVW P07949 
RET Y952 EIVTLGGNPyPGIPPER P07949 
RET Y981 RPDNCSEEMyRLMLQCW P07949 
RET Y1015 EKMMVKRRDyLDLAAST P07949 
RET Y1029 ASTPSDSLIyDDGLSEE P07949 
RET Y1062 PSTWIENKLyGMSDPNW P07949 
RET Y1090 DGTNTGFPRyPNDSVYA P07949 
RET Y1096 FPRYPNDSVyANWMLSP P07949 
ROR1 Y786 PVSNLSNPRyPNYMFPS Q01973 
ROR1 Y789 NLSNPRYPNyMFPSQGI Q01973 
ROR1 Y828 INGYPIPPGyAAFPAAH Q01973 
ROR1 Y836 GYAAFPAAHyQPTGPPR Q01973 
ROS1 Y1923 AGVGLANACyAIHTLPT P08922 
ROS1 Y2110 GDFGLARDIyKNDYYRK P08922 
ROS1 Y2114 LARDIYKNDyYRKRGEG P08922 
ROS1 Y2115 ARDIYKNDYyRKRGEGL P08922 
ROS1 Y2274 ETKNREGLNyMVLATEC P08922 
ROS1 Y2323 DFCQEKQVAyCPSGKPE P08922 
ROS1 Y2334 PSGKPEGLNyACLTHSG P08922 
ROS1 Y2342 NYACLTHSGyGDGSD-- P08922 
TEK Y992 FGLSRGQEVyVKKTMGR Q02763 
TEK Y1048 YCGMTCAELyEKLPQGY Q02763 
TEK Y1102 NRMLEERKTyVNTTLYE Q02763 
TEK Y1108 RKTYVNTTLyEKFTYAG Q02763 
TEK Y1113 NTTLYEKFTyAGIDCSA Q02763 
TYRO3 Y681 ADFGLSRKIySGDYYRQ Q06418 
TYRO3 Y685 LSRKIYSGDyYRQGCAS Q06418 
TYRO3 Y686 SRKIYSGDYyRQGCASK Q06418 





























Focusing only on the initial recruitment of adaptors to RTKs provides an incomplete 
view of the full complexity of early RTK signaling. Adaptors can themselves become tyrosine 
phosphorylated and interact with each other, forming multi-protein complexes at the receptor. By 
systematically probing our SH2/PTB domain microarrays with phosphopeptides derived from 
334 known pTyr sites on adaptor proteins, we identified a dense network of interactions among 
the adaptor proteins themselves (Fig. 3.1A and Table 6.2 in the appendix). For example, the 
well-studied tyrosine kinase ABL1, which is responsible for driving the development of chronic 
myeloid leukemia when fused with the protein BCR, is currently annotated to mediate 15 
interactions through its SH2 domain (Colicelli 2010). In our study, we identified 53 biochemical 
binding partners (Figure 3.1B), including known interactions with DAB1, ERBB2, PTK2 and 
SHC1 (Colicelli 2010).  Our data may also resolve some outstanding questions in the field. For 
example, it has previously been reported that the Vav1 SH2 domain binds to a phosphorylation 
site on BCR/ABL and that this interaction is critical for activation of Rac-1 and BCR/ABL-
mediated leukemogenesis. Previous attempts to identify the site of binding by constructing a 
series of Tyr to Phe mutants, focusing in particular on the Vav1 consensus binding motif, were 
unsuccessful (Bassermann et al. 2002). Our data reveal an interaction between Vav1 and 
pTyr917 of BCR/ABL (Uniprot id: A9UF07), which was not included in the earlier mutagenesis 
experiments. 
RTK-mediated activation of the MAPK pathway is well studied (Tidyman and Rauen 
2009; McKay and Morrison 2007), but we nevertheless find many new interactions that impinge 






such as SHC1, GRB2, and PTPN11. Here, we find that these adaptors have the potential to 
interact with many other signaling proteins as well, increasing the complexity of MAPK pathway 
activation (Fig. 3.1 D). This view aligns well with the idea that RTKs function not as discrete 
molecular machines, as typically depicted, but as pleomorphic ensembles that are highly 
complex and dynamic with many rapidly interchanging states (Mayer, Blinov, and Loew 2009; 










Figure 3.1: Adaptors are densely interconnected. (A) Adaptor proteins displayed in a circle 
with the size of the band corresponding to protein length (Krzywinski et al. 2009). Lines begin at 
sites of tyrosine phosphorylation and terminate in either a yellow triangle corresponding to a 
PTB domain or a blue triangle corresponding to an SH2 domain and are color coded according to 
affinity. (B) Visualization of the binding partners of ABL1 SH2 domain (in-links) and 
phosphorylation sites of ABL1 (out-links). (C) RTK activation of the MAPK cascade is a varied 
process that integrates binding of GRB2 to SHC1 and SHP2 as well as to the RTK.  (D) The 
combinatorial complexity of RTK activation of MAPK is liable to be even greater as GRB2, 
SHC1 and PTPN11 (SHP2) are also capable of binding other adaptors, as can be seen by the 







3.2 Oncogenic adaptors are highly connected 
To probe the relationship between connectivity and oncogenicity in the adaptor-adaptor 
layer of binding, we organized domains by sequence similarity (Fig. 3.2A) (Letunic and Bork 
2011). The blue bars indicate how many peptides bind to each domain (in-links) and the green 
bars show how many binding partners interact with phosphorylation sites on the corresponding 
protein (out-links). Simple inspection reveals a wide range of binding promiscuity within the 
SH2 and PTB domain families. For example, proteins in the SRC, HCK, and PI3K N-terminal 
families of domains have relatively high numbers of binding partners and are frequently 
annotated as oncogenes. When we sort the domains by the number of in-links and out-links, from 
least to most connected, it is clear that oncogenic proteins (red) are preferentially enriched 
among proteins with high in-connectivity (median 20 vs. 8 in-links, Mann-Whitney U test p= 
3.4x10-3), high out-connectivity (median 9 vs. 1 out-links, Mann-Whitney U test p=1.0x10-4), or 
both (Fig. 4B). Because the adaptors are likely to amplify signals downstream of RTKs, 
especially those without intrinsic catalytic activity themselves, we used an expanded definition 










Figure 3.2: Oncogenic adaptors are more highly promiscuous. (A) Phylogeny of adaptors 
shows that genetically related domains share similar binding profiles. For example the SRC class 
(SRC, YES1, FGR) of tyrosine kinases all show a large number of in-links. This can be due to 
sequence determinants of selectivity as well as the bias in the phosphoproteome to sequences that 
interact with the domain family. (B) Adaptors sorted according to the number of peptides with 
which they interact (in-links; the X axis) and the number of adaptors that interact with them (out-
links; Y axis). Oncogenic adaptors have both higher median in-links (20 vs. 8, Mann-Whitney U 
test p= 3.4x10-3) and out-links (9 vs. 1, Mann-Whitney U test p=1.0x10-4) than non-oncogenic 
adaptors. SH2 domains bind a higher median number of peptides (15.5 vs. 2, Mann-Whitney U 







The quantitative interaction data generated in this study should prove generally useful in 
the fields of network modeling (Chen et al. 2009) and interaction prediction (Miller et al. 2008). 
With the caveat that our data necessarily include false positives and false negatives, we also hope 
that the novel interactions identified in these studies will aid efforts to uncover signaling 
pathways downstream of RTKs.  
 Our work shows that the genes whose mutation or overexpression drives cancer tend to 
be highly connected hubs. Moreover, the most highly connected proteins in our networks are the 
primary targets of anti-cancer drugs (e.g., erlotonib for EGFR (Raymond, Faivre, and Armand 
2000), lapatanib for ERBB2 (Burris et al. 2005), vandetanib for RET (Degrauwe et al. 2012), 
sunitinib for KIT (Demetri et al. 14), and imatanib for ABL1 (Druker et al. 2001)). Analogously, 
viral proteins preferentially target hub proteins during infection (Calderwood et al. 2007; Shapira 
et al. 2009). This combined evidence suggests that disease states arise preferentially from the 
perturbation of network hubs and drugs should target these same hub proteins.  
In conclusion, we have generated a systematic map covering a substantial fraction of the 
potential interactions between SH2 or PTB domains and sites of tyrosine phosphorylation on 
RTKs and adaptor proteins. These interactions are very poorly represented in existing unbiased 
human interactomes (Rual et al. 2005; Venkatesan et al. 2009) despite extensive evidence that 
they play essential roles in signal transduction. We observe a high degree of connectivity among 
RTKs and adaptor proteins, and among adaptor proteins themselves. This is in contrast to the 
usual depiction of receptor-proximal signaling as a series of linear pathways connecting sites of 
tyrosine phosphorylation on RTKs to a few adaptor proteins and then to a few core signaling 






any particular cell type depends not only on the affinities of the interactions, as determined here, 
but also on the relative abundance of RTKs and SH2/PTB-containing proteins. mRNA 
sequencing data of 1430 diverse tumor types collected by the TCGA consortium shows that they 
express a median of 78% of the phosphotyrosine signaling proteins analyzed in this study. In 
fact, over half of these proteins are expressed ubiquitously (in >95% of the tumor samples; 
Figure 3.3). Thus, it is highly likely that receptor and adaptor proteins combine to form a highly 
interconnected mesh with the potential to perform complex signal processing functions. 
 
Figure 3.3 Tumors Widely Express RTKs and adaptors. (A) Tumor expression data of 1437 
tumors from breast cancer, colon and rectal adenocarcinoma, and clear cell kidney cancer 
collected by The CancerGenome Atlas Network was analyzed for RTK and adaptor protein 
expression. Tumors express a median of 78% of the phosphotyrosine signaling proteins. (B) 
Expression of signaling proteins varies widely with 52% of phosphotyrosine signaling proteins 
are expressed nearly ubiquitously (>95%) of tumors and other proteins having more restricted 
expression. 
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Supplementary Figure 2. Tumors Widely Express RTKs and adaptors. (A) Tumor expression data of 1437 tumors
from breast cancer, colon and rectal adenocarcinoma, and clear cell kidney cancer collected by The Cancer
Genome Atlas Network was analyzed for RTK and adaptor protein expression. Tumors express a median of 
78% of the phosphotyrosine signaling proteins. (B) Expression of signaling proteins varies widely with 52% of 
phosphotyro ine sign ling proteins are expressed nearly ubiquitously (>95%) of tumors and other proteins having







3.3 Materials and methods 
The protocols for this chapter are identical to those of Part 2, except where described below. 
 
3.3.1 Determining onocogene status 
Since many SH2/PTB domain-containing proteins have no catalytic activity of their own, they 
serve principally to amplify and propagate signals from upstream proteins, a less stringent 
criterion for oncogene assignment was used. For this reason, adaptors were assigned as having a 
role in cancer by their presence in a union of the Sanger list and other cancer gene lists (Huret et 
al. 2000; Sjöblom et al. 2006; Akagi et al. 2004) compiled by the Bushman lab 
(http://microb230.med.upenn.edu/links/genelist). 
3.3.2 RTK and adaptor expression in tumor samples 
cBio Cancer Genomics Data Server Matlab Toolbox v1.04 was used to retrieve mRNA 
sequencing data corresponding to 1437 tumors from breast cancer, colon and rectal 
adenocarcinoma (T. C. G. A. Network 2012) and clear cell kidney cancer collected by The 
Cancer Genome Atlas Network. We used a 1 read per kilobase of exon model per million 
mapped reads (RPKM) threshold to separate genes that are expressed. This threshold has been 
shown to correspond to 1 transcript per C2C12 cell (Mortazavi et al. 2008) and optimizes overlap 
with mass spectrometry results in HeLa cells (Nagaraj et al. 2011). We consider this to be an 
upper bound estimate to the total number of potential interaction partners. 
 









Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
Gene Uniprot pTyr Peptide Sequence 
ABL1 P00519 Y89 NDPNLFVALyDFVASGD 
ABL1 P00519 Y134 NGQGWVPSNyITPVNSL 
ABL1 P00519 Y191 ISLRYEGRVyHYRINTA 
ABL1 P00519 Y204 INTASDGKLyVSSESRF 
ABL1 P00519 Y234 ADGLITTLHyPAPKRNK 
ABL1 P00519 Y245 APKRNKPTVyGVSPNYD 
ABL1 P00519 Y251 PTVYGVSPNyDKWEMER 
ABL1 P00519 Y272 MKHKLGGGQyGEVYEGV 
ABL1 P00519 Y276 LGGGQYGEVyEGVWKKY 
ABL1 P00519 Y283 EVYEGVWKKySLTVAVK 
ABL1 P00519 Y412 LSRLMTGDTyTAHAGAK 
ABL1 P00519 Y488 RPEGCPEKVyELMRACW 
ABL2 P42684 Y161 NGQGWVPSNyITPVNSL 
ABL2 P42684 Y231 INTTADGKVyVTAESRF 
ABL2 P42684 Y261 ADGLVTTLHyPAPKCNK 
ABL2 P42684 Y272 APKCNKPTVyGVSPIHD 
ABL2 P42684 Y303 LGGGQYGEVyVGVWKKY 
ABL2 P42684 Y515 QPEGCPPKVyELMRACW 
ABL2 P42684 Y568 AASSSSVVPyLPRLPIL 
ABL2 P42684 Y683 EMENQPHKKyELTGNFS 
ABL2 P42684 Y718 EANLVPPKCyGGSFAQR 
ANKS1A Q92625 Y454 AAREEDEHPyELLLTAE 
ANKS1A Q92625 Y833 IIASLADRPyEEPPQKP 
APBB1 O00213 Y547 ELVQKFQVYyLGNVPVA 
APBB3 O95704 Y291 DAVSQAAQKyEALYMGT 
BCAR3 O75815 Y42 PLAEHRPDAyQDVSIHG 
BCAR3 O75815 Y117 PHLLDPTVEyVKFSKER 
BCAR3 O75815 Y266 VPLRCLEEHyGTSPGQA 
BCAR3 O75815 Y429 SAWLNSEANyCELNPAF 
BLNK Q8WV28 Y72 QWSDDFDSDyENPDEHS 
BLNK Q8WV28 Y84 PDEHSDSEMyVMPAEEN 
BLNK Q8WV28 Y96 PAEENADDSyEPPPVEQ 
BLNK Q8WV28 Y178 KGLLEDEADyVVPVEDN 







Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
BMX P51813 Y40 FVLTKTNLSyYEYDKMK 
BMX P51813 Y216 PSSSTSLAQyDSNSKKI 
BMX P51813 Y224 QYDSNSKKIyGSQPNFN 
BMX P51813 Y566 MTRYVLDDQyVSSVGTK 
BTK Q06187 Y223 SELKKVVALyDYMPMNA 
BTK Q06187 Y225 LKKVVALYDyMPMNAND 
BTK Q06187 Y361 FSTIPELINyHQHNSAG 
BTK Q06187 Y375 SAGLISRLKyPVSQQNK 
BTK Q06187 Y511 CKDVCEAMEyLESKQFL 
BTK Q06187 Y551 LSRYVLDDEyTSSVGSK 
CBL P22681 Y337 LIDGFREGFyLFPDGRN 
CBL P22681 Y368 DHIKVTQEQyELYCEMG 
CBL P22681 Y371 KVTQEQYELyCEMGSTF 
CBL P22681 Y455 GAEGAPSPNyDDDDDER 
CBL P22681 Y552 PPPPPPDRPySVGAESR 
CBL P22681 Y674 KPSSSANAIySLAARPL 
CBL P22681 Y700 QCEGEEDTEyMTPSSRP 
CBL P22681 Y731 CDQQIDSCTyEAMYNIQ 
CBL P22681 Y774 EESENEDDGyDVPKPPV 
CBLB Q13191 Y363 KVTQEQYELyCEMGSTF 
CBLB Q13191 Y709 DPVEEDDDEyKIPSSHP 
CBLB Q13191 Y889 VKTNRTSQDyDQLPSCS 
CBLC Q9ULV8 Y144 LHALFPGGKyCGHMYQL 
CHN2 P52757 Y21 SSVSSDAEEyQPPIWKS 
CHN2 P52757 Y153 ISKMTTNPIyEHIGYAT 
CHN2 P52757 Y158 TNPIYEHIGyATLLREK 
CHN2 P52757 Y1087 PLLSSQRRSyAFETQAN 
CRK P46108 Y108 ALLEFYKIHyLDTTTLI 
CRK P46108 Y136 VILRQEEAEyVRALFDF 
CRK P46108 Y190 MIPVPYVEKyRPASASV 
CRK P46108 Y221 PLGGPEPGPyAQPSVNT 
CRK P46108 Y251 VIQKRVPNAyDKTALAL 
CRKL P46109 Y127 LPTAEDNLEyVRTLYDF 
CRKL P46109 Y132 DNLEYVRTLyDFPGNDA 
CRKL P46109 Y198 KHGNRNSNSyGIPEPAH 
CRKL P46109 Y207 YGIPEPAHAyAQPQTTT 






Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
CSK P41240 Y184 GTVAAQDEFyRSGWALN 
CSK P41240 Y263 VIVEEKGGLyIVTEYMA 
CTNNB1 P35222 Y30 AVSHWQQQSyLDSGIHS 
CTNNB1 P35222 Y64 EDVDTSQVLyEWEQGFS 
CTNNB1 P35222 Y86 EQVADIDGQyAMTRAQR 
CTNNB1 P35222 Y142 KHAVVNLINyQDDAELA 
CTNNB1 P35222 Y331 QALVNIMRTyTYEKLLW 
CTNNB1 P35222 Y333 LVNIMRTYTyEKLLWTT 
CTNNB1 P35222 Y489 MAQNAVRLHyGLPVVVK 
CTNNB1 P35222 Y654 HSRNEGVATyAAAVLFR 
CTNNB1 P35222 Y670 RMSEDKPQDyKKRLSVE 
CTNNB1 P35222 Y716 LGYRQDDPSyRSFHSGG 
DAB1 O75553 Y198 LEEDVEDPVyQYIVFEA 
DAB1 O75553 Y220 RDPETEENIyQVPTSQK 
DAB1 O75553 Y232 PTSQKKEGVyDVPKSQP 
DAB2 P98082 Y170 DLKDLFQVIyNVKKKEE 
DAB2 P98082 Y342 NGPLNGDVDyFGQQFDQ 
DOK1 Q99704 Y146 ALEMLENSLySPTWEGS 
DOK1 Q99704 Y203 ILEPLLSWPyTLLRRYG 
DOK1 Q99704 Y296 ELLDSPPALyAEPLDSL 
DOK1 Q99704 Y315 APCPSQDSLySDPLDST 
DOK1 Q99704 Y337 EGVQRKKPLyWDLYEHA 
DOK1 Q99704 Y341 RKKPLYWDLyEHAQQQL 
DOK1 Q99704 Y362 LTDPKEDPIyDEPEGLA 
DOK1 Q99704 Y377 LAPVPPQGLyDLPREPK 
DOK1 Q99704 Y398 CQARVKEEGyELPYNPA 
DOK1 Q99704 Y402 VKEEGYELPyNPATDDY 
DOK1 Q99704 Y409 LPYNPATDDyAVPPPRS 
DOK1 Q99704 Y449 GIKSHNSALySQVQKSG 
DOK2 O60496 Y139 RPCMEENELySSAVTVG 
DOK2 O60496 Y271 ASLPRPDSPySRPHDSL 
DOK2 O60496 Y299 PRPRGQEGEyAVPFDAV 
DOK2 O60496 Y345 TLPPRPDHIyDEPEGVA 
DOK3 Q7L591 Y208 LVPMEENSIySSWQEVG 
DOK3 Q7L591 Y381 EPNDLASGLyASVCKRA 
DOK3 Q7L591 Y432 SRSPTTSPIyHNGQDLS 






Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
DOK4 Q8TEW6 Y165 KLQITHENIyLWDIHNP 
DOK4 Q8TEW6 Y255 RLLNKGTEHySYPCTPT 
FER P16591 Y229 KALKGIFDEySQITSLV 
FER P16591 Y402 GKEPPPVVNyEEDARSV 
FER P16591 Y615 LQEAKILKQyDHPNIVK 
FER P16591 Y714 MSRQEDGGVySSSGLKQ 
FES P07332 Y156 RDSAQAKRKyQEASKDK 
FES P07332 Y261 AARIQPEAEyQGFLRQY 
FES P07332 Y614 LQEARILKQySHPNIVR 
FES P07332 Y713 MSREEADGVyAASGGLR 
FES P07332 Y811 GQRPSFSTIyQELQSIR 
FGR P09769 Y28 AGLEGDFRSyGAADHYG 
FGR P09769 Y34 FRSYGAADHyGPDPTKA 
FGR P09769 Y180 RESETTKGAySLSIRDW 
FGR P09769 Y208 KIRKLDMGGyYITTRVQ 
FGR P09769 Y209 IRKLDMGGYyITTRVQF 
FGR P09769 Y412 LARLIKDDEyNPCQGSK 
FGR P09769 Y523 DYFTSAEPQyQPGDQT- 
FRS2 Q8WU20 Y196 LVAEEQVHTyVNTTGVQ 
FRS2 Q8WU20 Y306 DAPSVNKLVyENINGLS 
FRS2 Q8WU20 Y349 AQRRTALLNyENLPSLP 
FRS2 Q8WU20 Y392 HNNLDPMHNyVNTENVT 
FRS2 Q8WU20 Y436 PSLEHRQLNyIQVDLEG 
FYN P06241 Y28 DGSLNQSSGyRYGTDPT 
FYN P06241 Y185 RESETTKGAySLSIRDW 
FYN P06241 Y213 KIRKLDNGGyYITTRAQ 
FYN P06241 Y214 IRKLDNGGYyITTRAQF 
FYN P06241 Y420 LARLIEDNEyTARQGAK 
FYN P06241 Y440 KWTAPEAALyGRFTIKS 
FYN P06241 Y531 DYFTATEPQyQPGENL- 
GAB1 Q13480 Y242 NGFFQQQMIyDSPPSRA 
GAB1 Q13480 Y259 PSASVDSSLyNLPRSYS 
GAB1 Q13480 Y285 SSTEADGELyVFNTPSG 
GAB1 Q13480 Y307 TQMRHVSISyDIPPTPG 
GAB1 Q13480 Y317 DIPPTPGNTyQIPRTFP 
GAB1 Q13480 Y373 RTASDTDSSyCIPTAGM 






Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
GAB1 Q13480 Y447 VSSEELDENyVPMNPNS 
GAB1 Q13480 Y472 FTEPIQEANyVPMTPGT 
GAB2 Q9UQC2 Y643 SVTSDEKVDyVQVDKEK 
GRAP2 O75791 Y45 KAELGSQEGyVPKNFID 
GRB10 Q13322 Y67 DMNASLESLySACSMQS 
GRB10 Q13322 Y404 RLLKYGMLLyQNYRIPQ 
GRB2 P62993 Y209 GQTGMFPRNyVTPVNRN 
GRB7 Q14451 Y107 ASRPHVVKVySEDGACR 
HCK P08631 Y127 RSLATRKEGyIPSNYVA 
HCK P08631 Y209 IRTLDNGGFyISPRSTF 
HCK P08631 Y411 LARVIEDNEyTAREGAK 
HCK P08631 Y515 YIQSVLDDFyTATESQY 
HCK P08631 Y522 DFYTATESQyQQQP--- 
HSH2D Q96JZ2 Y265 GDPTSGDRGyTDPCVAT 
INPPL1 O15357 Y671 RYERGSRDTyAWHKQKP 
INPPL1 O15357 Y886 ERLGTRERLyEWISIDK 
INPPL1 O15357 Y986 PKNSFNNPAyYVLEGVP 
INPPL1 O15357 Y987 KNSFNNPAYyVLEGVPH 
INPPL1 O15357 Y1135 MAKTLSEVDyAPAGPAR 
INPPL1 O15357 Y1162 QPPRGLPSDyGRPLSFP 
IRS1 P35568 Y46 EAGGPARLEyYENEKKW 
IRS1 P35568 Y465 ARGEEELSNyICMGGKG 
IRS1 P35568 Y612 SSTLHTDDGyMPMSPGV 
IRS1 P35568 Y632 PSGRKGSGDyMPMSPKS 
IRS1 P35568 Y662 HPQRVDPNGyMMMSPSG 
IRS1 P35568 Y732 GKLLPCTGDyMNMSPVG 
IRS1 P35568 Y896 PPEPKSPGEyVNIEFGS 
IRS1 P35568 Y941 REEETGTEEyMKMDLGP 
IRS1 P35568 Y989 RAVPSSRGDyMTMQMSC 
IRS1 P35568 Y1179 AGGLENGLNyIDLDLVK 
IRS1 P35568 Y1229 RRSSEDLSAyASISFQK 
IRS2 Q9Y4H2 Y628 SSPKVAYHPyPEDYGDI 
IRS2 Q9Y4H2 Y632 VAYHPYPEDyGDIEIGS 
IRS2 Q9Y4H2 Y653 SSNLGADDGyMPMTPGA 
IRS2 Q9Y4H2 Y675 GSGSCRSDDyMPMSPAS 
IRS2 Q9Y4H2 Y823 YTCGGDSDQyVLMSSPV 






Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
IRS4 O14654 Y743 RSPFEDSRGyMMMFPRV 
IRS4 O14654 Y921 QREADSSSDyVNMDFTK 
IRS4 O14654 Y1038 MALADSAIRyDAETGRI 
ITK Q08881 Y180 PEETVVIALyDYQTNDP 
ITK Q08881 Y512 MTRFVLDDQyTSSTGTK 
JAK2 O60674 Y119 HNVLYRIRFyFPRWYCS 
JAK2 O60674 Y221 KCIRAKIQDyHILTRKR 
JAK2 O60674 Y570 KGVRREVGDyGQLHETE 
JAK2 O60674 Y790 ANLINNCMDyEPDFRPS 
JAK2 O60674 Y813 DLNSLFTPDyELLTEND 
JAK2 O60674 Y931 RRNLKLIMEyLPYGSLR 
JAK2 O60674 Y956 RIDHIKLLQyTSQICKG 
JAK2 O60674 Y966 TSQICKGMEyLGTKRYI 
JAK2 O60674 Y1007 TKVLPQDKEyYKVKEPG 
JAK2 O60674 Y1008 KVLPQDKEYyKVKEPGE 
JAK3 P52333 Y785 DLNSLISSDyELLSDPT 
JAK3 P52333 Y904 RQSLRLVMEyLPSGCLR 
JAK3 P52333 Y939 SSQICKGMEyLGSRRCV 
JAK3 P52333 Y980 AKLLPLDKDyYVVREPG 
JAK3 P52333 Y981 KLLPLDKDYyVVREPGQ 
LCK P06239 Y192 IRNLDNGGFyISPRITF 
LCK P06239 Y394 LARLIEDNEyTAREGAK 
LCK P06239 Y505 DFFTATEGQyQPQP--- 
LCP2 Q13094 Y113 GWSSFEEDDyESPNDDQ 
LCP2 Q13094 Y128 DQDGEDDGDyESPNEEE 
LCP2 Q13094 Y145 EAPVEDDADyEPPPSND 
LCP2 Q13094 Y173 KPFPNSNSMyIDRPPSG 
LYN P07948 Y32 PVRNTERTIyVRDPTSN 
LYN P07948 Y117 KKEGFIPSNyVAKLNTL 
LYN P07948 Y193 KIRSLDNGGyYISPRIT 
LYN P07948 Y194 IRSLDNGGYyISPRITF 
LYN P07948 Y265 GQFGEVWMGyYNNSTKV 
LYN P07948 Y306 LQHDKLVRLyAVVTREE 
LYN P07948 Y316 AVVTREEPIyIITEYMA 
LYN P07948 Y397 LARVIEDNEyTAREGAK 
LYN P07948 Y460 DVMTALSQGyRMPRVEN 
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LYN P07948 Y501 YLQSVLDDFyTATEGQY 
LYN P07948 Y508 DFYTATEGQyQQQP--- 
MAPRE1 Q15691 Y124 FDANYDGKDyDPVAARQ 
NCK1 P16333 Y105 SFVDPGERLyDLNMPAY 
NCK1 P16333 Y112 RLYDLNMPAyVKFNYMA 
NCK1 P16333 Y268 LEPSPPQCDyIRPSLTG 
NCK2 O43639 Y50 VRNAANRTGyVPSNYVE 
NCK2 O43639 Y99 SPTPSTDAEyPANGSGA 
NCK2 O43639 Y110 ANGSGADRIyDLNIPAF 
PIK3C2B O00750 Y228 QGRLLGSVDyDGINDAI 
PIK3C2B O00750 Y685 YGFAEPYNLySSLKELV 
PIK3C2B O00750 Y1056 KGIVPRDCSyFNSNAVP 
PIK3C2G O75747 Y419 IRKYDFHLKyLLKTQEN 
PIK3C2G O75747 Y1437 SVPLDKEKWyPLGNSII 
PIK3CA P42336 Y508 SVSREAGFSySHAGLSN 
PIK3CB P42338 Y246 KEDEVSPYDyVLQVSGR 
PIK3CB P42338 Y425 STKTINPSKyQTIRKAG 
PIK3CB P42338 Y772 NPCVILSELyVEKCKYM 
PIK3CB P42338 Y962 RERVPFILTyDFIHVIQ 
PIK3CD O00329 Y440 QLKTGERCLyMWPSVPD 
PIK3CD O00329 Y484 LPEVAPHPVyYPALEKI 
PIK3CD O00329 Y485 PEVAPHPVYyPALEKIL 
PIK3CD O00329 Y524 LERRGSGELyEHEKDLV 
PIK3CD O00329 Y936 RERVPFILTyDFVHVIQ 
PIK3R1 P27986 Y368 DASTKMHGDyTLTLRKG 
PIK3R1 P27986 Y452 EAVGKKLHEyNTQFQEK 
PIK3R1 P27986 Y463 TQFQEKSREyDRLYEEY 
PIK3R1 P27986 Y467 EKSREYDRLyEEYTRTS 
PIK3R1 P27986 Y470 REYDRLYEEyTRTSQEI 
PIK3R1 P27986 Y528 KEIQRIMHNyDKLKSRI 
PIK3R1 P27986 Y556 EDLKKQAAEyREIDKRM 
PIK3R1 P27986 Y580 IQLRKTRDQyLMWLTQK 
PIK3R1 P27986 Y607 LGNENTEDQySLVEDDE 
PIK3R1 P27986 Y699 YGFAEPYNLySSLKELV 
PIK3R2 O00459 Y365 DASSKIQGEyTLTLRKG 
PIK3R2 O00459 Y464 DKSREYDQLyEEYTRTS 
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PIK3R2 O00459 Y605 GIKNETEDQyALMEDED 
PIK3R3 Q92569 Y195 SQYQEKSKEyDRLYEEY 
PIK3R3 Q92569 Y199 EKSKEYDRLyEEYTRTS 
PIK3R3 Q92569 Y202 KEYDRLYEEyTRTSQEI 
PIK3R3 Q92569 Y341 IKNEDADENyFINEEDE 
PLCG1 P19174 Y472 HKKLAEGSAyEEVPTSM 
PLCG1 P19174 Y481 YEEVPTSMMySENDISN 
PLCG1 P19174 Y771 EKIGTAEPDyGALYEGR 
PLCG1 P19174 Y775 TAEPDYGALyEGRNPGF 
PLCG1 P19174 Y783 LYEGRNPGFyVEANPMP 
PLCG1 P19174 Y977 EKIGTERACyRDMSSFP 
PLCG1 P19174 Y1253 AREGSFESRyQQPFEDF 
PLCG2 P16885 Y733 SLYRKMRLRyPVTPELL 
PLCG2 P16885 Y743 PVTPELLERyNMERDIN 
PLCG2 P16885 Y753 NMERDINSLyDVSRMYV 
PLCG2 P16885 Y759 NSLYDVSRMyVDPSEIN 
PLCG2 P16885 Y780 QRTVKALYDyKAKRSDE 
PLCG2 P16885 Y1197 PVLESEEELySSCRQLR 
PLCG2 P16885 Y1217 EELNNQLFLyDTHQNLR 
PLCG2 P16885 Y1245 SVNENQLQLyQEKCNKR 
PTK2 Q05397 Y5 -----MAAAyLDPNLNH 
PTK2 Q05397 Y148 EDKPTLNFFyQQVKSDY 
PTK2 Q05397 Y155 FFYQQVKSDyMLEIADQ 
PTK2 Q05397 Y397 AVSVSETDDyAEIIDEE 
PTK2 Q05397 Y407 AEIIDEEDTyTMPSTRD 
PTK2 Q05397 Y441 QFGDVHQGIyMSPENPA 
PTK2 Q05397 Y570 KLGDFGLSRyMEDSTYY 
PTK2 Q05397 Y576 LSRYMEDSTyYKASKGK 
PTK2 Q05397 Y577 SRYMEDSTYyKASKGKL 
PTK2 Q05397 Y720 APPKPSRPGyPSPRSSE 
PTK2 Q05397 Y861 QGPIGNQHIyQPVGKPD 
PTK2 Q05397 Y925 NLDRSNDKVyENVTGLV 
PTK2 Q05397 Y1007 INKMKLAQQyVMTSLQQ 
PTK2B Q14289 Y402 ESCSIESDIyAEIPDET 
PTK2B Q14289 Y579 LSRYIEDEDyYKASVTR 
PTK2B Q14289 Y580 SRYIEDEDYyKASVTRL 
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PTK2B Q14289 Y699 AMEQERNARyRTPKILE 
PTK2B Q14289 Y722 PPPKPSRPKyRPPPQTN 
PTK2B Q14289 Y756 SPTLTSPMEyPSPVNSL 
PTK2B Q14289 Y819 KQQKQMVEDyQWLRQEE 
PTK2B Q14289 Y834 EEKSLDPMVyMNDKSPL 
PTK2B Q14289 Y849 PLTPEKEVGyLEFTGPP 
PTK2B Q14289 Y881 NLDRTDDLVyLNVMELV 
PTK2B Q14289 Y906 ELCQLPPEGyVVVVKNV 
PTK6 Q13882 Y114 RVSEKPSADyVLSVRDT 
PTK6 Q13882 Y342 LARLIKEDVyLSHDHNI 
PTK6 Q13882 Y351 YLSHDHNIPyKWTAPEA 
PTK6 Q13882 Y447 RERLSSFTSyENPT--- 
PTPN11 Q06124 Y62 HIKIQNTGDyYDLYGGE 
PTPN11 Q06124 Y63 IKIQNTGDYyDLYGGEK 
PTPN11 Q06124 Y279 RQENKNKNRyKNILPFD 
PTPN11 Q06124 Y304 GDPNEPVSDyINANIIM 
PTPN11 Q06124 Y546 QKSKRKGHEyTNIKYSL 
PTPN11 Q06124 Y584 EMREDSARVyENVGLMQ 
PTPN6 P29350 Y301 RDSNIPGSDyINANYIK 
PTPN6 P29350 Y374 TREVGMQRAyGPYSVTN 
PTPN6 P29350 Y377 VGMQRAYGPySVTNCGE 
PTPN6 P29350 Y390 NCGEHDTTEyKLRTLQV 
PTPN6 P29350 Y536 QSQKGQESEyGNITYPP 
PTPN6 P29350 Y541 QESEYGNITyPPAMKNA 
PTPN6 P29350 Y564 TSSKHKEDVyENLHTKN 
RASA1 P20936 Y239 FRIIAMCGDyYIGGRRF 
RASA1 P20936 Y460 NDTVDGKEIyNTIRRKT 
RASA1 P20936 Y615 LPVKHFTNPyCNIYLNS 
RIN1 Q13671 Y36 REKPAQDPLyDVPNASG 
RIN1 Q13671 Y632 CFQHLLRVAyQDPSSGC 
SH2B1 Q9NRF2 Y55 RLYLASHPQyAGPGAEA 
SH2B3 Q9UQQ2 Y273 TRLEMPDNLyTFVLKVK 
SH2D2A Q9NP31 Y39 TRRSCQNLGyTAASPQA 
SH2D2A Q9NP31 Y216 SKSQDPNPQySPIIKQG 
SH2D2A Q9NP31 Y260 AKPQLPPEVyTIPVPRH 
SH2D2A Q9NP31 Y280 PRPKPSNPIyNEPDEPI 
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SH2D2A Q9NP31 Y305 SPGEAPSNIyVEVEDEG 
SH2D3A Q9BRG2 Y16 GEDLAGQPWyHGLLSRQ 
SH2D3A Q9BRG2 Y95 PSIPALVHSyMTGRRPL 
SH2D3A Q9BRG2 Y231 PDASERPPTyCELVPRV 
SH2D3C Q8N5H7 Y183 AGEPEAGSDyVKFSKEK 
SH2D3C Q8N5H7 Y495 SYSDPDSGHyCQLQPPV 
SH3BP2 P78314 Y174 SPYPTDNEDyEHDDEDD 
SH3BP2 P78314 Y183 YEHDDEDDSyLEPDSPE 
SH3BP2 P78314 Y448 TGGDDSDEDyEKVPLPN 
SHB Q15464 Y96 QKERDFEDPyNGPGSSL 
SHB Q15464 Y114 KLRAMCRLDyCGGSGEP 
SHB Q15464 Y246 KDKVTIADDySDPFDAK 
SHB Q15464 Y268 KAGKGESAGyMEPYEAQ 
SHB Q15464 Y272 GESAGYMEPyEAQRIMT 
SHB Q15464 Y297 RSQHKGIQLyDTPYEPE 
SHB Q15464 Y301 KGIQLYDTPyEPEGQSV 
SHB Q15464 Y336 QDDDRPADEyDQPWEWN 
SHC1 P29353 Y349 EEEEPPDHQyYNDFPGK 
SHC1 P29353 Y350 EEEPPDHQYyNDFPGKE 
SHC1 P29353 Y427 GRELFDDPSyVNVQNLD 
SHC3 Q92529 Y341 EEGDGSDHPyYNSIPSK 
SHC3 Q92529 Y342 EGDGSDHPYyNSIPSKM 
SHC3 Q92529 Y379 AQFAGKEQTyYQGRHLG 
SHC3 Q92529 Y380 QFAGKEQTYyQGRHLGD 
SHC3 Q92529 Y406 PLRQGSSDIySTPEGKL 
SHC3 Q92529 Y424 DASSKIQGEyTLTLRKG 
SOS1 Q07889 Y1065 LQQEPRKISySRIPESE 
SRC P12931 Y187 RESETTKGAyCLSVSDF 
SRC P12931 Y216 IRKLDSGGFyITSRTQF 
SRC P12931 Y338 YAVVSEEPIyIVTEYMS 
SRC P12931 Y419 LARLIEDNEyTARQGAK 
SRC P12931 Y438 KWTAPEAALyGRFTIKS 
SRC P12931 Y521 EYLQAFLEDyFTSTEPQ 
SRC P12931 Y530 DYFTSTEPQyQPGENL- 
STAT1 P42224 Y203 QEQLLLKKMyLMLDNKR 
STAT1 P42224 Y701 ELDGPKGTGyIKTELIS 






Table 3.1 Adaptor Phosphopeptides  (Continued) 
 
STAT2 P52630 Y690 KVNLQERRKyLKHRLIV 
STAT3 P40763 Y539 EKLLGPGVNySGCQITW 
STAT3 P40763 Y686 IPKEEAFGKyCRPESQE 
STAT3 P40763 Y705 EADPGSAAPyLKTKFIC 
STAT4 Q14765 Y355 LLIKLPELNyQVKVKAS 
STAT4 Q14765 Y693 RPTERGDKGyVPSVFIP 
STAT5A P42229 Y90 FLLKIKLGHyATQLQKT 
STAT5A P42229 Y694 PVLAKAVDGyVKPQIKQ 
STAT5B P51692 Y90 FLLKIKLGHyATQLQNT 
STAT5B P51692 Y665 LADRLGDLNyLIYVFPD 
STAT5B P51692 Y679 FPDRPKDEVySKYYTPV 
STAT5B P51692 Y699 SATAKAVDGyVKPQIKQ 
STAT5B P51692 Y725 ADAGGGSATyMDQAPSP 
STAT5B P51692 Y740 SPAVCPQAHyNMYPQNP 
STAT5B P51692 Y743 VCPQAHYNMyPQNPDSV 
STAT6 P42226 Y641 EQMGKDGRGyVPATIKM 
SYK P43405 Y74 TIERELNGTyAIAGGRT 
SYK P43405 Y203 IRARDNNGSyALCLLHE 
SYK P43405 Y244 DTLWQLVEHySYKADGL 
SYK P43405 Y296 GGIISRIKSySFPKPGH 
SYK P43405 Y323 QESTVSFNPyEPELAPW 
SYK P43405 Y348 EALPMDTEVyESPYADP 
SYK P43405 Y352 MDTEVYESPyADPEEIR 
SYK P43405 Y525 SKALRADENyYKAQTHG 
SYK P43405 Y526 KALRADENYyKAQTHGK 
SYK P43405 Y568 GVLMWEAFSyGQKPYRG 
TEC P42680 Y206 DLRLERGQEyLILEKND 
TEC P42680 Y228 ARDKYGNEGyIPSNYVT 
TEC P42680 Y519 MARYVLDDQyTSSSGAK 
TENC1 Q63HR2 Y483 TRGPLDGSPyAQVQRPP 
TNS1 Q9HBL0 Y168 QPSQRRYVHyFSGLLSG 
TNS1 Q9HBL0 Y327 ENGPSVSVDyNTSDPLI 
TNS1 Q9HBL0 Y339 SDPLIRWDSyDNFSGHR 
TNS1 Q9HBL0 Y366 TQGPLDGSLyAKVKKKD 
TNS1 Q9HBL0 Y609 WPQPVTTSHyAHDPSGM 
TNS1 Q9HBL0 Y766 HPLTQSRSGyIPSGHSL 
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TNS1 Q9HBL0 Y903 RRRAASDGQyENQSPEA 
TNS1 Q9HBL0 Y1144 SPLPTVGSSySSPDYSL 
TNS1 Q9HBL0 Y1149 VGSSYSSPDySLQHFSS 
TNS1 Q9HBL0 Y1254 SLCRHPAGVyQVSGLHN 
TNS1 Q9HBL0 Y1323 SPCLDRHVAyGGYSTPE 
TNS1 Q9HBL0 Y1326 LDRHVAYGGySTPEDRR 
TNS1 Q9HBL0 Y1345 LSRQSSASGyQAPSTPS 
TNS1 Q9HBL0 Y1404 GDRAGSLPNyATINGKV 
TNS1 Q9HBL0 Y1440 SHTLPDFSKySMPDNSP 
TNS4 Q8IZW8 Y150 EESEALDIKyIEVTSAR 
TNS4 Q8IZW8 Y284 SASPVSDVSyMFGSSQS 
TXK P42681 Y91 EEKIQVKALyDFLPREP 
TXK P42681 Y420 MTRYVLDDEyVSSFGAK 
VAV1 P15498 Y142 EESVGDEDIySGLSDQI 
VAV1 P15498 Y160 DTVEEDEDLyDCVENEE 
VAV1 P15498 Y174 NEEAEGDEIyEDLMRSE 
VAV1 P15498 Y280 IKYKERFLVyGRYCSQV 
VAV1 P15498 Y791 KYFGTAKARyDFCARDR 
VAV1 P15498 Y826 QQGWWRGEIyGRVGWFP 
VAV2 P52735 Y142 ETTENDDDVyRSLEELA 
VAV2 P52735 Y159 DEHDLGEDIyDCVPCED 
VAV2 P52735 Y172 PCEDGGDDIyEDIIKVE 
VAV3 Q9UKW4 Y173 YGEDEGGEVyEDLMKAE 
YES1 P07947 Y32 EPVSTSVSHyGAEPTTV 
YES1 P07947 Y194 RESETTKGAySLSIRDW 
YES1 P07947 Y222 KIRKLDNGGyYITTRAQ 
YES1 P07947 Y223 IRKLDNGGYyITTRAQF 
YES1 P07947 Y426 LARLIEDNEyTARQGAK 
YES1 P07947 Y446 KWTAPEAALyGRFTIKS 
YES1 P07947 Y537 DYFTATEPQyQPGENL- 
ZAP70 P43403 Y46 RQCLRSLGGyVLSLVHD 
ZAP70 P43403 Y69 PIERQLNGTyAIAGGKA 
ZAP70 P43403 Y126 CLRDAMVRDyVRQTWKL 
ZAP70 P43403 Y164 TTAHERMPWyHSSLTRE 
ZAP70 P43403 Y178 TREEAERKLySGAQTDG 
ZAP70 P43403 Y248 LKLKADGLIyCLKEACP 
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ZAP70 P43403 Y315 RPMPMDTSVyESPYSDP 
ZAP70 P43403 Y319 MDTSVYESPySDPEELK 
ZAP70 P43403 Y474 RNVLLVNRHyAKISDFG 
ZAP70 P43403 Y492 SKALGADDSyYTARSAG 








































 High throughput approaches have led to an explosion of data on SH2 domain-mediated 
interactions. Despite this, there are two critical issues that limit their utility to biologists: 
completeness and accuracy. The continued discovery of new phosphorylation sites as well as 
mutations affecting these sites will ensure that an experimental dataset will be incomplete as 
soon as it is collected. Moreover, as is the limitation with all experimental approaches, the 
dataset will invariably contain false positive and false negatives. Further complicating the issue 
is that there is no confidence score associated with most interactions, meaning that large-scale 
datasets are potentially erroneous in unknown ways. 
 One can try to come to grips with these problems in an ad hoc manner. For example, if a 
researcher discovers a new phosphorylation site and is curious as to what it might interact with, 
they can find the closest peptide by sequence. However, two sequences might be very similar in 
regions that are irrelevant for SH2 domain recognition. To overcome this challenge the 
researcher will apply prior knowledge from crystal structures as to which residues make contact 
with the domain and are therefore likely to be of importance. To deal with the question of 
accuracy, one can also evaluate how similar a given interaction is to other related peptide-
domain pairs in the dataset. If it is more similar to the binders, then it is more likely to be a true 
positive interaction. The utility of ad hoc mental models for the task of identifying new 
interactions is nevertheless limited and this has spurred the creation of computational predictive 









Table 4.1: Summary of predictive SH2 domain models. There are five models that have 
previously been developed to analyze SH2 domains.  PSSM models have been the most popular 
in part because they are directly measured from experiment. All models use almost exclusively 
one data type to build the predictor. 
 
Method Name Model Type Training Data Reference 
Scansite  PSSM Peptide Library 
(Obenauer, 
Cantley, and Yaffe 
2003) 
SMALI PSSM OPAL (Huang et al. 2008) 
DomPep PSSM OPAL (Li et al. 2011) 
NetPhorest NN Peptide Array (Miller et al. 2008) 





The most common strategy, employed by the Scansite, SMALI and DomPep methods is 
to generate a position specific scoring matrix (PSSM). For the Scansite method, the underlying 
data are derived from a degenerate peptide library that is incubated with a target domain. The 
binding peptides are then isolated and sequenced by Edman degradation. In the oriented peptide 
library (OPAL) approach used by SMALI, a single residue is fixed at a given position. The 
peptides are synthesized on a membrane using the SPOTs method (Frank 2002) and incubated 
with a domain. Differences in spot intensity for the various mutants are used to infer peptide 
selectivity at a given position. Because of experimental uncertainty in the derived PSSMs, the 
same group that developed SMALI also derived an approach, termed DomPep, that would 
average similar PSSMs from sequence-related domains and find improvements in performance 
(Li et al. 2011). 
NetPhorest incorporates the PSSMs of SMALI and Scansite but also trains neural 
network (nn)-based models on peptide array data that were collected by the Cesarini lab (Miller 






method is an ensemble of optimal domain-specific models. The limitation of domain-specific 
models is that they do not allow for evidential support from closely related domains such as for 
example Crk and CrkL, which share many of the same binding partners. 
The Wunderlich model (Wunderlich and Mirny 2009) provides the principle foundation 
for the model that we will adopt in our approach. The model starts with the intuitive premise that 
the energy of binding of a given peptide and domain pair is the summation of the energies of all 
the amino acid – amino acid (AA-AA) contacts between the two. By incorporating structural 
information from SH2 domain-peptide complexes, Wunderlich and Mirny derived a contact map 
and fit an energy potential that maximally segregated the previously determined (Jones et al. 
2005) binding and non-binding complexes. The principle limitation of this approach is that it fits 
a single energy potential, thereby assuming that every contact has an identical energy profile. 
This was primarily driven by the limitation of using a small training dataset (190 positive 
interactions), which does not have enough information to constrain a more complex model and 
would therefore result in overfitting. 
The success of a computational modeling endeavor is dependent on many things 
including the choice of a suitable modeling approach, accuracy and diversity of the underlying 
training data, and the inclusion of prior knowledge.  Despite their success, we postulated that 
previous efforts can be improved in all these criteria. As a modeling approach, PSSMs are not 
very suitable for SH2 domains because they assume that all positions contribute equally to 
binding. This is in contradiction with knowledge about SH2 domain biology. All methods 
previous have also used almost exclusively a single data source for their training information. 
This allows for easy standardization and comparison of data points but incurs the risk of 






of the additional knowledge such as structure and amino acid composition of the SH2 domains to 
improve their performance. 
 
RESULTS AND DISUCSSION 
4.2 Model Inputs 
To expand beyond the previous modeling approaches, we made several improvements. 
We expanded the training data to include data derived from multiple publications (Table 4.2) 
spanning distinct assay types, including domain array (Koytiger et al. 2013), peptide array 
(Miller et al. 2008; B. A. Liu et al. 2012) and solution phase fluorescence polarization (Hause et 
al. 2012). We also sought to further expand the data types to use additional peptide array data 
(Huang et al. 2008) as well as low throughput experimental data annotated by Phospho.ELM 
(Dinkel et al. 2011) and PhosphositePlus (Hornbeck et al. 2011). 
 
Table 4.2: Input binding data for model training. We collated all available systematic data 
collection efforts on SH2 domain binding for model training across multiple assay types. 
 
Data Type Peptide # Domain # Binding # Reference 
Domain Array 724 88 2114 Koytiger et al. 2013 
Peptide Array 981 69 8114 Miller et al. 2008b 
Peptide Array 191 40 730 B. A. Liu et al. 2012 
FP 72 74 213 Hause et al. 2012 
 
 
The expansion of training data allows us to also use an improved modeling approach with 
minimal built in assumptions. However, there are two key assumptions in our model. The first is 






binder” is related to the energy of binding, which is the linear summation of the energy of the 
individual domain-peptide contacts (Figure 4.1).  
 
 
Figure 4.1: Schematic representation of the structure model. Amino acids on the SH2 
domain (blue) make contact (red lines) with the amino acids on the peptide (green). These 
interactions can be either repulsive or attractive and when summed correspond to the overall  
energy of the interaction between a peptide and a domain 
 
We used 25 structures of SH2 domains in complex with peptide ligands, downloaded 






structures, all domains and structures were aligned to the 106 amino acid Hidden Markov Model 
(HMM) profile of the SH2 domain from the SCOP database (Andreeva et al. 2007). The 
advantages of using a previously verified alignment over an in-house-generated multiple 
sequence alignment are that SCOP uses structural information to guide the alignment and that the 
entirety of SH2 domain sequence knowledge is used for the alignment instead of just the 
domains under study here. The SCOP HMM also generates a high quality, largely gap free 
alignment of the domains in a manner that is wholly transparent and reproducible by other 
researchers. We also standardized all peptides to 15-mer length, with the 8th position being the 
phosphotyrosine.  
We also made the approximation that the contact map among different domain-peptide 
pairs is the same. This is justified by analysis of the entirety of the solved structures of SH2 – 
phosphopeptide complexes showing minimal variation in the contact distances (Figure 4.2). 
When determining the contact distance we use the distance between the two closest atoms 







Table 4.3: SH2 Domain structures used in model construction. Each structure was retrieved 
from the PDB, aligned to the SCOP SH2 domain HMM and used to compute the average contact 





















































Figure 4.2 SH2-peptide complexes are structurally similar. (A) Average contact map of all 
structures of SH2 domain- peptide complexes. The x-axis corresponds to positions on the SH2 
domain aligned to the SCOP HMM and the y-axis to positions on the peptide. The darker the 
boxes indicate closer distances between the positions structurally. (B) Distribution of contact 
distances of all the structures. The blue sheet represents the average distance, the green sheet the 
minimal distance and the red the maximum. Areas where distance is 0 indicate regions of no 
data. 
 
4.3 Model Fitting 
The amino acid sequence of the peptide and SH2 domain are represented as a series of 21 
× 21 matrices (20 amino acid types plus a gap value). There is a single positive entry in this 






the peptide, this makes for 106×15 or 1590 pairwise interaction pairs. These inputs are then 
concatenated and reshaped into an input vector of length 701,190 (106×15×21×21).   
Since the number of input features is much larger than the training data, there is a great 
chance of model overfitting. This risk is mitigated in two ways: removing all features past a 
certain cutoff distance and using an L1 penalty for model complexity. L1 penalty’s effect is to 
shrink the coefficients of most parameters to 0, thus giving a sparse solution (Hastie, Tibshirani, 
and Friedman 2009). It requires as its input, a parameter lambda which dictates how aggressively 
this shrinkage will occur. This is intuitively useful, since we know in biology that recognition 
occurs by direct contact with a subset of positions.  Since we do not know a priori what is the 
optimal cutoff distance and lambda parameter, we use a cross validation approach to empirically 
determine their values (Figure 4.3). We perform 6-fold cross-validation, training the model on 
5/6ths of the dataset and assessing its performance on the remaining 1/6th. How we evaluated the 







Figure 4.3: Landscape of model performance. Shows the cross validation performance results 




 Because the actual modeling work was performed by my collaborator, Dr. Mohammed 
AlQuarashi, I will not discuss this work in great detail in this thesis. However, by framing the 
model as described above, we were able to derive a sparse, stable solution to the energetic 
contribution of each position. We found that a 15 angstrom cutoff distance optimized cross 
validation performance while balancing computational complexity of the model. The output of 
the model is a probability which can be directly interpretted as the probability in the training data 










Figure 4.4: Model probabilities are equivalent to experimental probabilities. Bins of data are 
taken along different model output probabilities (x-axis) and determined what fraction binds (y-






 The energetic terms fit by the model also largely behave as we would expect them to 
from biological intuition. Oppositely charged amino acids tend to favor binding and also distant 
contacts tend to have weaker energetic contributions to binding as compared to closer contacts 
(Figure 4.5). These intuitions were not included in the formulation of the model a priori and 
indicate that part of the performance of the model is likely due to its capturing information about 
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Figure 4.5: Energy matrices fit by the model (A) Peptide positions are in the y-axis and 
domain positions are in the x-axis. Every square at the intersection contains a predicted 21 x 2`1 
energy matrix (all amino acids plus gap value). The color indicates the sum of the terms in the 
matrix with blue indicating attraction and red indicating repulsion. (B) Average interaction 
matrix from all position pairs. Note the general recapitulation of known attraction between 
oppositely charged amino acids (K-E, D-R, etc.) (C) Potentials as they change by distance. Note 
the higher level of activity in more proximal pairs. Recapitulates known behavior of interactions 









3.4 Assessing Model Performance 
To assess the performance of the model and to facilitate its comparison to other modeling 
efforts, we use the area under the curve (AUC) of the receiver operating characteristic (ROC) 
(Mason and Graham 2002). Since our input data are largely negative (92%), we cannot use 
simple accuracy measures as a model would get 92% accuracy simply by assigning every 
prediction as non-binding. ROC curves are generated by plotting the true positive rate (TPR) or 
sensitivity of the model on the y-axis and the false positive rate (FPR) or the 1-specificity of the 
model on the x-axis. The equations for the two are: 
!!" = ! !"!" + !" !!!!!!!!!!!!!!"# = ! !"!" + !" 
 
 where TP is the number of true positives (predicted binding events that are 
experimentally confirmed), FN is the number of false negatives (predicted non-binding events 
that are experimentally determined to be binding), FP is the number of false positives (predicted 
binding events that are experimentally shown to be negative), and TN is the number of true 
negatives (correctly predicted non-binding events). The ROC curve is generated by relaxing the 
threshold by which the model calls a positive interaction, gradually bringing in lower confidence 
predictions and calculating the TPR and FPR at each threshold. Because this analysis can be 
confounded by experimental error in the training data, we chose to use the solution phase 
fluorescence polarization dataset (Hause et al. 2012), which is liable to be the highest quality. 
The fluorescence polarization data constitute 72 phospho-peptides derived from all tyrosine sites 
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Figure 4.6: Reciever operating characteristic (ROC) curves of predictive models  (A) 
Assesses the performance of 5 available predictors across the 72 peptides analyzed by 
fluorescence polarization of 15 domains common to all the predictors. This corresponds to 146 
positive and 2842 negative interactions. Numbers in bold show the area under the curve (AUC), 
for reference, a perfect predictor would have an AUC of 1 and a random predictor 0.5. 
(B) Similar to (A) but eliminates the Scansite predictor, which allows comparison of a larger 
subset of domains, 58 in total. All predictors here perform worse indicating these domains are 
harder to predict. (C) Restricts the analysis to the 6 peptides which have FP experimental 
replicates using larger peptides. The “scores” from the FP assay are their association constants. 




To compare the predictors in a fair way, we constructed ROC curves only on domains 
modeled by all of them. By taking the area under the curve (AUC) of the ROC curve, we get an 
unbiased metric of the performance of the predictors. For reference, a random predictor will have 






predictor will have and AUC of 1.0, corresponding to predicting all true positives and no false 
positives at all thresholds. When comparing all predictors, we see that the model described here 
substantially outperforms every other published method, with an AUC of 0.93 compared to the 
next nearest predictor of 0.79 (Figure 4.6A). Another way to assess model performance is to 
compare only on high confidence region of predictions, for example, only those that correspond 
to a false positive rate of 5%. At such a FPR, our model has a true positive rate (TPR) of 75%, 
whereas the next most accurate model, Scansite, has a 50% TPR. Since Scansite only offers 
predictions for a small subset of all human SH2 domains, we can also look more broadly by 
eliminating it from the analysis (Figure 4.6B). In this larger and more diverse subset of domains, 
our model still outperforms all other predictors with an AUC of 0.86 compared to 0.70 for the 
nearest predictor, DomPep.  Similarly at 5% FPR, Dompep has 40% TPR while our model has a 
60% TPR. In both tests, our model is able to predict 50% more accurately than previously 
developed methods.  
The ultimate test, however, is if the model can perform as well as high quality 
experimental data. To assess this, we again used the data of Hause et al.. In this case, we relied 
on experiments in which they re-probed 6 peptides using a slightly longer version of the peptide 
(18 vs 13-mers). As the additional length is far away from the SH2 domain binding site, this 
change should have no effect on the assay results. The peptides were probed on average  three 
times and the average KD was calculated. This should result in a very high quality dataset, better 
than most high throughput experimental data that were used to train our model. We assigned the 
score for the “predictions” of the 18-mers as being the association constant, because we reasoned 
that the stronger the binding, the more likely the interaction is to be real and rediscovered. As 






0.86. At 5% FPR, the 18-mer FP “predictions” have a TPR of 68%, whereas our model’s 
performance over this same subset is 51%, indicating the experiment is still better at high 
confidence threshold. However, as the two experiments are of the same type, they probably share 
similar systematic errors, including similar domains and peptide artifacts. The experiment was 
also not performed blind, thus replication of non-agreeing data points is likely. In the future, we 
will use for our “gold standard” data points which come at the intersection of these different 
assays. That is, we will count high confidence binding and non-binding events, those that have 
support from at least two distinct assays.  
3.5 Applying the model to study cancer 
 A functioning, high quality model allows us to derive an unbiased protein-protein 
interaction network mediated by phosphotyrosine. To do this, we extracted all known 
phosphorylation sites from PhosphositePlus (Hornbeck et al. 2011) and remove all sites that only 
have one reference to minimize spurious phosphorylation events. We then predicted, using our 
model, the SH2 domain binding profile of each site and integrated the probabilities to achieve an 
overall probability that the SH2 domain-containing and phosphotyrosine-containing proteins will 
interact. The resulting graph is shown in Figure 4.6 and represents a cutoff of 50% confidence in 
an interaction. This cutoff was chosen to ease visualization as the network increases rapidly in 
size as the threshold is lowered. As anticipated, the predicted network captures many known 
interactions (e.g. PI3K family with ERRB3, CRK family with BCAR1/p130Cas among others) 






investigating the biological relevance of some of these predicted interactions.
 
Figure 4.7: Proteome wide wild type signaling network.  Purple and pink circles indicate SH2 
domain containing proteins. Blue and pink circles indicate phosphotyrosine containing proteins. 
Arrows start from the SH2 protein and end at the phosphotyrosine protein. Horizontal white lines 
indicate oncogenes and vertical white lines indicate tumor suppressors. 
 
 Phosphotyrosine signaling plays a well-documented role in cancer. It is not surprising, 
therefore, that many of the somatic mutations being discovered by high throughput sequencing 
methods modify regions of sequence surrounding sites of tyrosine phosphorylation as well as 
regions of the SH2 domain. Our model potentially provides insight into how such mutations 
could rewire phosphotyrosine signaling networks. To investigate this application, we extracted 






(Bamford et al. 2004) and mapped them onto sites of tyrosine phosphorylation using a custom 
built MATLAB pipeline. This yielded in excess of 58,000 cancer mutations that affect sites of 
tyrosine phosphorylation (although significantly fewer if one only considers high confidence 
sites of tyrosine phosphorylation). Many of the SNPs are identical in sequence but come from 
multiple samples or affect the same phosphorylation site; this gives us an additional genomic 
prior when interpreting the data. We can compute the probability that, given a random mutation 
that affects the sequence surrounding a site of tyrosine phosphorylation, it will affect a protein-
protein interaction, either by forming a new interaction or removing an existing interaction. We 
perform this analysis on individual cancer types in the data and map the interactions that are 
highly likely to get rewired (Figure 4.7). We are seeking to experimentally validate the predicted 
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Figure 4.8: Integrated probabilities of network rewiring. Likely new edges are colored green, 
likely destroyed edges are colored in orange. For additional information on interpreting the 
graph, see the caption for Figure 4.6.  
 
 We are also seeking to expand the analysis further to understand network rewiring from 
short deletions, truncations, insertions and rearrangements. Another avenue of analysis is to 
incorporate protein expression levels from mRNAseq data to understand how fluctuations in 






the information will come from the TCGA project’s efforts in characterizing tumor samples (T. 
C. G. A. R. Network 2011) from a wide variety of cancer types. The model provides the 
organizing framework to facilitate our understanding of how networks function under changing 
contexts and how they are rewired to promote oncogenesis. This process is performed in a 
completely unbiased manner, which has the potential to shed light on interesting new biology 
and hopefully ultimately inform patient treatment. 
Another avenue of research enabled by the model is a result of its capacity to take as its 
input an arbitrary SH2 domain. Researchers studying model organism systems such as mice can 
generate similar interaction graphs as those highlighted here for mouse SH2 domains. Knowing 
where the networks are similar to humans and where they diverge can facilitate cross-species 
comparative network biology. This can also be useful when studying drug action and efficacy in 
other organisms, to understand where an animal is an appropriate model system. Relevant pre-
clinical results are more likely from networks that are predicted to be highly conserved cross-
species.  
 In conclusion, the modeling work presented here enables multiple areas of further 
research. To facilitate this, we plan to develop an accessible web-based tool that will allow the 
































 In this chapter, I will speculate as to the implications of the research presented above and 
the overall future direction of the field. Largely this chapter will discuss how this and related 
work is supplementing our current understanding of molecular biology, which is based on mental 
models and taxonomy. What is emerging is a more holistic and systematic understanding enabled 
by large-scale data and computation, where the criterion of understanding is prediction. 
5. 1 From Molecular Machines to Pleomorphic Ensembles 
 Much of our current understanding of biology comes from pioneering discovery studies 
that would identify a new gene and attempt to characterize its particular function. However, it is 
now understood that genes do not convey function in isolation. Conversely, most traits are 
complex; there is no single “obesity gene” for instance. The study of protein interactions has also 
started with with publication of a new protein-protein interaction followed by some basic 
characterization as to “what it does.” This too is reductionist as proteins interactions are 
embedded in a dense network, in which function changes with context and fluctuation in 
concentration. The explosion of characterized biochemical interactions resulting from high 
throughput and predictive approaches has provided a challenge in understanding what they all 
do. 
 The common framework for understanding such interactions is to imagine protein 
complexes as molecular machines that carry out some discrete function. An example of this 
would be the complexes nucleated by an RTK and GRB2, namely GRB2-SOS1 and GRB2-
GAB1. The RTK-GRB2-SOS1 machine recruits and activates the components of the MAPK 
pathway (as described in the introduction) and RTK-GRB2-GAB1 has a similar function for the 






is one of the foundational pieces of “what we really know” about RTK signaling. The diagrams 
and the mental models implicitly assume that identity of the RTK is irrelevant and the 
concentrations of the components of this machine are irrelevant except in the trivial case where 
the components are non-expressed. These mental models simply cannot integrate a piece of 
information such as a recent study showing that in signaling downstream of the RTK RON 
(MST1R), which is very closely related to MET, GRB2 plays an antagonistic role in activation 
of the MAPK and PI3K pathways. In fact, siRNA-mediated knockdown of GRB2 led to a nearly 
three-fold increase in phospho-AKT and a twofold increase in phospho-MAPK downstream of 
RON activation (Chaudhuri et al. 2011). Mutation of the RON phosphotyrosine site responsible 
for GRB2 recruitment to the sequence found in MET did not change this antagonistic role of 
GRB2, ruling out an affinity argument. This example highlights the challenges in linking even 
well studied molecular complexes to phenotypes and function and the ability of the same core 
components to carry out different function in even subtly different contexts.  
 Examples such as these as well as the rich binding data collected in the research detailed 
in this thesis highlight the need to rethink how signaling complexes behave in vivo. Activated 
receptors nucleate a wide variety of complexes that interact with each other in many unexpected 
and subtle ways to generate a phenotypic outcome. This allows these networks to have distinct 
input-output relationships depending on context. Understanding this complex, dynamic process 
will remain a daunting challenge, requiring the extensive use of computational modeling. 
5.2 From Data Explosion to Data Saturation 
 The sequencing of the human genome greatly enabled the study of molecular biology 






human proteome has enabled us to study them as a family instead of single proteins. The 
concomitant development of new technologies in miniaturization (e.g. microarrays) has allowed 
these studies to proceed in a cost-economical and scalable way. Numerous studies such as ours 
were enabled and this led to a massive increase in the data generated in the field.  
 Development of the computational model presented in this work shows us the utility and 
limitation of the large quantity of data generated since then. We have built a model that performs 
as well as biochemical methods in identifying interactions. This allows us to make the next leap 
of several orders of magnitude over experimental data. Future researchers will no longer need to 
perform unbiased high throughput SH2 domain research such as the type that I have described in 
Part 1 and 2. We seem to have the data necessary to train computational models and thereby infer 
the remainder of the interactome. There might be a need for targeted approaches that seek to 
probe domains or peptides that are currently poorly predicted by our model or which behave 
poorly in current experimental set ups. However, even new methodologies that identify SH2 
domain binding partners, when used in the same unbiased way that currently serves to train our 
model, would suffer from the rule of diminishing returns.  
A similar development is going on in the complementary field of phosphotyrosine site 
identification. In our study, we performed mass spectrometry on six receptors in 2008 and found 
many sites of tyrosine phosphorylation, the vast majority of them being novel. However, in the 
process of collecting and analyzing our data other labs performing high throughput mass 
spectrometry discovered all of the novel sites that we identified. This rapid transition highlights 
that much of the effort needed to identify new sites is redundant data and that truly new sites of 






Moreover, whereas previous studies requiring a comprehensive list of phosphorylation sites 
would merge multiple different databases, in this study we actually pruned data out of one 
database to choose only the high confidence data. This again due to the transition that has rapidly 
occurred from being data quality not quantity limited.  
These arguments are of course not to say that we have saturated all the potential data 
types. For instance, we do not know what cell types these predicted interactions would be active 
in, the interplay of these interacting proteins and the dynamic properties of these systems in the 
cell. Development of new experimental methods will allow the collection of new complementary 
data types to those that are currently available and will greatly assist in this endeavor. Thus 
merging distinct data types into a coherent framework will be the way forward to understanding 
the cell and not merely the scaling up of existing data collection endeavors. Genomics has 
provided us the nodes of the protein interaction network, proteomics the edges, but the 
challenging part of interpreting these data systematically is still largely in its infancy. 
5.3 From Narrative Knowledge to Database Knowledge 
 The explosion of journals and articles focused on the life sciences coupled with the 
massive increase in data generation has rendered the individual researcher unable to acquire and 
evaluate any significant portion of the current scientific output. Coupled with the fact that results 
of scientific inquiry are often ambiguous and filled with false positives and false negatives, it 
will increasingly be realized that without computation our ability to process scientific 






 This problem is especially manifest in “omics” data. In a prototypical high-throughput 
study, the generated large-scale dataset is used to cherry pick a couple of data points for follow 
up research and “assay validation.” To perhaps the majority of the readership of the final paper, 
the high throughput data become irrelevant and only the narrative constructed around the small-
scale study is understood and remembered. Our ability to generate genuinely useful and 
predictive models out of the high throughput data is currently limited. 
 Low throughput experiments suffer a related problem. While in isolation they often 
convey an understandable narrative and couch results in familiar cause-effect structure, that 
coherency is lost when the information is aggregated. This is a product of several related factors: 
literature text mining is in its infancy, extracting data computationally from free flowing text 
very difficult (and time consuming, even for knowledgeable researchers), experimental results 
are by their nature ambiguous and often incommensurate with each other. For instance, in the 
determination of a protein-protein interaction, it is often not known whether the interaction is 
indirect or direct, what its affinity is, and what post translational modifications are required, 
making comparison of different assay results challenging. In our experience in generating the 
model in Section 3, we found that database aggregation of previously published, low throughput 
experiments was on the whole of worse quality than high throughput data (data not shown), 
similar to the experience of others (Cusick et al. 2009). 
 Despite the caveats of computation, data that are not computationally interpretable will 
become progressively marginalized as we try to understand the totality of molecular biology. 
Integrating publications mentally is already highly difficult if not impossible. Our work on the 






combining what is known about SH2 domain sequence, its structure and the plethora of 
computationally interpretable binding data in an intuitive framework, we have generated a 
program that understands SH2 domain binding in a way that a human brain simply cannot. 
Computation will not replace but instead augment researchers in their investigations into 
biological systems. 
 Our model is a dynamic program that sits at the intersection of five different databases: 
Uniprot, PhosphositePlus (Hornbeck et al. 2011), the PDB, COSMIC (Bamford et al. 2004) and 
the informal database merging all known SH2 domain-mediated interactions. This allows our 
model to dynamically process and keep up to date with all these data sources in a way that static 
papers do not. Moreover, our assumptions and analyses are codified such that anyone who finds 
methodological improvements can immediately make changes. This is in contrast to much of the 
experimental literature that is often ambiguous, making it extremely difficult to disprove or 
improve upon.  
 In conclusion, biology is truly complex. If we hope to understand it in totality, we must 
organize experimental data in machine readable databases and develop computational algorithms 
that link these databases with each other. This will allow for the systematic synthesis of all the 
information and the generation of predictive models across multiple scales, from the biochemical 
(e.g. SH2 domain-peptide interactions) to molecular biology (e.g. cell signaling models) with the 
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Table 6.1: SH2 and PTB Domains Used in These Studies  (Continued) 
 
Domain Uniprot Domain Start End 
ABL1 P00519 SH2 112 232 
BCAR3 O75815 SH2 135 260 
BLK P51451 SH2 112 231 
BLNK Q8WV28 SH2 333 456 
BMX P51813 SH2 284 404 
BTK Q06187 SH2 265 396 
CBL P22681 SH2 47 351 
CHN2 P52757 SH2 49 161 
CRK P46108 SH2 1 129 
CRKL P46109 SH2 1 114 
DAPP1 Q9UN19 SH2 20 144 
FER P16591 SH2 444 557 
FES P07332 SH2 450 553 
FGR P09769 SH2 127 251 
GRAP Q13588 SH2 49 158 
GRB10 Q13322 SH2 479 592 
GRB14 Q14449 SH2 424 538 
GRB2 P62993 SH2 46 158 
GRB7 Q14451 SH2 417 532 
HCK P08631 SH2 134 253 
HSH2D Q96JZ2 SH2 14 132 
INPPL1 O15357 SH2 8 131 
ITK Q08881 SH2 220 348 
JAK2 O60674 SH2 385 505 
JAK3 P52333 SH2 358 484 
LCK P06239 SH2 110 234 
LCP2 Q13094 SH2 410 533 
LYN P07948 SH2 114 236 
MATK P42679 SH2 108 224 
NCK1 P16333 SH2 270 377 
NCK2 O43639 SH2 270 378 
PIK3R1-N P27986 SH2 319 432 
PIK3R1-C P27986 SH2 610 722 







Table 6.1: SH2 and PTB Domains Used in These Studies  (Continued) 
 
PIK3R2-N O00459 SH2 318 431 
PIK3R2-C O00459 SH2 608 726 
PIK3R2-NC O00459 SH2 431 610 
PIK3R3-N Q92569 SH2 53 166 
PIK3R3-C Q92569 SH2 345 461 
PIK3R3-NC Q92569 SH2 166 345 
PLCG1-N P19174 SH2 537 660 
PLCG1-C P19174 SH2 652 762 
PLCG1-NC P19174 SH2 539 664 
PLCG2 P16885 SH2 518 643 
PLCG2-C P16885 SH2 631 747 
PLCG2-NC P16885 SH2 520 749 
PTK6 Q13882 SH2 62 182 
PTPN11-N Q06124 SH2 1 103 
PTPN11-C Q06124 SH2 101 222 
PTPN11-NC Q06124 SH2 1 222 
PTPN6 P29350 SH2 97 221 
PTPN6-N P29350 SH2 1 102 
PTPN6-NC P29350 SH2 1 221 
RASA1-C P20936 SH2 335 448 
RASA1-NC P20936 SH2 168 452 
RIN1 Q13671 SH2 54 175 
SH2B1 Q9NRF2 SH2 510 630 
SH2B2 O14492 SH2 404 523 
SH2B3 Q9UQQ2 SH2 348 495 
SH2D1A O60880 SH2 1 108 
SH2D1B O14796 SH2 1 110 
SH2D2A Q9NP31 SH2 79 232 
SH2D3A Q9BRG2 SH2 3 120 
SH2D3C Q8N5H7 SH2 207 326 
SH2D5 Q6ZV89 SH2 200 312 
SH3BP2 P78314 SH2 449 559 
SHB Q15464 SH2 394 507 
SHC1 P29353 SH2 474 581 
SHC3 Q92529 SH2 484 592 
SHD Q96IW2 SH2 229 340 






Table 6.1: SH2 and PTB Domains Used in These Studies  (Continued) 
 
SHF Q7M4L6 SH2 311 423 
SLA2 Q9H6Q3 SH2 82 201 
SRC P12931 SH2 134 258 
STAP1 Q9ULZ2 SH2 167 285 
STAT1 P42224 SH2 565 698 
STAT2 P52630 SH2 562 684 
STAT3 P40763 SH2 567 688 
STAT4 Q14765 SH2 557 679 
STAT5A P42229 SH2 577 687 
STAT6 P42226 SH2 521 630 
SUPT6H Q7KZ85 SH2 1304 1446 
SYK-C P43405 SH2 147 269 
SYK-N P43405 SH2 1 112 
SYK-NC P43405 SH2 1 273 
TEC P42680 SH2 235 357 
TENC1 Q63HR2 SH2 1121 1259 
TNS1 Q9HBL0 SH2 1442 1573 
TNS3 Q68CZ2 SH2 1161 1286 
TNS4 Q8IZW8 SH2 438 564 
TXK P42681 SH2 138 256 
VAV1 P15498 SH2 658 769 
VAV2 P52735 SH2 659 772 
VAV3 Q9UKW4 SH2 656 768 
YES1 P07947 SH2 144 266 
ZAP70-C P43403 SH2 142 264 
ZAP70-N P43403 SH2 1 118 
ZAP70-NC P43403 SH2 1 268 
ANKS1A Q92625 PTB 924 1092 
ANKS1B Q7Z6G8 PTB 1023 1225 
APBA1 Q02410 PTB 420 671 
APBA2 Q99767 PTB 313 581 
APBA3 O96018 PTB 179 387 
APBB1-N O00213 PTB 332 522 
APBB1-C O00213 PTB 523 708 
APBB1-NC O00213 PTB 332 710 
APBB2-N Q92870 PTB 417 565 






Table 6.1: SH2 and PTB Domains Used in These Studies  (Continued) 
 
APBB2-NC Q92870 PTB 419 759 
APBB3-N O95704 PTB 81 266 
APBB3-C O95704 PTB 266 481 
APBB3-NC O95704 PTB 81 505 
APPL1 Q9UKG1 PTB 491 632 
CCM2 Q9BSQ5 PTB 51 235 
DAB1 O75553 PTB 1 227 
DAB2 P98082 PTB 1 226 
DOK1 Q99704 PTB 121 290 
DOK2 O60496 PTB 115 280 
DOK4 Q8TEW6 PTB 101 258 
DOK5 Q9P104 PTB 101 268 
DOK6 Q6PKX4 PTB 105 262 
EPS8L2 Q9H6S3 PTB 52 204 
FRS3 O43559 PTB 1 140 
GULP1 Q9UBP9 PTB 13 165 
IRS1 P35568 PTB 114 308 
IRS4 O14654 PTB 199 364 
NUMB P49757 PTB 1 220 
NUMBL Q9Y6R0 PTB 51 251 
SHC1-PTB P29353 PTB 121 379 
SHC2 P98077 PTB 94 330 
SHC3 Q92529 PTB 224 319 
TENC1-PTB Q63HR2 PTB 1260 1405 



















PIK3R1-N P27986 EPHA3 Y779 P29320 0.992842 
PIK3R1-N P27986 EPHA4 Y779 P54764 0.992842 
PIK3R1-N P27986 EPHA5 Y833 P54756 0.992842 
PIK3R1-N P27986 EPHA4 Y602 P54764 0.431994 
PIK3R1-N P27986 FGFR1 Y730 P11362 0.426785 
PIK3R1-N P27986 FGFR3 Y724 P22607 0.244469 
PIK3R1-N P27986 FLT1 Y1213 P17948 0.796538 
PIK3R1-N P27986 KDR Y1059 P35968 0.762434 
PIK3R1-N P27986 KIT Y900 P10721 0.513097 
PIK3R1-N P27986 MST1R Y1317 Q04912 0.216106 
PIK3R1-N P27986 NTRK2 Y706 Q16620 0.786309 
PIK3R1-N P27986 NTRK3 Y709 Q16288 0.786309 
PIK3R1-N P27986 NTRK2 Y707 Q16620 0.395866 
PIK3R1-N P27986 NTRK3 Y710 Q16288 0.395866 
PIK3R1-N P27986 PDGFRA Y742 P16234 0.360627 
PIK3R1-N P27986 PDGFRB Y740 P09619 0.155778 
PIK3R1-N P27986 ERBB4 Y1056 Q15303 0.710236 
PIK3R1-N P27986 ERBB2 Y1139 P04626 0.753057 
PIK3R1-N P27986 ERBB3 Y1197 P21860 0.147163 
PIK3R1-N P27986 ABL2 Y515 P42684 0.295444 
PIK3R1-N P27986 ZAP70 Y493 P43403 0.629901 
PIK3R1-N P27986 TXK Y420 P42681 0.393795 
PIK3R1-N P27986 FES Y811 P07332 0.386173 
PIK3R1-N P27986 PLCG1 Y775 P19174 0.698607 
PIK3R1-N P27986 PLCG2 Y1217 P16885 0.667422 
PIK3R1-N P27986 GRAP2 Y45 O75791 0.526474 
PIK3R1-N P27986 NCK1 Y268 P16333 0.578606 
PIK3R1-N P27986 SHC1 Y427 P29353 0.689798 
PIK3R1-N P27986 JAK3 Y785 P52333 0.180054 
PIK3R1-N P27986 SH2D3A Y231 Q9BRG2 0.694002 
PIK3R1-N P27986 SH2D2A Y280 Q9NP31 0.861829 
PIK3R1-N P27986 VAV2 Y172 P52735 0.713453 
PIK3R1-N P27986 PTPN6 Y536 P29350 0.654597 
PIK3R1-N P27986 CBL Y371 P22681 0.600737 
PIK3R1-N P27986 CBLB Y363 Q13191 0.600737 







Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PIK3R1-N P27986 EPHB4 Y774 P54760 0.145616 
PIK3R1-N P27986 IRS1 Y465 P35568 0.758214 
PIK3R1-N P27986 IRS1 Y612 P35568 0.297814 
PIK3R1-N P27986 IRS1 Y989 P35568 0.617862 
PIK3R1-N P27986 ZAP70 Y319 P43403 0.584842 
PIK3R1-N P27986 BMX Y216 P51813 0.507805 
PIK3R1-N P27986 PDGFRB Y934 P09619 0.612879 
PIK3R1-N P27986 ROS1 Y2342 P08922 0.675277 
PIK3R1-N P27986 PIK3CB Y246 P42338 0.653475 
PIK3R1-N P27986 NCK2 Y50 O43639 0.581543 
PIK3R1-N P27986 SHB Y272 Q15464 0.603671 
PIK3R1-N P27986 IRS4 Y921 O14654 0.306591 
PIK3R1-N P27986 ANKS1A Y454 Q92625 0.968243 
PIK3R1-C P27986 EPHA3 Y596 P29320 0.866703 
PIK3R1-C P27986 FGFR1 Y463 P11362 0.357871 
PIK3R1-C P27986 FGFR1 Y730 P11362 0.351668 
PIK3R1-C P27986 FGFR3 Y724 P22607 0.278032 
PIK3R1-C P27986 NTRK1 Y496 P04629 0.875405 
PIK3R1-C P27986 NTRK2 Y706 Q16620 0.992394 
PIK3R1-C P27986 NTRK3 Y709 Q16288 0.992394 
PIK3R1-C P27986 NTRK3 Y516 Q16288 0.867029 
PIK3R1-C P27986 ROS1 Y2334 P08922 0.956608 
PIK3R1-C P27986 RET Y952 P07949 0.726299 
PIK3R1-C P27986 EPHA2 Y735 P29317 0.867606 
PIK3R1-C P27986 ABL1 Y412 P00519 0.351166 
PIK3R1-C P27986 FGR Y412 P09769 0.948546 
PIK3R1-C P27986 PLCG1 Y783 P19174 0.830702 
PIK3R1-C P27986 VAV2 Y172 P52735 0.969825 
PIK3R1-C P27986 IRS1 Y662 P35568 0.647556 
PIK3R1-C P27986 IRS1 Y989 P35568 0.933089 
PIK3R1-C P27986 ZAP70 Y69 P43403 0.531278 
PIK3R1-C P27986 SRC Y521 P12931 0.472004 
PIK3R1-C P27986 BTK Y225 Q06187 0.220062 
PIK3R1-C P27986 IRS4 Y921 O14654 0.530788 
PIK3R1-NC P27986 EPHA3 Y602 P29320 0.989368 
PIK3R1-NC P27986 FGFR1 Y730 P11362 0.508023 
PIK3R1-NC P27986 FGFR3 Y724 P22607 0.24913 
PIK3R1-NC P27986 FLT1 Y1213 P17948 0.327832 
PIK3R1-NC P27986 IGF1R Y1346 P08069 0.563199 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PIK3R1-NC P27986 INSR Y1361 P06213 0.277565 
PIK3R1-NC P27986 KDR Y1059 P35968 0.998675 
PIK3R1-NC P27986 KIT Y900 P10721 0.157236 
PIK3R1-NC P27986 MET Y1356 P08581 0.408076 
PIK3R1-NC P27986 MST1R Y1317 Q04912 0.213602 
PIK3R1-NC P27986 NTRK1 Y496 P04629 0.72195 
PIK3R1-NC P27986 PDGFRA Y574 P16234 0.252781 
PIK3R1-NC P27986 PDGFRB Y579 P09619 0.995754 
PIK3R1-NC P27986 PDGFRB Y740 P09619 0.332446 
PIK3R1-NC P27986 PDGFRB Y763 P09619 0.423616 
PIK3R1-NC P27986 RET Y981 P07949 0.262998 
PIK3R1-NC P27986 ERBB4 Y1056 Q15303 0.814685 
PIK3R1-NC P27986 EGFR Y998 P00533 0.330541 
PIK3R1-NC P27986 EGFR Y1016 P00533 0.216375 
PIK3R1-NC P27986 EGFR Y1092 P00533 0.433733 
PIK3R1-NC P27986 EGFR Y1138 P00533 0.807115 
PIK3R1-NC P27986 ERBB2 Y1221 P04626 0.728121 
PIK3R1-NC P27986 ERBB3 Y1054 P21860 0.945453 
PIK3R1-NC P27986 ERBB3 Y1199 P21860 0.727357 
PIK3R1-NC P27986 ERBB3 Y1276 P21860 0.319315 
PIK3R1-NC P27986 RET Y952 P07949 0.619382 
PIK3R1-NC P27986 EPHA2 Y628 P29317 0.8053 
PIK3R1-NC P27986 EPHA2 Y921 P29317 0.745884 
PIK3R1-NC P27986 ABL2 Y515 P42684 0.137027 
PIK3R1-NC P27986 FYN Y420 P06241 0.453753 
PIK3R1-NC P27986 SRC Y419 P12931 0.453753 
PIK3R1-NC P27986 YES1 Y426 P07947 0.453753 
PIK3R1-NC P27986 ZAP70 Y248 P43403 0.720679 
PIK3R1-NC P27986 TXK Y420 P42681 0.222524 
PIK3R1-NC P27986 HCK Y209 P08631 0.729415 
PIK3R1-NC P27986 PTK6 Y342 Q13882 0.417406 
PIK3R1-NC P27986 FES Y811 P07332 0.677834 
PIK3R1-NC P27986 PLCG1 Y783 P19174 0.749776 
PIK3R1-NC P27986 NCK1 Y268 P16333 0.878331 
PIK3R1-NC P27986 SH3BP2 Y183 P78314 0.731312 
PIK3R1-NC P27986 JAK3 Y785 P52333 0.252956 
PIK3R1-NC P27986 BLNK Y84 Q8WV28 0.166578 
PIK3R1-NC P27986 VAV1 Y160 P15498 0.784962 
PIK3R1-NC P27986 VAV1 Y174 P15498 0.361554 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PIK3R1-NC P27986 CBL Y368 P22681 0.499943 
PIK3R1-NC P27986 CBL Y371 P22681 0.330579 
PIK3R1-NC P27986 CBLB Y363 Q13191 0.330579 
PIK3R1-NC P27986 CBL Y700 P22681 0.813982 
PIK3R1-NC P27986 DOK1 Y146 Q99704 0.718682 
PIK3R1-NC P27986 EPHB3 Y608 P54753 0.57567 
PIK3R1-NC P27986 IRS1 Y941 P35568 0.145369 
PIK3R1-NC P27986 IRS1 Y989 P35568 0.286464 
PIK3R1-NC P27986 IRS2 Y653 Q9Y4H2 0.566533 
PIK3R1-NC P27986 GAB1 Y373 Q13480 0.62363 
PIK3R1-NC P27986 CSK Y263 P41240 0.674614 
PLCG1-N P19174 KIT Y721 P10721 0.156814 
PLCG1-N P19174 ROS1 Y2274 P08922 0.321813 
PLCG1-N P19174 FRS2 Y436 Q8WU20 0.751277 
PLCG1-N P19174 ERBB2 Y1127 P04626 0.43883 
PLCG1-N P19174 FGFR2 Y466 P21802 0.447897 
PLCG1-N P19174 IRS4 Y921 O14654 0.846191 
PLCG1-C P19174 AXL Y866 P30530 0.467486 
PLCG1-C P19174 FGFR1 Y585 P11362 0.950479 
PLCG1-C P19174 NTRK1 Y496 P04629 0.767983 
PLCG1-C P19174 EPHA7 Y608 Q15375 0.829249 
PLCG1-C P19174 PLCG2 Y1245 P16885 0.649951 
PLCG1-C P19174 CBL Y371 P22681 0.645106 
PLCG1-C P19174 CBLB Y363 Q13191 0.645106 
PLCG1-C P19174 HSH2D Y265 Q96JZ2 0.640045 
PLCG1-C P19174 PTK2B Y849 Q14289 0.869204 
PLCG1-NC P19174 FGFR3 Y724 P22607 0.463045 
PLCG1-NC P19174 FLT1 Y1327 P17948 0.826507 
PLCG1-NC P19174 FLT1 Y1333 P17948 0.508594 
PLCG1-NC P19174 KIT Y721 P10721 0.341182 
PLCG1-NC P19174 KIT Y900 P10721 0.782461 
PLCG1-NC P19174 KIT Y936 P10721 0.895221 
PLCG1-NC P19174 MET Y1365 P08581 0.991527 
PLCG1-NC P19174 MST1R Y1317 Q04912 0.969104 
PLCG1-NC P19174 NTRK3 Y516 Q16288 0.920632 
PLCG1-NC P19174 ERBB2 Y1139 P04626 0.711685 
PLCG1-NC P19174 ERBB3 Y1289 P21860 0.604968 
PLCG1-NC P19174 TXK Y420 P42681 0.772389 
PLCG1-NC P19174 PLCG1 Y472 P19174 0.627038 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PLCG1-NC P19174 PLCG2 Y1217 P16885 0.617156 
PLCG1-NC P19174 NCK1 Y268 P16333 0.763537 
PLCG1-NC P19174 CBL Y371 P22681 0.698794 
PLCG1-NC P19174 CBLB Y363 Q13191 0.698794 
PLCG1-NC P19174 EPHA5 Y656 P54756 0.94524 
PLCG1-NC P19174 ERBB2 Y1127 P04626 0.284964 
PLCG1-NC P19174 IRS1 Y465 P35568 0.499646 
PLCG1-NC P19174 KIT Y730 P10721 0.792031 
PLCG1-NC P19174 FGFR2 Y466 P21802 0.498434 
PLCG1-NC P19174 ABL1 Y204 P00519 0.931565 
PLCG1-NC P19174 MERTK Y929 Q12866 0.904937 
PLCG1-NC P19174 PIK3CB Y246 P42338 0.907801 
PLCG1-NC P19174 PLCG1 Y1253 P19174 0.680696 
PLCG1-NC P19174 PLCG2 Y759 P16885 0.714683 
PLCG1-NC P19174 NCK1 Y112 P16333 0.596646 
PLCG1-NC P19174 BCAR3 Y117 O75815 0.566937 
PLCG1-NC P19174 BCAR3 Y429 O75815 0.912581 
PLCG1-NC P19174 PTPN6 Y541 P29350 0.570099 
PLCG1-NC P19174 CBL Y731 P22681 0.578916 
PLCG1-NC P19174 CBLB Y889 Q13191 0.724476 
PLCG1-NC P19174 STAT1 Y203 P42224 0.906056 
PLCG1-NC P19174 APBB1 Y547 O00213 0.787488 
PLCG1-NC P19174 IRS4 Y921 O14654 0.614164 
PLCG1-NC P19174 CSK Y263 P41240 0.928201 
PLCG1-NC P19174 PTK2 Y5 Q05397 0.3871 
PLCG1-NC P19174 PTK2B Y849 Q14289 0.48127 
PLCG1-NC P19174 CTNNB1 Y64 P35222 0.569265 
PTPN11-C Q06124 PDGFRB Y740 P09619 0.223661 
PTPN11-C Q06124 ROS1 Y2274 P08922 0.511486 
PTPN11-C Q06124 EPHA7 Y791 Q15375 0.782353 
PTPN11-C Q06124 FYN Y420 P06241 0.966945 
PTPN11-C Q06124 SRC Y419 P12931 0.966945 
PTPN11-C Q06124 YES1 Y426 P07947 0.966945 
PTPN11-C Q06124 GRB2 Y209 P62993 0.927502 
PTPN11-C Q06124 PIK3R1 Y467 P27986 0.896784 
PTPN11-C Q06124 TNS1 Y339 Q9HBL0 0.199096 
PTPN11-NC Q06124 FLT1 Y1327 P17948 0.492911 
PTPN11-NC Q06124 INSR Y1011 P06213 0.743534 
PTPN11-NC Q06124 FLT4 Y1063 P35916 0.753535 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PTPN11-NC Q06124 NTRK3 Y516 Q16288 0.790381 
PTPN11-NC Q06124 FRS2 Y436 Q8WU20 0.792149 
PTPN11-NC Q06124 PLCG2 Y1217 P16885 0.487206 
PTPN11-NC Q06124 PLCG2 Y1245 P16885 0.890514 
PTPN11-NC Q06124 CBL Y371 P22681 0.779886 
PTPN11-NC Q06124 CBLB Y363 Q13191 0.779886 
PTPN11-NC Q06124 DAB1 Y220 O75553 0.187434 
PTPN11-NC Q06124 DOK1 Y146 Q99704 0.434321 
PTPN11-NC Q06124 IRS2 Y675 Q9Y4H2 0.648714 
APBB1-N O00213 EPHA3 Y596 P29320 0.423237 
APBB1-N O00213 PLCG2 Y1245 P16885 0.963279 
APBB1-N O00213 DOK1 Y315 Q99704 0.754687 
APBB1-N O00213 IRS1 Y465 P35568 0.916948 
APBB1-N O00213 IRS2 Y675 Q9Y4H2 0.866369 
APBB1-N O00213 ABL2 Y683 P42684 0.946056 
APBB1-N O00213 SYK Y203 P43405 0.892074 
APBB1-C O00213 NTRK3 Y516 Q16288 0.868648 
APBB1-C O00213 IRS1 Y465 P35568 0.973194 
APBB2-N Q92870 VAV2 Y172 P52735 0.864078 
APBB3-N O95704 IRS1 Y989 P35568 0.746694 
APBB3-N O95704 ABL1 Y191 P00519 0.917416 
APBB3-C O95704 IRS2 Y675 Q9Y4H2 0.31856 
APBB3-C O95704 ABL1 Y191 P00519 0.777657 
APBA1 Q02410 SHC1 Y350 P29353 0.686694 
APBA2 Q99767 DOK1 Y315 Q99704 0.991871 
STAT1 P42224 ALK Y1092 Q9UM73 0.597352 
STAT1 P42224 ALK Y1096 Q9UM73 0.611407 
STAT1 P42224 FGFR1 Y730 P11362 0.377798 
STAT1 P42224 FGFR3 Y724 P22607 0.881298 
STAT1 P42224 FLT1 Y1327 P17948 0.923726 
STAT1 P42224 FLT3 Y597 P36888 0.551359 
STAT1 P42224 FLT3 Y599 P36888 0.4865 
STAT1 P42224 FLT4 Y1337 P35916 0.765492 
STAT1 P42224 IGF1R Y1161 P08069 0.865635 
STAT1 P42224 INSR Y1185 P06213 0.865635 
STAT1 P42224 IGF1R Y1280 P08069 0.675169 
STAT1 P42224 INSR Y1011 P06213 0.768642 
STAT1 P42224 KIT Y570 P10721 0.798863 
STAT1 P42224 KIT Y900 P10721 0.942345 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
STAT1 P42224 NTRK1 Y496 P04629 0.647238 
STAT1 P42224 NTRK2 Y706 Q16620 0.891127 
STAT1 P42224 NTRK3 Y709 Q16288 0.891127 
STAT1 P42224 NTRK2 Y707 Q16620 0.607542 
STAT1 P42224 NTRK3 Y710 Q16288 0.607542 
STAT1 P42224 NTRK3 Y516 Q16288 0.799565 
STAT1 P42224 PDGFRB Y581 P09619 0.625261 
STAT1 P42224 PDGFRB Y751 P09619 0.870689 
STAT1 P42224 PDGFRB Y775 P09619 0.463376 
STAT1 P42224 PDGFRB Y1021 P09619 0.925029 
STAT1 P42224 RET Y791 P07949 0.485331 
STAT1 P42224 RET Y806 P07949 0.642974 
STAT1 P42224 RET Y981 P07949 0.590296 
STAT1 P42224 TEK Y1102 Q02763 0.960307 
STAT1 P42224 ERBB2 Y1221 P04626 0.73832 
STAT1 P42224 ERBB2 Y1222 P04626 0.36864 
STAT1 P42224 FGR Y412 P09769 0.653203 
STAT1 P42224 ZAP70 Y315 P43403 0.934525 
STAT1 P42224 ZAP70 Y474 P43403 0.760738 
STAT1 P42224 FES Y811 P07332 0.488148 
STAT1 P42224 PLCG2 Y743 P16885 0.463266 
STAT1 P42224 GRAP2 Y45 O75791 0.43481 
STAT1 P42224 RASA1 Y615 P20936 0.575295 
STAT1 P42224 SH2D2A Y39 Q9NP31 0.70762 
STAT1 P42224 SH2D2A Y290 Q9NP31 0.955433 
STAT1 P42224 PTPN6 Y536 P29350 0.754849 
STAT1 P42224 DOK1 Y398 Q99704 0.653589 
STAT1 P42224 FLT4 Y853 P35916 0.817403 
STAT1 P42224 EPHA2 Y694 P29317 0.394144 
STAT1 P42224 PDGFRA Y958 P16234 0.955757 
STAT1 P42224 ABL2 Y568 P42684 0.596368 
STAT1 P42224 ABL1 Y191 P00519 0.869398 
STAT1 P42224 ZAP70 Y69 P43403 0.379163 
STAT1 P42224 STAT3 Y686 P40763 0.154844 
STAT1 P42224 TNS1 Y339 Q9HBL0 0.590149 
STAT1 P42224 TNS1 Y1404 Q9HBL0 0.84694 
STAT1 P42224 DOK3 Y432 Q7L591 0.380145 
STAT1 P42224 CSK Y263 P41240 0.586253 
STAT1 P42224 PTK2 Y5 Q05397 0.538651 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
STAT2 P52630 AXL Y866 P30530 0.786808 
STAT2 P52630 FGFR1 Y730 P11362 0.971215 
STAT2 P52630 FGFR3 Y724 P22607 0.453742 
STAT2 P52630 FLT1 Y1333 P17948 0.634384 
STAT2 P52630 FLT3 Y591 P36888 0.902217 
STAT2 P52630 FLT3 Y597 P36888 0.319258 
STAT2 P52630 FLT3 Y599 P36888 0.474452 
STAT2 P52630 FLT4 Y1337 P35916 0.764998 
STAT2 P52630 IGF1R Y1280 P08069 0.747779 
STAT2 P52630 INSR Y1011 P06213 0.547969 
STAT2 P52630 KDR Y996 P35968 0.903331 
STAT2 P52630 KIT Y570 P10721 0.551262 
STAT2 P52630 KIT Y900 P10721 0.760358 
STAT2 P52630 KIT Y936 P10721 0.778786 
STAT2 P52630 MET Y1313 P08581 0.393904 
STAT2 P52630 MET Y1356 P08581 0.434497 
STAT2 P52630 MST1R Y1317 Q04912 0.352203 
STAT2 P52630 NTRK3 Y516 Q16288 0.396016 
STAT2 P52630 PDGFRB Y1009 P09619 0.835574 
STAT2 P52630 RET Y981 P07949 0.154832 
STAT2 P52630 RET Y1096 P07949 0.966577 
STAT2 P52630 ROS1 Y2274 P08922 0.780933 
STAT2 P52630 ERBB2 Y1023 P04626 0.70289 
STAT2 P52630 ERBB2 Y1221 P04626 0.56298 
STAT2 P52630 ERBB2 Y1222 P04626 0.307909 
STAT2 P52630 LCK Y192 P06239 0.718302 
STAT2 P52630 PLCG2 Y1245 P16885 0.88968 
STAT2 P52630 RASA1 Y615 P20936 0.336722 
STAT2 P52630 INSR Y1149 P06213 0.434825 
STAT2 P52630 IRS1 Y732 P35568 0.828657 
STAT2 P52630 IRS2 Y628 Q9Y4H2 0.595462 
STAT2 P52630 IRS2 Y823 Q9Y4H2 0.96041 
STAT2 P52630 MERTK Y929 Q12866 0.723573 
STAT2 P52630 PIK3R3 Y199 Q92569 0.460031 
STAT2 P52630 PIK3R3 Y202 Q92569 0.885941 
STAT2 P52630 FER Y615 P16591 0.188177 
STAT2 P52630 PTPN11 Y279 Q06124 0.136066 
STAT2 P52630 TNS1 Y339 Q9HBL0 0.977454 
STAT2 P52630 TNS1 Y609 Q9HBL0 0.161107 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
STAT3 P40763 EPHA4 Y596 P54764 0.967603 
STAT3 P40763 ABL1 Y412 P00519 0.6392 
STAT3 P40763 DOK1 Y315 Q99704 0.634271 
STAT3 P40763 IRS1 Y732 P35568 0.96908 
STAT3 P40763 IRS2 Y675 Q9Y4H2 0.782215 
STAT4 Q14765 ABL1 Y412 P00519 0.768737 
STAT4 Q14765 ABL1 Y488 P00519 0.718808 
STAT4 Q14765 DOK1 Y315 Q99704 0.96734 
STAT5A P42229 FLT4 Y1068 P35916 0.136262 
STAT5A P42229 INSR Y1149 P06213 0.542657 
STAT5A P42229 IRS1 Y465 P35568 0.69113 
STAT5A P42229 IRS2 Y823 Q9Y4H2 0.791466 
STAT5A P42229 TNS1 Y366 Q9HBL0 0.741576 
STAT5A P42229 TNS1 Y796 Q9HBL0 0.405017 
STAT5A P42229 CSK Y263 P41240 0.999448 
STAT6 P42226 PLCG2 Y1245 P16885 0.996953 
STAT6 P42226 ABL1 Y191 P00519 0.839248 
STAT6 P42226 TNS1 Y796 Q9HBL0 0.785009 
FGR P09769 ALK Y1092 Q9UM73 0.807365 
FGR P09769 EPHA4 Y602 P54764 0.692983 
FGR P09769 EPHB1 Y600 P54762 0.813246 
FGR P09769 EPHB2 Y602 P29323 0.813246 
FGR P09769 FGFR3 Y724 P22607 0.652358 
FGR P09769 FGFR3 Y770 P22607 0.961136 
FGR P09769 FLT3 Y589 P36888 0.961136 
FGR P09769 FLT3 Y597 P36888 0.283126 
FGR P09769 FLT3 Y599 P36888 0.356976 
FGR P09769 FLT4 Y1063 P35916 0.461362 
FGR P09769 KDR Y1054 P35968 0.461362 
FGR P09769 KIT Y721 P10721 0.4756 
FGR P09769 KIT Y900 P10721 0.415806 
FGR P09769 KIT Y936 P10721 0.650369 
FGR P09769 MET Y1313 P08581 0.209711 
FGR P09769 MET Y1356 P08581 0.947853 
FGR P09769 MST1R Y1317 Q04912 0.495535 
FGR P09769 NTRK1 Y496 P04629 0.845914 
FGR P09769 NTRK2 Y702 Q16620 0.768861 
FGR P09769 NTRK3 Y705 Q16288 0.768861 
FGR P09769 PDGFRB Y740 P09619 0.705074 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
FGR P09769 RET Y1096 P07949 0.755762 
FGR P09769 EGFR Y1172 P00533 0.681239 
FGR P09769 ERBB2 Y1221 P04626 0.431439 
FGR P09769 ERBB3 Y1197 P21860 0.706646 
FGR P09769 ERBB3 Y1289 P21860 0.358075 
FGR P09769 EPHA2 Y735 P29317 0.969841 
FGR P09769 EPHA7 Y597 Q15375 0.673411 
FGR P09769 EPHA7 Y614 Q15375 0.660769 
FGR P09769 ABL1 Y245 P00519 0.782787 
FGR P09769 ABL1 Y276 P00519 0.369299 
FGR P09769 FYN Y420 P06241 0.532507 
FGR P09769 SRC Y419 P12931 0.532507 
FGR P09769 YES1 Y426 P07947 0.532507 
FGR P09769 EPHA1 Y605 P21709 0.69312 
FGR P09769 SYK Y323 P43405 0.475592 
FGR P09769 HCK Y209 P08631 0.909464 
FGR P09769 PTK6 Y342 Q13882 0.546378 
FGR P09769 LCK Y192 P06239 0.930584 
FGR P09769 FES Y811 P07332 0.769762 
FGR P09769 PLCG1 Y771 P19174 0.917296 
FGR P09769 PTPN11 Y62 Q06124 0.860495 
FGR P09769 SH3BP2 Y174 P78314 0.6036 
FGR P09769 SH3BP2 Y183 P78314 0.659309 
FGR P09769 SHC1 Y349 P29353 0.368218 
FGR P09769 SHC1 Y427 P29353 0.920724 
FGR P09769 JAK3 Y785 P52333 0.889518 
FGR P09769 LCP2 Y128 Q13094 0.587323 
FGR P09769 LCP2 Y145 Q13094 0.846775 
FGR P09769 BLNK Y72 Q8WV28 0.562045 
FGR P09769 BLNK Y84 Q8WV28 0.841612 
FGR P09769 BLNK Y178 Q8WV28 0.717231 
FGR P09769 SH2D2A Y305 Q9NP31 0.809557 
FGR P09769 SH2D3C Y495 Q8N5H7 0.852269 
FGR P09769 VAV1 Y142 P15498 0.721767 
FGR P09769 VAV1 Y174 P15498 0.550635 
FGR P09769 VAV2 Y159 P52735 0.576858 
FGR P09769 VAV2 Y172 P52735 0.686303 
FGR P09769 CBL Y368 P22681 0.620303 
FGR P09769 CBL Y371 P22681 0.702645 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
FGR P09769 CBL Y774 P22681 0.501711 
FGR P09769 DAB1 Y198 O75553 0.389253 
FGR P09769 DOK1 Y146 Q99704 0.752308 
FGR P09769 DOK1 Y296 Q99704 0.732111 
FGR P09769 DOK1 Y315 Q99704 0.771126 
FGR P09769 DOK1 Y362 Q99704 0.708328 
FGR P09769 DOK1 Y377 Q99704 0.849714 
FGR P09769 DOK2 Y345 O60496 0.979642 
FGR P09769 EPHA3 Y937 P29320 0.65836 
FGR P09769 EPHB3 Y608 P54753 0.827312 
FGR P09769 EPHB3 Y754 P54753 0.66284 
FGR P09769 EPHB4 Y596 P54760 0.947729 
FGR P09769 IRS1 Y662 P35568 0.562586 
FGR P09769 IRS1 Y896 P35568 0.953107 
FGR P09769 IRS1 Y989 P35568 0.766203 
FGR P09769 IRS1 Y1179 P35568 0.805941 
FGR P09769 IRS2 Y632 Q9Y4H2 0.76278 
FGR P09769 IRS2 Y653 Q9Y4H2 0.996095 
FGR P09769 IRS2 Y823 Q9Y4H2 0.962522 
FGR P09769 GAB1 Y406 Q13480 0.271278 
FGR P09769 FGFR2 Y466 P21802 0.872532 
FGR P09769 EPHA2 Y930 P29317 0.8007 
FGR P09769 ZAP70 Y319 P43403 0.995828 
FGR P09769 PIK3R1 Y528 P27986 0.876338 
FGR P09769 ZAP70 Y69 P43403 0.772009 
FGR P09769 SYK Y203 P43405 0.985349 
FGR P09769 PLCG1 Y1253 P19174 0.896801 
FGR P09769 PTPN11 Y584 Q06124 0.83587 
FGR P09769 RIN1 Y632 Q13671 0.707133 
FGR P09769 CHN2 Y21 P52757 0.893389 
FGR P09769 BCAR3 Y429 O75815 0.765136 
FGR P09769 VAV1 Y826 P15498 0.443437 
FGR P09769 VAV3 Y173 Q9UKW4 0.749646 
FGR P09769 SHB Y297 Q15464 0.765108 
FGR P09769 SHB Y336 Q15464 0.359336 
FGR P09769 TNS1 Y796 Q9HBL0 0.794286 
FGR P09769 CBL Y731 P22681 0.430551 
FGR P09769 APBB1 Y547 O00213 0.766893 
FGR P09769 DAB2 Y342 P98082 0.607378 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
FGR P09769 DOK4 Y255 Q8TEW6 0.626702 
FGR P09769 IRS4 Y921 O14654 0.611249 
FGR P09769 CSK Y263 P41240 0.574304 
FGR P09769 PTK2 Y861 Q05397 0.734391 
FGR P09769 PTK2B Y580 Q14289 0.602848 
FGR P09769 PTK2B Y834 Q14289 0.821619 
GRB2 P62993 FGFR3 Y724 P22607 0.762506 
GRB2 P62993 FLT1 Y1213 P17948 0.366702 
GRB2 P62993 INSR Y1011 P06213 0.807897 
GRB2 P62993 KIT Y936 P10721 0.406433 
GRB2 P62993 MET Y1313 P08581 0.90774 
GRB2 P62993 MET Y1356 P08581 0.262136 
GRB2 P62993 MST1R Y1317 Q04912 0.970287 
GRB2 P62993 RET Y1096 P07949 0.158621 
GRB2 P62993 TEK Y1113 Q02763 0.954263 
GRB2 P62993 FRS2 Y196 Q8WU20 0.761346 
GRB2 P62993 EGFR Y1092 P00533 0.312085 
GRB2 P62993 EGFR Y1138 P00533 0.38272 
GRB2 P62993 ERBB2 Y1139 P04626 0.529508 
GRB2 P62993 EPHA7 Y614 Q15375 0.67471 
GRB2 P62993 ABL1 Y276 P00519 0.47088 
GRB2 P62993 FYN Y420 P06241 0.363214 
GRB2 P62993 SRC Y419 P12931 0.363214 
GRB2 P62993 YES1 Y426 P07947 0.363214 
GRB2 P62993 PLCG2 Y1217 P16885 0.169385 
GRB2 P62993 EPHB1 Y575 P54762 0.689033 
GRB2 P62993 ERBB2 Y735 P04626 0.701509 
GRB2 P62993 ERBB2 Y1005 P04626 0.903653 
GRB2 P62993 ABL2 Y272 P42684 0.582755 
GRB2 P62993 ABL2 Y683 P42684 0.977271 
GRB2 P62993 ABL1 Y191 P00519 0.820656 
GRB2 P62993 ABL1 Y234 P00519 0.849815 
GRB2 P62993 SRC Y521 P12931 0.804124 
GRB2 P62993 SYK Y203 P43405 0.342176 
GRB2 P62993 FYN Y531 P06241 0.63852 
GRB2 P62993 YES1 Y537 P07947 0.63852 
GRB2 P62993 PTPN11 Y279 Q06124 0.306572 
GRB2 P62993 PTPN11 Y304 Q06124 0.628023 
GRB2 P62993 PTPN11 Y584 Q06124 0.43784 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
GRB2 P62993 TNS1 Y903 Q9HBL0 0.828437 
GRB2 P62993 CSK Y263 P41240 0.65581 
GRAP Q13588 INSR Y1011 P06213 0.473537 
GRAP Q13588 MET Y1356 P08581 0.971152 
GRAP Q13588 NTRK1 Y496 P04629 0.654807 
GRAP Q13588 PDGFRB Y581 P09619 0.454764 
GRAP Q13588 RET Y1096 P07949 0.834892 
GRAP Q13588 ABL2 Y515 P42684 0.788826 
GRAP Q13588 ABL1 Y276 P00519 0.535505 
GRAP Q13588 PLCG1 Y775 P19174 0.953276 
GRAP Q13588 ANKS1A Y833 Q92625 0.416368 
CRK P46108 ALK Y1092 Q9UM73 0.960923 
CRK P46108 FGFR1 Y653 P11362 0.782345 
CRK P46108 FGFR1 Y654 P11362 0.867506 
CRK P46108 FGFR3 Y648 P22607 0.470982 
CRK P46108 FGFR3 Y724 P22607 0.544314 
CRK P46108 FLT1 Y1327 P17948 0.537132 
CRK P46108 KIT Y900 P10721 0.334269 
CRK P46108 KIT Y936 P10721 0.855645 
CRK P46108 PDGFRB Y581 P09619 0.809281 
CRK P46108 PDGFRB Y775 P09619 0.348979 
CRK P46108 RET Y981 P07949 0.242159 
CRK P46108 RET Y1062 P07949 0.890518 
CRK P46108 ZAP70 Y248 P43403 0.865993 
CRK P46108 AXL Y759 P30530 0.420886 
CRK P46108 TXK Y91 P42681 0.84179 
CRK P46108 HCK Y209 P08631 0.17982 
CRK P46108 LCK Y192 P06239 0.355726 
CRK P46108 RASA1 Y460 P20936 0.93526 
CRK P46108 VAV2 Y172 P52735 0.844312 
CRK P46108 CBL Y337 P22681 0.916979 
CRK P46108 CBL Y700 P22681 0.250844 
CRK P46108 CBL Y774 P22681 0.96678 
CRK P46108 DAB1 Y220 O75553 0.827471 
CRK P46108 ERBB2 Y1127 P04626 0.913481 
CRK P46108 FLT1 Y1048 P17948 0.530287 
CRK P46108 KIT Y730 P10721 0.807238 
CRK P46108 SYK Y352 P43405 0.14203 
CRK P46108 TYRO3 Y686 Q06418 0.780138 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
CRK P46108 PIK3CD Y440 O00329 0.87878 
CRK P46108 SRC Y187 P12931 0.951278 
CRK P46108 LYN Y194 P07948 0.366867 
CRK P46108 LYN Y265 P07948 0.329713 
CRK P46108 LYN Y460 P07948 0.472918 
CRK P46108 SHC3 Y342 Q92529 0.439218 
CRK P46108 RIN1 Y632 Q13671 0.532582 
CRK P46108 SHB Y297 Q15464 0.7483 
CRK P46108 TNS1 Y339 Q9HBL0 0.857306 
CRK P46108 TNS1 Y1345 Q9HBL0 0.580296 
CRK P46108 CBLB Y709 Q13191 0.410687 
CRK P46108 CBLB Y889 Q13191 0.212974 
CRK P46108 STAT1 Y203 P42224 0.367567 
CRK P46108 DOK4 Y255 Q8TEW6 0.173799 
CRK P46108 PTK2B Y834 Q14289 0.296704 
NCK1 P16333 RIN1 Y36 Q13671 0.773345 
NCK1 P16333 CBL Y368 P22681 0.61497 
NCK1 P16333 IRS2 Y675 Q9Y4H2 0.969245 
NCK1 P16333 SHB Y297 Q15464 0.712148 
SRC P12931 ALK Y1092 Q9UM73 0.60043 
SRC P12931 ALK Y1096 Q9UM73 0.832896 
SRC P12931 AXL Y866 P30530 0.920576 
SRC P12931 FGFR1 Y653 P11362 0.910884 
SRC P12931 FGFR3 Y724 P22607 0.600336 
SRC P12931 FLT1 Y1327 P17948 0.728706 
SRC P12931 FLT1 Y1333 P17948 0.714631 
SRC P12931 FLT3 Y591 P36888 0.946893 
SRC P12931 FLT3 Y597 P36888 0.304586 
SRC P12931 FLT4 Y1337 P35916 0.83551 
SRC P12931 IGF1R Y1161 P08069 0.893775 
SRC P12931 INSR Y1185 P06213 0.893775 
SRC P12931 IGF1R Y1165 P08069 0.84471 
SRC P12931 INSR Y1189 P06213 0.84471 
SRC P12931 IGF1R Y1281 P08069 0.929541 
SRC P12931 INSR Y1011 P06213 0.656615 
SRC P12931 INSR Y1355 P06213 0.902995 
SRC P12931 FLT4 Y1063 P35916 0.530055 
SRC P12931 KDR Y1054 P35968 0.530055 
SRC P12931 KIT Y721 P10721 0.865338 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SRC P12931 MET Y1313 P08581 0.620978 
SRC P12931 MET Y1349 P08581 0.579156 
SRC P12931 MET Y1356 P08581 0.48307 
SRC P12931 MET Y1365 P08581 0.82532 
SRC P12931 MST1R Y1317 Q04912 0.850414 
SRC P12931 NTRK2 Y707 Q16620 0.893073 
SRC P12931 NTRK3 Y710 Q16288 0.893073 
SRC P12931 NTRK2 Y817 Q16620 0.329342 
SRC P12931 NTRK3 Y516 Q16288 0.442639 
SRC P12931 PDGFRA Y574 P16234 0.581626 
SRC P12931 PDGFRB Y581 P09619 0.954544 
SRC P12931 PDGFRB Y778 P09619 0.975133 
SRC P12931 RET Y981 P07949 0.342694 
SRC P12931 RET Y1096 P07949 0.752956 
SRC P12931 TEK Y1048 Q02763 0.357874 
SRC P12931 ERBB2 Y1139 P04626 0.991981 
SRC P12931 ERBB2 Y1222 P04626 0.283326 
SRC P12931 ERBB3 Y1197 P21860 0.697298 
SRC P12931 ERBB3 Y1276 P21860 0.755275 
SRC P12931 RET Y952 P07949 0.484765 
SRC P12931 EPHA2 Y575 P29317 0.840205 
SRC P12931 EPHA2 Y735 P29317 0.958006 
SRC P12931 EPHA2 Y772 P29317 0.752683 
SRC P12931 EPHA7 Y597 Q15375 0.908591 
SRC P12931 ABL2 Y515 P42684 0.993295 
SRC P12931 ABL1 Y276 P00519 0.507701 
SRC P12931 EPHA1 Y605 P21709 0.963384 
SRC P12931 TXK Y91 P42681 0.617408 
SRC P12931 PTK6 Y447 Q13882 0.951337 
SRC P12931 PLCG1 Y472 P19174 0.763502 
SRC P12931 PLCG2 Y743 P16885 0.995082 
SRC P12931 GRAP2 Y45 O75791 0.745513 
SRC P12931 SH3BP2 Y183 P78314 0.853914 
SRC P12931 BLNK Y72 Q8WV28 0.83476 
SRC P12931 SH2D2A Y305 Q9NP31 0.765588 
SRC P12931 VAV1 Y160 P15498 0.557238 
SRC P12931 VAV2 Y172 P52735 0.94891 
SRC P12931 CBL Y337 P22681 0.977717 
SRC P12931 CBL Y368 P22681 0.748399 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SRC P12931 DOK1 Y146 Q99704 0.810844 
SRC P12931 DOK1 Y203 Q99704 0.79574 
SRC P12931 DOK1 Y315 Q99704 0.935102 
SRC P12931 DOK1 Y409 Q99704 0.619481 
SRC P12931 EPHB3 Y754 P54753 0.924912 
SRC P12931 ERBB2 Y1127 P04626 0.706778 
SRC P12931 IRS1 Y732 P35568 0.864099 
SRC P12931 IRS1 Y989 P35568 0.836248 
SRC P12931 IRS2 Y632 Q9Y4H2 0.786089 
SRC P12931 GAB1 Y373 Q13480 0.762992 
SRC P12931 GAB1 Y406 Q13480 0.917565 
SRC P12931 KIT Y553 P10721 0.902571 
SRC P12931 PDGFRB Y934 P09619 0.689683 
SRC P12931 ROS1 Y2115 P08922 0.911802 
SRC P12931 TENC1 Y483 Q63HR2 0.935817 
SRC P12931 PIK3R1 Y607 P27986 0.858838 
SRC P12931 ABL2 Y231 P42684 0.791048 
SRC P12931 ZAP70 Y69 P43403 0.969035 
SRC P12931 FGR Y180 P09769 0.969423 
SRC P12931 FYN Y185 P06241 0.969423 
SRC P12931 YES1 Y194 P07947 0.969423 
SRC P12931 SRC Y521 P12931 0.648028 
SRC P12931 VAV1 Y826 P15498 0.947995 
SRC P12931 VAV3 Y173 Q9UKW4 0.896622 
SRC P12931 TNS1 Y609 Q9HBL0 0.908339 
SRC P12931 TNS1 Y796 Q9HBL0 0.444779 
SRC P12931 CBLB Y889 Q13191 0.704231 
SRC P12931 APBB3 Y291 O95704 0.717352 
SRC P12931 ANKS1A Y454 Q92625 0.680003 
SRC P12931 CSK Y263 P41240 0.871967 
SRC P12931 PTK2 Y397 Q05397 0.957421 
SRC P12931 PTK2 Y1007 Q05397 0.867812 
SRC P12931 CTNNB1 Y142 P35222 0.647832 
ZAP70-C P43403 EPHA4 Y602 P54764 0.956248 
ZAP70-C P43403 NTRK3 Y516 Q16288 0.962351 
ZAP70-C P43403 RET Y1062 P07949 0.955927 
ZAP70-C P43403 PLCG2 Y1217 P16885 0.435345 
ZAP70-C P43403 NCK1 Y268 P16333 0.317429 
ZAP70-C P43403 DOK1 Y398 Q99704 0.943764 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
ZAP70-C P43403 IRS2 Y675 Q9Y4H2 0.375981 
SYK-C P43405 MST1R Y1360 Q04912 0.82143 
SYK-C P43405 NTRK1 Y496 P04629 0.849088 
SYK-C P43405 PDGFRA Y574 P16234 0.598208 
SYK-C P43405 PDGFRB Y1009 P09619 0.371276 
SYK-C P43405 PDGFRB Y1021 P09619 0.702923 
SYK-C P43405 EPHA7 Y791 Q15375 0.428996 
SYK-C P43405 PLCG2 Y1245 P16885 0.871387 
SYK-C P43405 NCK1 Y268 P16333 0.535432 
SYK-C P43405 EPHB3 Y754 P54753 0.761628 
SYK-C P43405 IRS1 Y46 P35568 0.826141 
SYK-C P43405 IRS1 Y989 P35568 0.802592 
SYK-C P43405 IRS2 Y675 Q9Y4H2 0.895185 
SYK-C P43405 PIK3R2 Y365 O00459 0.80629 
SYK-C P43405 SHC3 Y424 Q92529 0.80629 
SYK-C P43405 ABL1 Y191 P00519 0.542141 
SYK-C P43405 TNS1 Y366 Q9HBL0 0.408698 
TEC P42680 EPHA4 Y596 P54764 0.465051 
TEC P42680 EPHB1 Y600 P54762 0.637167 
TEC P42680 EPHB2 Y602 P29323 0.637167 
TEC P42680 FGFR1 Y653 P11362 0.4387 
TEC P42680 FLT3 Y597 P36888 0.448936 
TEC P42680 INSR Y999 P06213 0.912736 
TEC P42680 INSR Y1011 P06213 0.830824 
TEC P42680 KIT Y900 P10721 0.937649 
TEC P42680 MET Y1313 P08581 0.991099 
TEC P42680 MST1R Y1317 Q04912 0.990729 
TEC P42680 NTRK1 Y496 P04629 0.655992 
TEC P42680 ERBB2 Y1139 P04626 0.995131 
TEC P42680 ERBB2 Y1221 P04626 0.602349 
TEC P42680 FES Y811 P07332 0.851665 
TEC P42680 NCK1 Y268 P16333 0.285169 
TEC P42680 SH2D3A Y231 Q9BRG2 0.870873 
TEC P42680 VAV1 Y160 P15498 0.748368 
TEC P42680 DOK1 Y315 Q99704 0.900355 
TEC P42680 IRS2 Y823 Q9Y4H2 0.876621 
TEC P42680 ABL1 Y191 P00519 0.688003 
TEC P42680 CSK Y263 P41240 0.970701 
TEC P42680 CTNNB1 Y142 P35222 0.162082 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
LYN P07948 FLT1 Y1327 P17948 0.493988 
LYN P07948 FLT3 Y591 P36888 0.786342 
LYN P07948 INSR Y1011 P06213 0.616429 
LYN P07948 KIT Y721 P10721 0.462819 
LYN P07948 MET Y1313 P08581 0.562721 
LYN P07948 MET Y1356 P08581 0.61833 
LYN P07948 MST1R Y1317 Q04912 0.725729 
LYN P07948 PDGFRA Y572 P16234 0.874822 
LYN P07948 PDGFRB Y581 P09619 0.921378 
LYN P07948 PDGFRB Y1009 P09619 0.73063 
LYN P07948 PDGFRB Y1021 P09619 0.945782 
LYN P07948 RET Y981 P07949 0.544262 
LYN P07948 ERBB2 Y1221 P04626 0.466276 
LYN P07948 ABL1 Y276 P00519 0.751777 
LYN P07948 FGR Y412 P09769 0.669368 
LYN P07948 PLCG1 Y472 P19174 0.78483 
LYN P07948 PLCG1 Y771 P19174 0.818827 
LYN P07948 PLCG1 Y783 P19174 0.846372 
LYN P07948 PLCG2 Y743 P16885 0.766496 
LYN P07948 PLCG2 Y1217 P16885 0.866726 
LYN P07948 RASA1 Y615 P20936 0.177009 
LYN P07948 SH2D2A Y39 Q9NP31 0.915167 
LYN P07948 VAV1 Y160 P15498 0.91412 
LYN P07948 CBL Y368 P22681 0.968486 
LYN P07948 EPHA3 Y937 P29320 0.784812 
LYN P07948 IRS1 Y612 P35568 0.449398 
LYN P07948 IRS1 Y732 P35568 0.559194 
LYN P07948 IRS1 Y896 P35568 0.66083 
LYN P07948 IRS2 Y823 Q9Y4H2 0.960953 
LYN P07948 PIK3R1 Y607 P27986 0.905318 
LYN P07948 PIK3R1 Y463 P27986 0.719716 
LYN P07948 SYK Y203 P43405 0.655063 
LYN P07948 VAV3 Y173 Q9UKW4 0.913258 
LYN P07948 SHB Y336 Q15464 0.45712 
LYN P07948 ANKS1A Y454 Q92625 0.820219 
LYN P07948 PTK2 Y925 Q05397 0.881321 
VAV1 P15498 MET Y1313 P08581 0.378954 
VAV1 P15498 MET Y1356 P08581 0.515973 
VAV1 P15498 ERBB2 Y1139 P04626 0.860416 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
VAV1 P15498 PLCG2 Y1245 P16885 0.772974 
VAV1 P15498 CBL Y368 P22681 0.691798 
VAV1 P15498 CBL Y371 P22681 0.695921 
VAV1 P15498 CBLB Y363 Q13191 0.695921 
VAV1 P15498 CBL Y700 P22681 0.89631 
VAV1 P15498 DOK1 Y398 Q99704 0.745427 
VAV1 P15498 IRS1 Y465 P35568 0.832949 
VAV1 P15498 IRS2 Y675 Q9Y4H2 0.590692 
TNS3 Q68CZ2 EPHB1 Y600 P54762 0.915587 
TNS3 Q68CZ2 EPHB2 Y602 P29323 0.915587 
TNS3 Q68CZ2 FGFR3 Y724 P22607 0.521275 
TNS3 Q68CZ2 FLT1 Y1333 P17948 0.165855 
TNS3 Q68CZ2 FLT3 Y591 P36888 0.708676 
TNS3 Q68CZ2 INSR Y1011 P06213 0.918871 
TNS3 Q68CZ2 KDR Y996 P35968 0.847783 
TNS3 Q68CZ2 KDR Y1214 P35968 0.547381 
TNS3 Q68CZ2 MET Y1230 P08581 0.928767 
TNS3 Q68CZ2 MET Y1313 P08581 0.855099 
TNS3 Q68CZ2 MST1R Y1317 Q04912 0.582801 
TNS3 Q68CZ2 PDGFRB Y740 P09619 0.532523 
TNS3 Q68CZ2 PDGFRB Y778 P09619 0.356537 
TNS3 Q68CZ2 RET Y1029 P07949 0.906173 
TNS3 Q68CZ2 RET Y1062 P07949 0.974042 
TNS3 Q68CZ2 AXL Y759 P30530 0.88015 
TNS3 Q68CZ2 VAV1 Y160 P15498 0.904452 
TNS3 Q68CZ2 VAV2 Y159 P52735 0.997128 
TNS3 Q68CZ2 CBL Y368 P22681 0.778722 
TNS3 Q68CZ2 DOK1 Y315 Q99704 0.816009 
TNS3 Q68CZ2 ABL1 Y191 P00519 0.686554 
TNS3 Q68CZ2 VAV3 Y173 Q9UKW4 0.621131 
TNS3 Q68CZ2 TNS1 Y339 Q9HBL0 0.621933 
BLK P51451 ALK Y1092 Q9UM73 0.311961 
BLK P51451 ALK Y1096 Q9UM73 0.754373 
BLK P51451 ALK Y1507 Q9UM73 0.689454 
BLK P51451 AXL Y866 P30530 0.979741 
BLK P51451 CSF1R Y561 P07333 0.242463 
BLK P51451 EPHB1 Y600 P54762 0.80471 
BLK P51451 EPHB2 Y602 P29323 0.80471 
BLK P51451 EPHB2 Y596 P29323 0.588141 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
BLK P51451 FGFR1 Y730 P11362 0.6997 
BLK P51451 FGFR3 Y724 P22607 0.51551 
BLK P51451 FGFR3 Y760 P22607 0.709331 
BLK P51451 FLT1 Y1327 P17948 0.578464 
BLK P51451 FLT3 Y591 P36888 0.617824 
BLK P51451 IGF1R Y1280 P08069 0.642896 
BLK P51451 INSR Y999 P06213 0.794899 
BLK P51451 INSR Y1011 P06213 0.281975 
BLK P51451 KDR Y996 P35968 0.892938 
BLK P51451 FLT4 Y1063 P35916 0.938482 
BLK P51451 KDR Y1054 P35968 0.938482 
BLK P51451 KDR Y1214 P35968 0.937494 
BLK P51451 KIT Y721 P10721 0.931329 
BLK P51451 KIT Y900 P10721 0.166929 
BLK P51451 KIT Y936 P10721 0.572169 
BLK P51451 MET Y1313 P08581 0.279024 
BLK P51451 MET Y1356 P08581 0.979099 
BLK P51451 MET Y1365 P08581 0.548638 
BLK P51451 MST1R Y1317 Q04912 0.452987 
BLK P51451 NTRK1 Y496 P04629 0.656727 
BLK P51451 NTRK3 Y516 Q16288 0.352913 
BLK P51451 PDGFRA Y572 P16234 0.845157 
BLK P51451 PDGFRA Y574 P16234 0.982432 
BLK P51451 PDGFRA Y731 P16234 0.852887 
BLK P51451 PDGFRB Y562 P09619 0.958547 
BLK P51451 PDGFRB Y751 P09619 0.672591 
BLK P51451 PDGFRB Y1021 P09619 0.933105 
BLK P51451 RET Y791 P07949 0.221836 
BLK P51451 RET Y900 P07949 0.896467 
BLK P51451 RET Y1062 P07949 0.914228 
BLK P51451 RET Y1096 P07949 0.768643 
BLK P51451 ROS1 Y2274 P08922 0.412125 
BLK P51451 ROS1 Y2334 P08922 0.687176 
BLK P51451 TEK Y1048 Q02763 0.266521 
BLK P51451 TEK Y1102 Q02763 0.662038 
BLK P51451 ERBB4 Y1066 Q15303 0.451814 
BLK P51451 ERBB4 Y1284 Q15303 0.945438 
BLK P51451 EGFR Y1016 P00533 0.97281 
BLK P51451 EGFR Y1172 P00533 0.827142 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
BLK P51451 ERBB2 Y1023 P04626 0.578631 
BLK P51451 ERBB2 Y1221 P04626 0.275989 
BLK P51451 ERBB2 Y1222 P04626 0.238877 
BLK P51451 ERBB3 Y1197 P21860 0.696158 
BLK P51451 ERBB3 Y1276 P21860 0.844846 
BLK P51451 EPHA2 Y772 P29317 0.697581 
BLK P51451 EPHA7 Y597 Q15375 0.972784 
BLK P51451 ABL2 Y515 P42684 0.776505 
BLK P51451 ABL1 Y276 P00519 0.334744 
BLK P51451 EPHA1 Y599 P21709 0.579535 
BLK P51451 PLCG1 Y472 P19174 0.542661 
BLK P51451 PLCG1 Y771 P19174 0.93885 
BLK P51451 PLCG1 Y783 P19174 0.947249 
BLK P51451 PLCG2 Y1217 P16885 0.952709 
BLK P51451 RASA1 Y460 P20936 0.878273 
BLK P51451 RASA1 Y615 P20936 0.306404 
BLK P51451 SH2D2A Y39 Q9NP31 0.762461 
BLK P51451 SH2D2A Y305 Q9NP31 0.990522 
BLK P51451 VAV2 Y159 P52735 0.646544 
BLK P51451 CBL Y371 P22681 0.772872 
BLK P51451 CBLB Y363 Q13191 0.772872 
BLK P51451 DOK1 Y315 Q99704 0.960368 
BLK P51451 DOK1 Y398 Q99704 0.21348 
BLK P51451 DOK2 Y345 O60496 0.588753 
BLK P51451 EPHB3 Y754 P54753 0.954192 
BLK P51451 ERBB2 Y1005 P04626 0.846865 
BLK P51451 IRS1 Y46 P35568 0.899254 
BLK P51451 IRS1 Y896 P35568 0.516524 
BLK P51451 IRS2 Y675 Q9Y4H2 0.603569 
BLK P51451 IRS2 Y823 Q9Y4H2 0.746569 
BLK P51451 PIK3R1 Y607 P27986 0.972204 
BLK P51451 ABL1 Y191 P00519 0.87592 
BLK P51451 SYK Y203 P43405 0.654192 
BLK P51451 LYN Y501 P07948 0.923185 
BLK P51451 VAV1 Y826 P15498 0.335587 
BLK P51451 TNS1 Y903 Q9HBL0 0.940374 
BLK P51451 CTNNB1 Y670 P35222 0.236333 
TNS1 Q9HBL0 MET Y1356 P08581 0.875463 
TNS1 Q9HBL0 NTRK3 Y516 Q16288 0.611884 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
TNS1 Q9HBL0 FRS2 Y436 Q8WU20 0.391508 
TNS1 Q9HBL0 PTK6 Y342 Q13882 0.89789 
TNS1 Q9HBL0 PLCG1 Y775 P19174 0.993887 
TNS1 Q9HBL0 DAB1 Y198 O75553 0.480213 
TNS1 Q9HBL0 DOK1 Y315 Q99704 0.818917 
TNS1 Q9HBL0 IRS1 Y732 P35568 0.622766 
NCK2 O43639 EPHA3 Y596 P29320 0.951239 
NCK2 O43639 EPHA3 Y602 P29320 0.776285 
NCK2 O43639 EPHA4 Y602 P54764 0.698356 
NCK2 O43639 EPHB1 Y600 P54762 0.565206 
NCK2 O43639 EPHB2 Y602 P29323 0.565206 
NCK2 O43639 FGFR1 Y653 P11362 0.805978 
NCK2 O43639 FGFR1 Y730 P11362 0.948439 
NCK2 O43639 FLT1 Y1213 P17948 0.663572 
NCK2 O43639 FLT1 Y1327 P17948 0.668134 
NCK2 O43639 FLT3 Y591 P36888 0.398276 
NCK2 O43639 FLT4 Y1063 P35916 0.409639 
NCK2 O43639 KDR Y1054 P35968 0.409639 
NCK2 O43639 KDR Y1214 P35968 0.587666 
NCK2 O43639 KIT Y900 P10721 0.273641 
NCK2 O43639 KIT Y936 P10721 0.439134 
NCK2 O43639 MET Y1356 P08581 0.765058 
NCK2 O43639 MST1R Y1317 Q04912 0.310058 
NCK2 O43639 NTRK1 Y496 P04629 0.84544 
NCK2 O43639 NTRK1 Y791 P04629 0.374247 
NCK2 O43639 NTRK2 Y706 Q16620 0.593753 
NCK2 O43639 NTRK3 Y709 Q16288 0.593753 
NCK2 O43639 NTRK3 Y516 Q16288 0.40704 
NCK2 O43639 PDGFRB Y771 P09619 0.883413 
NCK2 O43639 TEK Y1048 Q02763 0.981106 
NCK2 O43639 FRS2 Y306 Q8WU20 0.569164 
NCK2 O43639 EGFR Y1138 P00533 0.464281 
NCK2 O43639 ERBB2 Y1023 P04626 0.521967 
NCK2 O43639 ERBB2 Y1196 P04626 0.69839 
NCK2 O43639 EPHA2 Y575 P29317 0.963606 
NCK2 O43639 EPHA2 Y588 P29317 0.812319 
NCK2 O43639 EPHA2 Y735 P29317 0.890666 
NCK2 O43639 EPHA2 Y921 P29317 0.914271 
NCK2 O43639 FYN Y420 P06241 0.693538 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
NCK2 O43639 YES1 Y426 P07947 0.693538 
NCK2 O43639 EPHA1 Y605 P21709 0.936811 
NCK2 O43639 SYK Y348 P43405 0.582365 
NCK2 O43639 TEC Y206 P42680 0.970587 
NCK2 O43639 LYN Y508 P07948 0.386666 
NCK2 O43639 TXK Y91 P42681 0.394609 
NCK2 O43639 TXK Y420 P42681 0.839778 
NCK2 O43639 FER Y402 P16591 0.949682 
NCK2 O43639 LCK Y192 P06239 0.830437 
NCK2 O43639 FES Y811 P07332 0.979915 
NCK2 O43639 PLCG1 Y775 P19174 0.894273 
NCK2 O43639 PLCG1 Y783 P19174 0.633912 
NCK2 O43639 PLCG2 Y753 P16885 0.721693 
NCK2 O43639 PLCG2 Y1217 P16885 0.952832 
NCK2 O43639 PLCG2 Y1245 P16885 0.718534 
NCK2 O43639 CRKL Y207 P46109 0.658348 
NCK2 O43639 JAK3 Y785 P52333 0.865833 
NCK2 O43639 LCP2 Y128 Q13094 0.575424 
NCK2 O43639 BLNK Y178 Q8WV28 0.707321 
NCK2 O43639 SH2D2A Y39 Q9NP31 0.435623 
NCK2 O43639 SH2D2A Y280 Q9NP31 0.650341 
NCK2 O43639 VAV1 Y160 P15498 0.242317 
NCK2 O43639 VAV1 Y174 P15498 0.875792 
NCK2 O43639 VAV2 Y159 P52735 0.554906 
NCK2 O43639 VAV2 Y172 P52735 0.657495 
NCK2 O43639 INPPL1 Y886 O15357 0.845583 
NCK2 O43639 SHB Y246 Q15464 0.568756 
NCK2 O43639 CBL Y337 P22681 0.760231 
NCK2 O43639 CBL Y368 P22681 0.347346 
NCK2 O43639 CBL Y700 P22681 0.529221 
NCK2 O43639 DAB1 Y198 O75553 0.721225 
NCK2 O43639 DAB1 Y220 O75553 0.747136 
NCK2 O43639 DAB1 Y232 O75553 0.795318 
NCK2 O43639 DOK1 Y146 Q99704 0.45217 
NCK2 O43639 DOK1 Y315 Q99704 0.334554 
NCK2 O43639 EPHA3 Y937 P29320 0.82661 
NCK2 O43639 EPHB3 Y754 P54753 0.94914 
NCK2 O43639 EPHB3 Y924 P54753 0.872637 
NCK2 O43639 EPHB4 Y596 P54760 0.766664 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
NCK2 O43639 IRS1 Y465 P35568 0.660747 
NCK2 O43639 IRS1 Y662 P35568 0.73198 
NCK2 O43639 IRS1 Y732 P35568 0.881102 
NCK2 O43639 IRS1 Y989 P35568 0.684974 
NCK2 O43639 IRS2 Y823 Q9Y4H2 0.557295 
NCK2 O43639 GAB1 Y406 Q13480 0.660844 
NCK2 O43639 ABL1 Y272 P00519 0.387665 
NCK2 O43639 PIK3CB Y772 P42338 0.969031 
NCK2 O43639 PIK3CD Y440 O00329 0.857561 
NCK2 O43639 SRC Y521 P12931 0.964647 
NCK2 O43639 SYK Y203 P43405 0.553831 
NCK2 O43639 SHC3 Y406 Q92529 0.467301 
NCK2 O43639 RIN1 Y632 Q13671 0.505348 
NCK2 O43639 VAV3 Y173 Q9UKW4 0.979011 
NCK2 O43639 HSH2D Y265 Q96JZ2 0.875152 
NCK2 O43639 SHB Y297 Q15464 0.958097 
NCK2 O43639 SHB Y336 Q15464 0.592232 
NCK2 O43639 TNS1 Y1440 Q9HBL0 0.732241 
NCK2 O43639 PTK2 Y861 Q05397 0.84555 
VAV3 Q9UKW4 FGFR3 Y724 P22607 0.631686 
VAV3 Q9UKW4 IGF1R Y1280 P08069 0.634733 
VAV3 Q9UKW4 INSR Y1011 P06213 0.718289 
VAV3 Q9UKW4 MET Y1313 P08581 0.716443 
VAV3 Q9UKW4 MET Y1356 P08581 0.509291 
VAV3 Q9UKW4 MST1R Y1317 Q04912 0.374723 
VAV3 Q9UKW4 NTRK1 Y496 P04629 0.655709 
VAV3 Q9UKW4 NTRK1 Y676 P04629 0.629983 
VAV3 Q9UKW4 NTRK2 Y706 Q16620 0.973482 
VAV3 Q9UKW4 NTRK3 Y709 Q16288 0.973482 
VAV3 Q9UKW4 NTRK2 Y707 Q16620 0.943959 
VAV3 Q9UKW4 NTRK3 Y710 Q16288 0.943959 
VAV3 Q9UKW4 NTRK3 Y516 Q16288 0.863065 
VAV3 Q9UKW4 PDGFRB Y581 P09619 0.944868 
VAV3 Q9UKW4 RET Y1096 P07949 0.934777 
VAV3 Q9UKW4 ERBB2 Y1023 P04626 0.79232 
VAV3 Q9UKW4 ERBB2 Y1221 P04626 0.570909 
VAV3 Q9UKW4 ERBB2 Y1222 P04626 0.324798 
VAV3 Q9UKW4 RET Y952 P07949 0.626448 
VAV3 Q9UKW4 EPHA2 Y960 P29317 0.470523 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
VAV3 Q9UKW4 ABL1 Y276 P00519 0.619277 
VAV3 Q9UKW4 ZAP70 Y474 P43403 0.676668 
VAV3 Q9UKW4 SYK Y525 P43405 0.955027 
VAV3 Q9UKW4 TXK Y91 P42681 0.736731 
VAV3 Q9UKW4 PLCG1 Y771 P19174 0.778522 
VAV3 Q9UKW4 PLCG2 Y743 P16885 0.955008 
VAV3 Q9UKW4 PLCG2 Y753 P16885 0.979992 
VAV3 Q9UKW4 GRAP2 Y45 O75791 0.656461 
VAV3 Q9UKW4 SH3BP2 Y183 P78314 0.511169 
VAV3 Q9UKW4 JAK3 Y785 P52333 0.953899 
VAV3 Q9UKW4 BLNK Y72 Q8WV28 0.761605 
VAV3 Q9UKW4 BLNK Y84 Q8WV28 0.855743 
VAV3 Q9UKW4 BLNK Y178 Q8WV28 0.872183 
VAV3 Q9UKW4 RASA1 Y460 P20936 0.841192 
VAV3 Q9UKW4 RASA1 Y615 P20936 0.25379 
VAV3 Q9UKW4 DAB1 Y198 O75553 0.912819 
VAV3 Q9UKW4 DAB1 Y220 O75553 0.707196 
VAV3 Q9UKW4 DOK1 Y203 Q99704 0.985796 
VAV3 Q9UKW4 DOK1 Y362 Q99704 0.881641 
VAV3 Q9UKW4 DOK1 Y398 Q99704 0.75636 
VAV3 Q9UKW4 DOK2 Y345 O60496 0.746521 
VAV3 Q9UKW4 EPHB3 Y600 P54753 0.787584 
VAV3 Q9UKW4 IRS1 Y896 P35568 0.735172 
VAV3 Q9UKW4 IRS2 Y675 Q9Y4H2 0.984852 
VAV3 Q9UKW4 ANKS1A Y454 Q92625 0.769611 
VAV2 P52735 EPHA3 Y602 P29320 0.666383 
VAV2 P52735 EPHA4 Y596 P54764 0.924083 
VAV2 P52735 EPHB1 Y600 P54762 0.338282 
VAV2 P52735 EPHB2 Y602 P29323 0.338282 
VAV2 P52735 FGFR3 Y724 P22607 0.397303 
VAV2 P52735 FLT3 Y597 P36888 0.517517 
VAV2 P52735 IGF1R Y1161 P08069 0.628211 
VAV2 P52735 INSR Y1185 P06213 0.628211 
VAV2 P52735 PDGFRB Y775 P09619 0.300923 
VAV2 P52735 RET Y1096 P07949 0.518714 
VAV2 P52735 ERBB4 Y1162 Q15303 0.388247 
VAV2 P52735 EGFR Y1016 P00533 0.19408 
VAV2 P52735 EGFR Y1092 P00533 0.493044 
VAV2 P52735 EGFR Y1138 P00533 0.527405 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
VAV2 P52735 ERBB2 Y1196 P04626 0.203923 
VAV2 P52735 EPHA2 Y772 P29317 0.520572 
VAV2 P52735 ZAP70 Y315 P43403 0.635398 
VAV2 P52735 PLCG2 Y1245 P16885 0.787083 
VAV2 P52735 NCK1 Y268 P16333 0.619488 
VAV2 P52735 BLNK Y178 Q8WV28 0.231245 
VAV2 P52735 VAV2 Y172 P52735 0.992273 
VAV2 P52735 CBL Y700 P22681 0.48309 
VAV2 P52735 DAB1 Y220 O75553 0.358264 
VAV2 P52735 DOK1 Y315 Q99704 0.536042 
VAV2 P52735 EPHB4 Y596 P54760 0.608327 
VAV2 P52735 IRS1 Y896 P35568 0.693549 
VAV2 P52735 CSK Y263 P41240 0.957677 
ITK Q08881 ALK Y1092 Q9UM73 0.372164 
ITK Q08881 AXL Y821 P30530 0.893144 
ITK Q08881 FGFR3 Y724 P22607 0.467283 
ITK Q08881 FGFR3 Y760 P22607 0.286035 
ITK Q08881 FLT1 Y1327 P17948 0.414692 
ITK Q08881 FLT3 Y591 P36888 0.483081 
ITK Q08881 IGF1R Y1281 P08069 0.855365 
ITK Q08881 INSR Y1011 P06213 0.449406 
ITK Q08881 KIT Y721 P10721 0.771895 
ITK Q08881 KIT Y900 P10721 0.221157 
ITK Q08881 MET Y1356 P08581 0.721717 
ITK Q08881 MST1R Y1317 Q04912 0.263779 
ITK Q08881 NTRK1 Y496 P04629 0.927361 
ITK Q08881 NTRK2 Y706 Q16620 0.95243 
ITK Q08881 NTRK3 Y709 Q16288 0.95243 
ITK Q08881 NTRK2 Y817 Q16620 0.390874 
ITK Q08881 NTRK3 Y516 Q16288 0.402405 
ITK Q08881 PDGFRB Y581 P09619 0.582678 
ITK Q08881 PDGFRB Y778 P09619 0.585723 
ITK Q08881 RET Y791 P07949 0.226029 
ITK Q08881 RET Y981 P07949 0.251441 
ITK Q08881 RET Y1096 P07949 0.657518 
ITK Q08881 ROS1 Y2274 P08922 0.674864 
ITK Q08881 ROS1 Y2334 P08922 0.741821 
ITK Q08881 ERBB2 Y1023 P04626 0.642546 
ITK Q08881 ERBB2 Y1222 P04626 0.215427 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
ITK Q08881 EPHA7 Y614 Q15375 0.695234 
ITK Q08881 ABL1 Y276 P00519 0.536265 
ITK Q08881 SYK Y323 P43405 0.993644 
ITK Q08881 LCK Y192 P06239 0.861133 
ITK Q08881 FES Y811 P07332 0.924129 
ITK Q08881 PLCG1 Y472 P19174 0.903925 
ITK Q08881 PLCG1 Y775 P19174 0.961216 
ITK Q08881 PLCG2 Y743 P16885 0.92498 
ITK Q08881 PLCG2 Y1217 P16885 0.90778 
ITK Q08881 GRAP2 Y45 O75791 0.7629 
ITK Q08881 NCK1 Y268 P16333 0.954886 
ITK Q08881 JAK3 Y785 P52333 0.961036 
ITK Q08881 BLNK Y72 Q8WV28 0.947949 
ITK Q08881 RASA1 Y460 P20936 0.499338 
ITK Q08881 RASA1 Y615 P20936 0.432281 
ITK Q08881 SH2D2A Y290 Q9NP31 0.862876 
ITK Q08881 SH2D3C Y495 Q8N5H7 0.870204 
ITK Q08881 VAV1 Y174 P15498 0.816334 
ITK Q08881 VAV2 Y172 P52735 0.871924 
ITK Q08881 CBL Y368 P22681 0.580656 
ITK Q08881 CBL Y371 P22681 0.917349 
ITK Q08881 CBLB Y363 Q13191 0.917349 
ITK Q08881 CBL Y700 P22681 0.862738 
ITK Q08881 DAB1 Y198 O75553 0.952965 
ITK Q08881 DOK1 Y146 Q99704 0.970119 
ITK Q08881 DOK1 Y315 Q99704 0.579054 
ITK Q08881 DOK1 Y398 Q99704 0.612668 
ITK Q08881 EPHA3 Y937 P29320 0.794982 
ITK Q08881 EPHB3 Y754 P54753 0.77223 
ITK Q08881 IRS1 Y465 P35568 0.829644 
ITK Q08881 IRS1 Y732 P35568 0.695192 
ITK Q08881 IRS1 Y1179 P35568 0.604916 
ITK Q08881 IRS2 Y675 Q9Y4H2 0.98248 
ITK Q08881 GAB1 Y406 Q13480 0.606705 
ITK Q08881 ZAP70 Y319 P43403 0.954391 
ITK Q08881 PIK3R1 Y607 P27986 0.653629 
ITK Q08881 ABL1 Y191 P00519 0.673676 
ITK Q08881 SYK Y203 P43405 0.704784 
ITK Q08881 VAV1 Y826 P15498 0.674055 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
ITK Q08881 SHB Y336 Q15464 0.435671 
ITK Q08881 TNS1 Y366 Q9HBL0 0.995223 
ITK Q08881 TNS1 Y609 Q9HBL0 0.76557 
ITK Q08881 DOK3 Y208 Q7L591 0.726065 
ITK Q08881 PTK2 Y5 Q05397 0.697399 
YES1 P07947 ALK Y1092 Q9UM73 0.543299 
YES1 P07947 ALK Y1096 Q9UM73 0.685897 
YES1 P07947 AXL Y821 P30530 0.780827 
YES1 P07947 AXL Y866 P30530 0.871889 
YES1 P07947 EPHB1 Y600 P54762 0.877021 
YES1 P07947 EPHB2 Y602 P29323 0.877021 
YES1 P07947 FGFR1 Y463 P11362 0.678075 
YES1 P07947 FGFR1 Y605 P11362 0.798665 
YES1 P07947 FGFR1 Y730 P11362 0.890589 
YES1 P07947 FGFR3 Y724 P22607 0.632292 
YES1 P07947 FLT1 Y1327 P17948 0.787302 
YES1 P07947 FLT1 Y1333 P17948 0.486804 
YES1 P07947 FLT3 Y591 P36888 0.920378 
YES1 P07947 FLT3 Y597 P36888 0.22779 
YES1 P07947 FLT3 Y599 P36888 0.169964 
YES1 P07947 FLT4 Y1337 P35916 0.896426 
YES1 P07947 IGF1R Y1161 P08069 0.967256 
YES1 P07947 INSR Y1185 P06213 0.967256 
YES1 P07947 IGF1R Y1165 P08069 0.866891 
YES1 P07947 INSR Y1189 P06213 0.866891 
YES1 P07947 INSR Y1011 P06213 0.539684 
YES1 P07947 KDR Y801 P35968 0.925086 
YES1 P07947 FLT4 Y1063 P35916 0.793059 
YES1 P07947 KDR Y1054 P35968 0.793059 
YES1 P07947 KIT Y721 P10721 0.740977 
YES1 P07947 KIT Y936 P10721 0.575454 
YES1 P07947 MET Y1313 P08581 0.570601 
YES1 P07947 MET Y1356 P08581 0.585255 
YES1 P07947 MET Y1365 P08581 0.811167 
YES1 P07947 MST1R Y1317 Q04912 0.462757 
YES1 P07947 MST1R Y1353 Q04912 0.62886 
YES1 P07947 NTRK1 Y496 P04629 0.907454 
YES1 P07947 NTRK3 Y516 Q16288 0.287207 
YES1 P07947 PDGFRA Y574 P16234 0.654427 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
YES1 P07947 PDGFRB Y751 P09619 0.992637 
YES1 P07947 PDGFRB Y763 P09619 0.693615 
YES1 P07947 RET Y791 P07949 0.359942 
YES1 P07947 RET Y900 P07949 0.79969 
YES1 P07947 RET Y981 P07949 0.317781 
YES1 P07947 RET Y1096 P07949 0.601162 
YES1 P07947 ROS1 Y2274 P08922 0.756808 
YES1 P07947 ROS1 Y2334 P08922 0.919651 
YES1 P07947 TEK Y1048 Q02763 0.457668 
YES1 P07947 TEK Y1102 Q02763 0.920997 
YES1 P07947 FRS2 Y196 Q8WU20 0.838552 
YES1 P07947 EGFR Y1092 P00533 0.934067 
YES1 P07947 EGFR Y1172 P00533 0.809628 
YES1 P07947 ERBB2 Y1023 P04626 0.926775 
YES1 P07947 ERBB2 Y1222 P04626 0.254196 
YES1 P07947 ERBB3 Y1197 P21860 0.546518 
YES1 P07947 ERBB3 Y1289 P21860 0.361518 
YES1 P07947 RET Y952 P07949 0.238772 
YES1 P07947 EPHA2 Y960 P29317 0.630127 
YES1 P07947 EPHA7 Y614 Q15375 0.395618 
YES1 P07947 EPHA7 Y791 Q15375 0.982929 
YES1 P07947 ABL2 Y515 P42684 0.790254 
YES1 P07947 ABL1 Y276 P00519 0.451235 
YES1 P07947 FYN Y420 P06241 0.920565 
YES1 P07947 SRC Y419 P12931 0.920565 
YES1 P07947 YES1 Y426 P07947 0.920565 
YES1 P07947 EPHA1 Y599 P21709 0.779634 
YES1 P07947 EPHA1 Y605 P21709 0.610979 
YES1 P07947 EPHA1 Y781 P21709 0.767157 
YES1 P07947 SYK Y323 P43405 0.731821 
YES1 P07947 TXK Y91 P42681 0.728357 
YES1 P07947 GRB2 Y209 P62993 0.730525 
YES1 P07947 GRAP2 Y45 O75791 0.262348 
YES1 P07947 SH2D2A Y290 Q9NP31 0.562926 
YES1 P07947 CBL Y368 P22681 0.837451 
YES1 P07947 CBL Y774 P22681 0.574869 
YES1 P07947 DAB1 Y198 O75553 0.677169 
YES1 P07947 DOK1 Y203 Q99704 0.88107 
YES1 P07947 DOK1 Y296 Q99704 0.569766 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
YES1 P07947 DOK1 Y377 Q99704 0.811104 
YES1 P07947 DOK2 Y299 O60496 0.647832 
YES1 P07947 EPHA3 Y937 P29320 0.660281 
YES1 P07947 EPHA5 Y656 P54756 0.610199 
YES1 P07947 EPHB1 Y634 P54762 0.748088 
YES1 P07947 ERBB2 Y1127 P04626 0.544232 
YES1 P07947 IRS1 Y465 P35568 0.984137 
YES1 P07947 IRS1 Y732 P35568 0.698915 
YES1 P07947 IRS1 Y896 P35568 0.74887 
YES1 P07947 IRS2 Y823 Q9Y4H2 0.867405 
YES1 P07947 PIK3R1 Y368 P27986 0.158593 
YES1 P07947 PIK3R1 Y467 P27986 0.324605 
YES1 P07947 PIK3R1 Y556 P27986 0.899202 
YES1 P07947 PIK3CB Y772 P42338 0.762953 
YES1 P07947 PIK3CD Y440 O00329 0.931903 
YES1 P07947 ABL2 Y683 P42684 0.816455 
YES1 P07947 ABL1 Y191 P00519 0.97613 
YES1 P07947 SRC Y521 P12931 0.748584 
YES1 P07947 SYK Y203 P43405 0.514539 
YES1 P07947 TEC Y519 P42680 0.931513 
YES1 P07947 PTPN11 Y304 Q06124 0.770958 
YES1 P07947 PTPN11 Y584 Q06124 0.773108 
YES1 P07947 SHB Y336 Q15464 0.664768 
YES1 P07947 ANKS1A Y454 Q92625 0.305026 
YES1 P07947 ANKS1A Y833 Q92625 0.618299 
YES1 P07947 CTNNB1 Y333 P35222 0.774805 
SH2D1A O60880 EPHB1 Y778 P54762 0.603919 
SH2D1A O60880 FLT1 Y1327 P17948 0.998294 
SH2D1A O60880 FLT3 Y597 P36888 0.680484 
SH2D1A O60880 MST1R Y1317 Q04912 0.741659 
SH2D1A O60880 NTRK1 Y496 P04629 0.786467 
SH2D1A O60880 RET Y981 P07949 0.553292 
SH2D1A O60880 DAB1 Y198 O75553 0.535907 
SH2D1A O60880 ERBB2 Y735 P04626 0.831209 
SH2D1A O60880 IRS1 Y465 P35568 0.782444 
SH2D1A O60880 TNS1 Y366 Q9HBL0 0.921502 
SH2D1A O60880 TNS1 Y796 Q9HBL0 0.340946 
SH2D1A O60880 TNS1 Y1144 Q9HBL0 0.556188 
SH2D1A O60880 MAPRE1 Y124 Q15691 0.88945 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
STAP1 Q9ULZ2 NTRK1 Y496 P04629 0.244684 
STAP1 Q9ULZ2 NTRK2 Y706 Q16620 0.296647 
STAP1 Q9ULZ2 NTRK3 Y709 Q16288 0.296647 
STAP1 Q9ULZ2 PDGFRB Y775 P09619 0.87605 
STAP1 Q9ULZ2 ERBB3 Y1276 P21860 0.777912 
STAP1 Q9ULZ2 SRC Y216 P12931 0.956353 
STAP1 Q9ULZ2 CSF1R Y923 P07333 0.743592 
STAP1 Q9ULZ2 ZAP70 Y493 P43403 0.496419 
STAP1 Q9ULZ2 EPHA3 Y937 P29320 0.778831 
STAP1 Q9ULZ2 EPHB1 Y575 P54762 0.765845 
STAP1 Q9ULZ2 ROS1 Y2110 P08922 0.402391 
STAP1 Q9ULZ2 FGR Y34 P09769 0.354288 
STAP1 Q9ULZ2 FGR Y180 P09769 0.385959 
STAP1 Q9ULZ2 FYN Y185 P06241 0.385959 
STAP1 Q9ULZ2 YES1 Y194 P07947 0.385959 
STAP1 Q9ULZ2 FER Y229 P16591 0.561097 
STAP1 Q9ULZ2 CRK Y251 P46108 0.694957 
STAP1 Q9ULZ2 NCK1 Y105 P16333 0.900628 
STAP1 Q9ULZ2 CHN2 Y21 P52757 0.304796 
STAP1 Q9ULZ2 TNS1 Y1254 Q9HBL0 0.543282 
STAP1 Q9ULZ2 CBL Y455 P22681 0.156049 
STAP1 Q9ULZ2 ANKS1A Y454 Q92625 0.542409 
STAP1 Q9ULZ2 CTNNB1 Y333 P35222 0.885761 
MATK P42679 NTRK3 Y516 Q16288 0.754724 
MATK P42679 FGR Y523 P09769 0.513811 
MATK P42679 SH2D3A Y231 Q9BRG2 0.658169 
MATK P42679 CBL Y368 P22681 0.54414 
MATK P42679 SYK Y203 P43405 0.724206 
MATK P42679 VAV3 Y173 Q9UKW4 0.522787 
MATK P42679 ANKS1A Y454 Q92625 0.939014 
MATK P42679 ITK Y180 Q08881 0.591884 
CRKL P46109 ALK Y1092 Q9UM73 0.219929 
CRKL P46109 FGFR1 Y605 P11362 0.695285 
CRKL P46109 FGFR1 Y653 P11362 0.448418 
CRKL P46109 FGFR1 Y654 P11362 0.95011 
CRKL P46109 FGFR3 Y577 P22607 0.53939 
CRKL P46109 FGFR3 Y648 P22607 0.483277 
CRKL P46109 FGFR3 Y724 P22607 0.45485 
CRKL P46109 FLT1 Y1327 P17948 0.888565 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
CRKL P46109 KDR Y1054 P35968 0.926868 
CRKL P46109 KDR Y1214 P35968 0.594696 
CRKL P46109 KIT Y721 P10721 0.461127 
CRKL P46109 KIT Y900 P10721 0.409294 
CRKL P46109 NTRK1 Y496 P04629 0.413195 
CRKL P46109 NTRK2 Y706 Q16620 0.769762 
CRKL P46109 NTRK3 Y709 Q16288 0.769762 
CRKL P46109 NTRK2 Y707 Q16620 0.887397 
CRKL P46109 NTRK3 Y710 Q16288 0.887397 
CRKL P46109 RET Y981 P07949 0.140384 
CRKL P46109 RET Y1062 P07949 0.695025 
CRKL P46109 ERBB4 Y1150 Q15303 0.297338 
CRKL P46109 EGFR Y1016 P00533 0.611695 
CRKL P46109 ERBB2 Y1139 P04626 0.763613 
CRKL P46109 ABL1 Y276 P00519 0.400045 
CRKL P46109 ZAP70 Y248 P43403 0.792141 
CRKL P46109 AXL Y759 P30530 0.460065 
CRKL P46109 CSF1R Y923 P07333 0.520611 
CRKL P46109 HCK Y209 P08631 0.412363 
CRKL P46109 FES Y811 P07332 0.593265 
CRKL P46109 PLCG1 Y472 P19174 0.655119 
CRKL P46109 PLCG2 Y1245 P16885 0.493439 
CRKL P46109 GRB2 Y209 P62993 0.424817 
CRKL P46109 GRAP2 Y45 O75791 0.808536 
CRKL P46109 NCK1 Y268 P16333 0.310166 
CRKL P46109 RIN1 Y36 Q13671 0.778559 
CRKL P46109 SH2D3A Y231 Q9BRG2 0.858953 
CRKL P46109 RASA1 Y460 P20936 0.818124 
CRKL P46109 VAV2 Y159 P52735 0.824773 
CRKL P46109 VAV2 Y172 P52735 0.614711 
CRKL P46109 CBL Y337 P22681 0.792233 
CRKL P46109 CBL Y368 P22681 0.632281 
CRKL P46109 CBL Y371 P22681 0.948081 
CRKL P46109 CBLB Y363 Q13191 0.948081 
CRKL P46109 CBL Y700 P22681 0.416924 
CRKL P46109 CBL Y774 P22681 0.431384 
CRKL P46109 STAT1 Y701 P42224 0.861119 
CRKL P46109 DAB1 Y220 O75553 0.430091 
CRKL P46109 DAB1 Y232 O75553 0.443463 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
CRKL P46109 DOK1 Y377 Q99704 0.912864 
CRKL P46109 DOK1 Y409 Q99704 0.716559 
CRKL P46109 DOK2 Y139 O60496 0.712137 
CRKL P46109 ERBB2 Y1127 P04626 0.71267 
CRKL P46109 FLT1 Y1048 P17948 0.396923 
CRKL P46109 IRS1 Y46 P35568 0.709646 
CRKL P46109 IRS1 Y465 P35568 0.75858 
CRKL P46109 IRS1 Y732 P35568 0.678611 
CRKL P46109 IRS1 Y989 P35568 0.589271 
CRKL P46109 IRS2 Y675 Q9Y4H2 0.540616 
CRKL P46109 IRS2 Y823 Q9Y4H2 0.835534 
CRKL P46109 GAB1 Y259 Q13480 0.436496 
CRKL P46109 GAB1 Y307 Q13480 0.256631 
CRKL P46109 PIK3R1 Y528 P27986 0.452313 
CRKL P46109 SRC Y338 P12931 0.351545 
CRKL P46109 LYN Y265 P07948 0.474606 
CRKL P46109 LYN Y460 P07948 0.674566 
CRKL P46109 SHC3 Y342 Q92529 0.750788 
CRKL P46109 SHB Y297 Q15464 0.860242 
CRKL P46109 TNS1 Y1345 Q9HBL0 0.70022 
CRKL P46109 CBLB Y709 Q13191 0.569345 
CRKL P46109 CBLB Y889 Q13191 0.377268 
CRKL P46109 DOK4 Y255 Q8TEW6 0.225536 
ABL1 P00519 FGFR1 Y653 P11362 0.355881 
ABL1 P00519 FGFR3 Y724 P22607 0.503969 
ABL1 P00519 FLT1 Y1327 P17948 0.849695 
ABL1 P00519 KIT Y721 P10721 0.830683 
ABL1 P00519 KIT Y936 P10721 0.425751 
ABL1 P00519 MET Y1313 P08581 0.84276 
ABL1 P00519 MET Y1356 P08581 0.398738 
ABL1 P00519 MST1R Y1317 Q04912 0.422593 
ABL1 P00519 RET Y1096 P07949 0.590385 
ABL1 P00519 FRS2 Y349 Q8WU20 0.779255 
ABL1 P00519 ERBB2 Y1139 P04626 0.858463 
ABL1 P00519 ERBB2 Y1221 P04626 0.702392 
ABL1 P00519 EPHA7 Y614 Q15375 0.410672 
ABL1 P00519 EPHA1 Y605 P21709 0.169489 
ABL1 P00519 LCK Y192 P06239 0.672862 
ABL1 P00519 FES Y811 P07332 0.270901 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
ABL1 P00519 GRB2 Y209 P62993 0.612147 
ABL1 P00519 CRK Y221 P46108 0.769494 
ABL1 P00519 CRKL Y207 P46109 0.416854 
ABL1 P00519 NCK1 Y268 P16333 0.477597 
ABL1 P00519 SHC1 Y349 P29353 0.655595 
ABL1 P00519 SH2D3A Y231 Q9BRG2 0.683377 
ABL1 P00519 SH2D2A Y39 Q9NP31 0.543909 
ABL1 P00519 PTPN6 Y564 P29350 0.973907 
ABL1 P00519 INPPL1 Y986 O15357 0.418427 
ABL1 P00519 DAB1 Y220 O75553 0.854103 
ABL1 P00519 DOK1 Y315 Q99704 0.778252 
ABL1 P00519 DOK1 Y362 Q99704 0.704623 
ABL1 P00519 DOK1 Y377 Q99704 0.765606 
ABL1 P00519 DOK1 Y398 Q99704 0.930068 
ABL1 P00519 DOK1 Y409 Q99704 0.924244 
ABL1 P00519 DOK2 Y139 O60496 0.822369 
ABL1 P00519 DOK2 Y345 O60496 0.475108 
ABL1 P00519 EPHB3 Y600 P54753 0.660109 
ABL1 P00519 EPHB3 Y608 P54753 0.801441 
ABL1 P00519 ERBB2 Y1127 P04626 0.491165 
ABL1 P00519 IRS1 Y989 P35568 0.992784 
ABL1 P00519 IRS2 Y675 Q9Y4H2 0.724796 
ABL1 P00519 IRS2 Y823 Q9Y4H2 0.805011 
ABL1 P00519 EPHA2 Y930 P29317 0.59984 
ABL1 P00519 FGR Y180 P09769 0.609982 
ABL1 P00519 FYN Y185 P06241 0.609982 
ABL1 P00519 YES1 Y194 P07947 0.609982 
ABL1 P00519 SRC Y187 P12931 0.958418 
ABL1 P00519 RIN1 Y632 Q13671 0.457947 
ABL1 P00519 SH2D2A Y260 Q9NP31 0.997651 
ABL1 P00519 HSH2D Y265 Q96JZ2 0.993784 
ABL1 P00519 TNS1 Y366 Q9HBL0 0.821566 
ABL1 P00519 TNS1 Y903 Q9HBL0 0.945005 
ABL1 P00519 ANKS1A Y454 Q92625 0.889422 
ABL1 P00519 PTK2 Y861 Q05397 0.672341 
ABL1 P00519 CTNNB1 Y333 P35222 0.683762 
BTK Q06187 NTRK3 Y516 Q16288 0.9837 
BTK Q06187 ABL1 Y412 P00519 0.518411 
BTK Q06187 FES Y811 P07332 0.432744 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
BTK Q06187 CBL Y368 P22681 0.769571 
BTK Q06187 DOK1 Y398 Q99704 0.232044 
BTK Q06187 CSK Y263 P41240 0.99661 
RASA1-C P20936 FGFR1 Y605 P11362 0.599984 
RASA1-C P20936 DOK1 Y315 Q99704 0.485755 
RASA1-C P20936 DOK1 Y398 Q99704 0.715569 
RASA1-C P20936 DOK2 Y299 O60496 0.175922 
RASA1-C P20936 FLT3 Y768 P36888 0.933255 
RASA1-C P20936 INSR Y1149 P06213 0.176842 
RASA1-C P20936 IRS1 Y989 P35568 0.708626 
RASA1-C P20936 IRS2 Y675 Q9Y4H2 0.88627 
RASA1-C P20936 IRS2 Y823 Q9Y4H2 0.495175 
RASA1-C P20936 ABL1 Y272 P00519 0.505701 
RASA1-C P20936 TYRO3 Y681 Q06418 0.82646 
RASA1-C P20936 SHB Y268 Q15464 0.758566 
RIN1 Q13671 EPHB1 Y600 P54762 0.883072 
RIN1 Q13671 EPHB2 Y602 P29323 0.883072 
RIN1 Q13671 FGFR1 Y463 P11362 0.869991 
RIN1 Q13671 FGFR3 Y724 P22607 0.513299 
RIN1 Q13671 FLT3 Y591 P36888 0.605648 
RIN1 Q13671 INSR Y1011 P06213 0.985535 
RIN1 Q13671 MET Y1313 P08581 0.678785 
RIN1 Q13671 NTRK2 Y707 Q16620 0.903324 
RIN1 Q13671 NTRK3 Y710 Q16288 0.903324 
RIN1 Q13671 PDGFRA Y572 P16234 0.853178 
RIN1 Q13671 PDGFRB Y579 P09619 0.86938 
RIN1 Q13671 PDGFRB Y581 P09619 0.678939 
RIN1 Q13671 EPHA2 Y588 P29317 0.32045 
RIN1 Q13671 EPHA7 Y614 Q15375 0.654796 
RIN1 Q13671 PTPN6 Y536 P29350 0.380923 
RIN1 Q13671 CBL Y368 P22681 0.877574 
RIN1 Q13671 CBL Y371 P22681 0.841153 
RIN1 Q13671 CBLB Y363 Q13191 0.841153 
RIN1 Q13671 CBL Y774 P22681 0.411072 
RIN1 Q13671 DAB1 Y198 O75553 0.866356 
RIN1 Q13671 EPHB3 Y614 P54753 0.654991 
RIN1 Q13671 EPHB3 Y754 P54753 0.783583 
RIN1 Q13671 IRS1 Y896 P35568 0.662331 
RIN1 Q13671 FGR Y180 P09769 0.763023 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
RIN1 Q13671 YES1 Y194 P07947 0.763023 
RIN1 Q13671 FYN Y213 P06241 0.605996 
RIN1 Q13671 YES1 Y222 P07947 0.605996 
SH2D3A Q9BRG2 EPHB1 Y600 P54762 0.966169 
SH2D3A Q9BRG2 EPHB2 Y602 P29323 0.966169 
SH2D3A Q9BRG2 FGFR1 Y730 P11362 0.788883 
SH2D3A Q9BRG2 FGFR3 Y760 P22607 0.42686 
SH2D3A Q9BRG2 FLT3 Y597 P36888 0.800497 
SH2D3A Q9BRG2 FLT3 Y599 P36888 0.44494 
SH2D3A Q9BRG2 INSR Y1011 P06213 0.453908 
SH2D3A Q9BRG2 MET Y1313 P08581 0.827226 
SH2D3A Q9BRG2 MET Y1356 P08581 0.549067 
SH2D3A Q9BRG2 MST1R Y1317 Q04912 0.500147 
SH2D3A Q9BRG2 NTRK1 Y496 P04629 0.702813 
SH2D3A Q9BRG2 PDGFRA Y572 P16234 0.899985 
SH2D3A Q9BRG2 PDGFRB Y579 P09619 0.916942 
SH2D3A Q9BRG2 PDGFRB Y581 P09619 0.342383 
SH2D3A Q9BRG2 RET Y1062 P07949 0.458924 
SH2D3A Q9BRG2 EGFR Y944 P00533 0.859063 
SH2D3A Q9BRG2 ERBB2 Y1023 P04626 0.948664 
SH2D3A Q9BRG2 EPHA2 Y791 P29317 0.66773 
SH2D3A Q9BRG2 EPHA7 Y597 Q15375 0.741536 
SH2D3A Q9BRG2 EPHA7 Y791 Q15375 0.466488 
SH2D3A Q9BRG2 ABL2 Y515 P42684 0.562387 
SH2D3A Q9BRG2 TEC Y206 P42680 0.998668 
SH2D3A Q9BRG2 LCK Y192 P06239 0.957713 
SH2D3A Q9BRG2 LCP2 Y128 Q13094 0.138652 
SH2D3A Q9BRG2 BLNK Y72 Q8WV28 0.810974 
SH2D3A Q9BRG2 CBL Y371 P22681 0.630585 
SH2D3A Q9BRG2 CBLB Y363 Q13191 0.630585 
SH2D3A Q9BRG2 DAB1 Y198 O75553 0.401498 
SH2D3A Q9BRG2 DOK1 Y377 Q99704 0.866017 
SH2D3A Q9BRG2 EPHB3 Y754 P54753 0.888254 
SH2D3A Q9BRG2 EPHB4 Y581 P54760 0.957693 
SH2D3A Q9BRG2 FLT4 Y853 P35916 0.706449 
SH2D3A Q9BRG2 IRS1 Y465 P35568 0.977151 
SH2D3A Q9BRG2 IRS1 Y732 P35568 0.582665 
SH2D3A Q9BRG2 ABL1 Y204 P00519 0.926085 
SH2D3A Q9BRG2 MST1R Y1017 Q04912 0.908901 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SH2D3A Q9BRG2 FGR Y180 P09769 0.967097 
SH2D3A Q9BRG2 FYN Y185 P06241 0.967097 
SH2D3A Q9BRG2 YES1 Y194 P07947 0.967097 
SH2D3A Q9BRG2 SRC Y187 P12931 0.907968 
SH2D3A Q9BRG2 SYK Y203 P43405 0.627685 
SH2D3A Q9BRG2 VAV1 Y826 P15498 0.699675 
SH2D3A Q9BRG2 DOK3 Y208 Q7L591 0.572099 
SH2D3A Q9BRG2 CSK Y263 P41240 0.717583 
SHC1 P29353 FLT1 Y1327 P17948 0.914727 
SHC1 P29353 KIT Y936 P10721 0.98892 
SHC1 P29353 MET Y1365 P08581 0.79406 
SHC1 P29353 MST1R Y1317 Q04912 0.640478 
SHC1 P29353 RET Y1062 P07949 0.670424 
SHC1 P29353 EPHA7 Y597 Q15375 0.968278 
SHC1 P29353 SRC Y216 P12931 0.896582 
SHC1 P29353 FES Y811 P07332 0.722493 
SHC1 P29353 VAV2 Y159 P52735 0.459699 
SHC1 P29353 VAV2 Y172 P52735 0.89636 
SHC1 P29353 DOK1 Y146 Q99704 0.509697 
SHC1 P29353 KIT Y553 P10721 0.811566 
SHC1 P29353 ROS1 Y2323 P08922 0.658073 
SHC1 P29353 PIK3R3 Y195 Q92569 0.374549 
SHC1 P29353 SYK Y203 P43405 0.638904 
SHC1 P29353 FYN Y214 P06241 0.814939 
SHC1 P29353 YES1 Y223 P07947 0.814939 
SHC1 P29353 VAV3 Y173 Q9UKW4 0.993958 
SHC1 P29353 APBB3 Y291 O95704 0.375934 
SHC1 P29353 ANKS1A Y454 Q92625 0.467479 
SHF Q7M4L6 AXL Y821 P30530 0.853941 
SHF Q7M4L6 EPHA4 Y596 P54764 0.933605 
SHF Q7M4L6 FGFR1 Y463 P11362 0.524018 
SHF Q7M4L6 FGFR3 Y724 P22607 0.86276 
SHF Q7M4L6 FLT3 Y591 P36888 0.962523 
SHF Q7M4L6 INSR Y1011 P06213 0.718041 
SHF Q7M4L6 MET Y1356 P08581 0.720497 
SHF Q7M4L6 MST1R Y1317 Q04912 0.778691 
SHF Q7M4L6 NTRK1 Y496 P04629 0.884303 
SHF Q7M4L6 NTRK3 Y516 Q16288 0.521326 
SHF Q7M4L6 PDGFRA Y572 P16234 0.94582 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SHF Q7M4L6 RET Y981 P07949 0.461952 
SHF Q7M4L6 RET Y1096 P07949 0.959153 
SHF Q7M4L6 ROS1 Y2274 P08922 0.674233 
SHF Q7M4L6 ROS1 Y2334 P08922 0.573481 
SHF Q7M4L6 ERBB2 Y1023 P04626 0.480214 
SHF Q7M4L6 ERBB2 Y1222 P04626 0.327447 
SHF Q7M4L6 PLCG2 Y753 P16885 0.696075 
SHF Q7M4L6 DAB1 Y198 O75553 0.66202 
SHF Q7M4L6 DOK1 Y203 Q99704 0.912882 
SHF Q7M4L6 IRS1 Y989 P35568 0.488923 
SHF Q7M4L6 SRC Y521 P12931 0.865283 
SHF Q7M4L6 SYK Y203 P43405 0.545188 
SHF Q7M4L6 RASA1 Y239 P20936 0.512163 
HSH2D Q96JZ2 CBL Y371 P22681 0.812317 
HSH2D Q96JZ2 CBLB Y363 Q13191 0.812317 
HSH2D Q96JZ2 IRS2 Y675 Q9Y4H2 0.494771 
HSH2D Q96JZ2 GAB1 Y242 Q13480 0.29667 
HSH2D Q96JZ2 GAB1 Y259 Q13480 0.345522 
HSH2D Q96JZ2 GAB1 Y373 Q13480 0.545967 
HSH2D Q96JZ2 SRC Y521 P12931 0.981861 
HSH2D Q96JZ2 TNS1 Y339 Q9HBL0 0.886332 
SH2B3 Q9UQQ2 EPHA3 Y779 P29320 0.82436 
SH2B3 Q9UQQ2 EPHA4 Y779 P54764 0.82436 
SH2B3 Q9UQQ2 EPHA5 Y833 P54756 0.82436 
SH2B3 Q9UQQ2 EPHB1 Y600 P54762 0.900365 
SH2B3 Q9UQQ2 EPHB2 Y602 P29323 0.900365 
SH2B3 Q9UQQ2 FLT1 Y1327 P17948 0.390351 
SH2B3 Q9UQQ2 FLT3 Y591 P36888 0.950048 
SH2B3 Q9UQQ2 FLT3 Y599 P36888 0.851233 
SH2B3 Q9UQQ2 KIT Y900 P10721 0.47522 
SH2B3 Q9UQQ2 PDGFRB Y1009 P09619 0.718058 
SH2B3 Q9UQQ2 PDGFRB Y1021 P09619 0.717367 
SH2B3 Q9UQQ2 RET Y981 P07949 0.503835 
SH2B3 Q9UQQ2 ERBB3 Y1197 P21860 0.680832 
SH2B3 Q9UQQ2 SYK Y203 P43405 0.924567 
GRB14 Q14449 NTRK1 Y496 P04629 0.914836 
GRB14 Q14449 ERBB2 Y1221 P04626 0.736905 
GRB14 Q14449 ABL1 Y412 P00519 0.33996 
GRB14 Q14449 GRB2 Y209 P62993 0.952851 
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GRB14 Q14449 EPHA3 Y937 P29320 0.593884 
GRB14 Q14449 IRS1 Y989 P35568 0.72146 
GRB14 Q14449 CSK Y263 P41240 0.868519 
GRB7 Q14451 ALK Y1092 Q9UM73 0.45134 
GRB7 Q14451 ALK Y1096 Q9UM73 0.518757 
GRB7 Q14451 FGFR1 Y730 P11362 0.511729 
GRB7 Q14451 FGFR3 Y724 P22607 0.428939 
GRB7 Q14451 FLT1 Y1327 P17948 0.33368 
GRB7 Q14451 FLT3 Y599 P36888 0.513266 
GRB7 Q14451 FLT4 Y1337 P35916 0.69102 
GRB7 Q14451 IGF1R Y1281 P08069 0.828358 
GRB7 Q14451 INSR Y1011 P06213 0.716986 
GRB7 Q14451 FLT4 Y1063 P35916 0.929303 
GRB7 Q14451 KDR Y1054 P35968 0.929303 
GRB7 Q14451 KDR Y1214 P35968 0.745536 
GRB7 Q14451 KIT Y900 P10721 0.340715 
GRB7 Q14451 KIT Y936 P10721 0.785127 
GRB7 Q14451 MET Y1313 P08581 0.247611 
GRB7 Q14451 MET Y1356 P08581 0.258721 
GRB7 Q14451 MET Y1365 P08581 0.663834 
GRB7 Q14451 MST1R Y1317 Q04912 0.244613 
GRB7 Q14451 NTRK1 Y496 P04629 0.583892 
GRB7 Q14451 NTRK2 Y707 Q16620 0.890769 
GRB7 Q14451 NTRK3 Y710 Q16288 0.890769 
GRB7 Q14451 NTRK3 Y516 Q16288 0.413316 
GRB7 Q14451 PDGFRB Y740 P09619 0.792496 
GRB7 Q14451 PDGFRB Y1009 P09619 0.681753 
GRB7 Q14451 RET Y791 P07949 0.239469 
GRB7 Q14451 RET Y1096 P07949 0.73196 
GRB7 Q14451 ROS1 Y2274 P08922 0.436249 
GRB7 Q14451 TEK Y1102 Q02763 0.413963 
GRB7 Q14451 ERBB2 Y1023 P04626 0.866054 
GRB7 Q14451 ERBB2 Y1222 P04626 0.267605 
GRB7 Q14451 ERBB3 Y1197 P21860 0.632773 
GRB7 Q14451 ERBB3 Y1276 P21860 0.888851 
GRB7 Q14451 RET Y952 P07949 0.654856 
GRB7 Q14451 EPHA2 Y588 P29317 0.752548 
GRB7 Q14451 ABL2 Y515 P42684 0.753065 
GRB7 Q14451 ABL1 Y134 P00519 0.905994 
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GRB7 Q14451 ABL1 Y276 P00519 0.952167 
GRB7 Q14451 ABL1 Y412 P00519 0.253791 
GRB7 Q14451 FGR Y412 P09769 0.861392 
GRB7 Q14451 ZAP70 Y474 P43403 0.670074 
GRB7 Q14451 PLCG1 Y771 P19174 0.755982 
GRB7 Q14451 PLCG2 Y1217 P16885 0.790899 
GRB7 Q14451 GRAP2 Y45 O75791 0.772831 
GRB7 Q14451 SH3BP2 Y174 P78314 0.738357 
GRB7 Q14451 BLNK Y189 Q8WV28 0.945351 
GRB7 Q14451 RASA1 Y615 P20936 0.205507 
GRB7 Q14451 VAV1 Y160 P15498 0.677236 
GRB7 Q14451 PTPN6 Y564 P29350 0.76629 
GRB7 Q14451 EPHB4 Y774 P54760 0.942949 
GRB7 Q14451 IRS1 Y46 P35568 0.658507 
GRB7 Q14451 IRS1 Y465 P35568 0.960939 
GRB7 Q14451 IRS1 Y732 P35568 0.630271 
GRB7 Q14451 IRS1 Y896 P35568 0.733502 
GRB7 Q14451 IRS1 Y989 P35568 0.918165 
GRB7 Q14451 IRS1 Y1179 P35568 0.565889 
GRB7 Q14451 IRS2 Y823 Q9Y4H2 0.896322 
GRB7 Q14451 SYK Y203 P43405 0.759572 
SHC3 Q92529 MET Y1313 P08581 0.862081 
SHC3 Q92529 MST1R Y1317 Q04912 0.719822 
SHC3 Q92529 NTRK1 Y496 P04629 0.93445 
SHC3 Q92529 FGR Y412 P09769 0.572803 
SHC3 Q92529 DOK1 Y146 Q99704 0.32464 
SHC3 Q92529 DOK2 Y139 O60496 0.589732 
SHC3 Q92529 EPHA3 Y937 P29320 0.795754 
SHC3 Q92529 SRC Y187 P12931 0.502884 
SHC3 Q92529 APBB3 Y291 O95704 0.583725 
SHC3 Q92529 ANKS1A Y454 Q92625 0.804342 
TENC1 Q63HR2 FGFR3 Y724 P22607 0.716622 
TENC1 Q63HR2 FLT1 Y1213 P17948 0.737434 
TENC1 Q63HR2 KDR Y1214 P35968 0.411641 
TENC1 Q63HR2 KIT Y721 P10721 0.883698 
TENC1 Q63HR2 KIT Y900 P10721 0.385778 
TENC1 Q63HR2 KIT Y936 P10721 0.713415 
TENC1 Q63HR2 MET Y1313 P08581 0.730233 
TENC1 Q63HR2 MET Y1356 P08581 0.453973 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
TENC1 Q63HR2 NTRK3 Y516 Q16288 0.848777 
TENC1 Q63HR2 PDGFRB Y581 P09619 0.519886 
TENC1 Q63HR2 PDGFRB Y740 P09619 0.526871 
TENC1 Q63HR2 PDGFRB Y771 P09619 0.573199 
TENC1 Q63HR2 ERBB4 Y1150 Q15303 0.319027 
TENC1 Q63HR2 ERBB2 Y1139 P04626 0.930297 
TENC1 Q63HR2 ERBB3 Y1276 P21860 0.455476 
TENC1 Q63HR2 ERBB3 Y1328 P21860 0.484319 
TENC1 Q63HR2 RET Y952 P07949 0.586642 
TENC1 Q63HR2 EPHA2 Y772 P29317 0.769131 
TENC1 Q63HR2 EPHA7 Y597 Q15375 0.857655 
TENC1 Q63HR2 PLCG2 Y1245 P16885 0.976023 
TENC1 Q63HR2 VAV1 Y160 P15498 0.828568 
TENC1 Q63HR2 VAV1 Y174 P15498 0.770818 
TENC1 Q63HR2 CBL Y368 P22681 0.740432 
TENC1 Q63HR2 CBL Y371 P22681 0.395747 
TENC1 Q63HR2 CBLB Y363 Q13191 0.395747 
TENC1 Q63HR2 CBL Y700 P22681 0.880105 
TENC1 Q63HR2 EPHA3 Y937 P29320 0.914168 
TENC1 Q63HR2 IRS1 Y46 P35568 0.684961 
TENC1 Q63HR2 IRS1 Y465 P35568 0.92929 
TENC1 Q63HR2 IRS1 Y896 P35568 0.675015 
TENC1 Q63HR2 IRS2 Y675 Q9Y4H2 0.888165 
TENC1 Q63HR2 KIT Y553 P10721 0.841111 
TENC1 Q63HR2 PDGFRB Y934 P09619 0.856345 
TENC1 Q63HR2 PIK3CD Y936 O00329 0.569839 
TENC1 Q63HR2 ABL2 Y303 P42684 0.437476 
TENC1 Q63HR2 LYN Y473 P07948 0.517021 
TENC1 Q63HR2 PTPN11 Y584 Q06124 0.957671 
TENC1 Q63HR2 PTPN6 Y377 P29350 0.831243 
TENC1 Q63HR2 CBL Y731 P22681 0.707449 
TENC1 Q63HR2 ANKS1A Y454 Q92625 0.957821 
TENC1 Q63HR2 CSK Y263 P41240 0.988652 
TENC1 Q63HR2 PTK2 Y861 Q05397 0.750946 
TENC1 Q63HR2 CTNNB1 Y64 P35222 0.782971 
PTPN6-C P29350 PLCG2 Y1245 P16885 0.819332 
FER P16591 EPHA3 Y779 P29320 0.998793 
FER P16591 EPHA4 Y779 P54764 0.998793 
FER P16591 EPHA5 Y833 P54756 0.998793 
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FER P16591 DOK1 Y398 Q99704 0.261434 
FER P16591 CSK Y263 P41240 0.73436 
PLCG2-N P16885 EPHA3 Y779 P29320 0.757021 
PLCG2-N P16885 EPHA4 Y779 P54764 0.757021 
PLCG2-N P16885 EPHA5 Y833 P54756 0.757021 
PLCG2-N P16885 FGFR1 Y730 P11362 0.854809 
PLCG2-N P16885 FLT3 Y597 P36888 0.607513 
PLCG2-N P16885 INSR Y1011 P06213 0.98185 
PLCG2-N P16885 KIT Y570 P10721 0.64871 
PLCG2-N P16885 MET Y1313 P08581 0.566648 
PLCG2-N P16885 MST1R Y1317 Q04912 0.822868 
PLCG2-N P16885 NTRK1 Y676 P04629 0.937962 
PLCG2-N P16885 NTRK3 Y516 Q16288 0.776769 
PLCG2-N P16885 ERBB2 Y1221 P04626 0.554374 
PLCG2-N P16885 ERBB2 Y1222 P04626 0.335818 
PLCG2-N P16885 RET Y952 P07949 0.742948 
PLCG2-N P16885 ABL1 Y412 P00519 0.248846 
PLCG2-N P16885 FGR Y523 P09769 0.393876 
PLCG2-N P16885 ZAP70 Y474 P43403 0.63844 
PLCG2-N P16885 PLCG1 Y783 P19174 0.821303 
PLCG2-N P16885 CBL Y368 P22681 0.783213 
PLCG2-N P16885 IRS1 Y989 P35568 0.878899 
PLCG2-N P16885 PDGFRA Y958 P16234 0.732083 
PLCG2-N P16885 PIK3CB Y772 P42338 0.979196 
PLCG2-N P16885 SYK Y203 P43405 0.651119 
SH2B2 O14492 EPHA7 Y791 Q15375 0.559303 
SH2B2 O14492 ITK Y512 Q08881 0.893845 
SH2B2 O14492 EPHA3 Y937 P29320 0.9614 
SH2B2 O14492 ZAP70 Y164 P43403 0.493915 
SH2B2 O14492 VAV3 Y173 Q9UKW4 0.692229 
SH2B2 O14492 TNS1 Y339 Q9HBL0 0.378155 
BCAR3 O75815 ALK Y1096 Q9UM73 0.494037 
BCAR3 O75815 FGFR3 Y724 P22607 0.356396 
BCAR3 O75815 FLT1 Y1327 P17948 0.292102 
BCAR3 O75815 FLT3 Y599 P36888 0.363848 
BCAR3 O75815 INSR Y1011 P06213 0.868934 
BCAR3 O75815 FLT4 Y1063 P35916 0.637009 
BCAR3 O75815 KDR Y1054 P35968 0.637009 
BCAR3 O75815 KDR Y1214 P35968 0.773519 
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BCAR3 O75815 MET Y1313 P08581 0.67768 
BCAR3 O75815 MET Y1356 P08581 0.557414 
BCAR3 O75815 MST1R Y1317 Q04912 0.502697 
BCAR3 O75815 NTRK1 Y496 P04629 0.691486 
BCAR3 O75815 NTRK1 Y676 P04629 0.427529 
BCAR3 O75815 NTRK3 Y516 Q16288 0.411087 
BCAR3 O75815 PDGFRB Y581 P09619 0.654723 
BCAR3 O75815 PDGFRB Y1021 P09619 0.891068 
BCAR3 O75815 RET Y1096 P07949 0.773999 
BCAR3 O75815 EGFR Y1172 P00533 0.765942 
BCAR3 O75815 ERBB2 Y1023 P04626 0.41601 
BCAR3 O75815 ERBB2 Y1222 P04626 0.246846 
BCAR3 O75815 ERBB3 Y1276 P21860 0.564928 
BCAR3 O75815 EPHA7 Y597 Q15375 0.917322 
BCAR3 O75815 ABL2 Y515 P42684 0.686584 
BCAR3 O75815 FGR Y523 P09769 0.687912 
BCAR3 O75815 PLCG1 Y771 P19174 0.758139 
BCAR3 O75815 PLCG1 Y775 P19174 0.898303 
BCAR3 O75815 PLCG2 Y1245 P16885 0.756659 
BCAR3 O75815 SH2D3C Y495 Q8N5H7 0.956048 
BCAR3 O75815 VAV1 Y160 P15498 0.940536 
BCAR3 O75815 VAV2 Y159 P52735 0.925868 
BCAR3 O75815 CBL Y371 P22681 0.791885 
BCAR3 O75815 CBLB Y363 Q13191 0.791885 
BCAR3 O75815 DAB1 Y198 O75553 0.649585 
BCAR3 O75815 DOK1 Y315 Q99704 0.855614 
BCAR3 O75815 EPHB3 Y754 P54753 0.301087 
BCAR3 O75815 IRS1 Y989 P35568 0.896659 
BCAR3 O75815 IRS2 Y675 Q9Y4H2 0.914456 
BCAR3 O75815 IRS2 Y823 Q9Y4H2 0.760997 
BCAR3 O75815 ABL2 Y231 P42684 0.970578 
BCAR3 O75815 ABL1 Y191 P00519 0.658787 
BCAR3 O75815 FGR Y180 P09769 0.839369 
BCAR3 O75815 FYN Y185 P06241 0.839369 
BCAR3 O75815 YES1 Y194 P07947 0.839369 
BCAR3 O75815 VAV1 Y826 P15498 0.660316 
BCAR3 O75815 TNS1 Y796 Q9HBL0 0.571856 
BCAR3 O75815 STAT1 Y203 P42224 0.926146 
BCAR3 O75815 CSK Y263 P41240 0.824616 
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SH2D1B O14796 INSR Y1011 P06213 0.570802 
SH2D1B O14796 MET Y1356 P08581 0.534264 
SH2D1B O14796 MST1R Y1317 Q04912 0.884884 
SH2D1B O14796 NTRK1 Y757 P04629 0.848683 
SH2D1B O14796 PDGFRB Y579 P09619 0.842866 
SH2D1B O14796 CBL Y371 P22681 0.44226 
SH2D1B O14796 CBLB Y363 Q13191 0.44226 
SH2D1B O14796 DOK1 Y315 Q99704 0.917328 
SH2D1B O14796 EPHB1 Y634 P54762 0.520868 
SH2D1B O14796 EPHB3 Y754 P54753 0.720247 
SH2D1B O14796 FLT4 Y830 P35916 0.753181 
SH2D1B O14796 IRS1 Y465 P35568 0.668617 
SH2D1B O14796 IRS2 Y823 Q9Y4H2 0.935713 
SH2D1B O14796 GAB1 Y373 Q13480 0.377863 
SH2D1B O14796 KIT Y553 P10721 0.935996 
SH2D1B O14796 PIK3R1 Y556 P27986 0.360513 
SH2D1B O14796 PIK3C2B Y685 O00750 0.730411 
SH2D1B O14796 PIK3R1 Y699 P27986 0.730411 
SH2D1B O14796 PIK3CB Y772 P42338 0.79986 
SH2D1B O14796 PIK3CB Y962 P42338 0.861442 
SH2D1B O14796 ABL1 Y191 P00519 0.729082 
SH2D1B O14796 SRC Y521 P12931 0.938069 
SH2D1B O14796 TNS1 Y366 Q9HBL0 0.898278 
SH2D1B O14796 CSK Y263 P41240 0.896904 
SH2D1B O14796 PTK2 Y861 Q05397 0.377777 
SH2D1B O14796 PTK2B Y906 Q14289 0.77001 
SHE Q5VZ18 TEK Y1048 Q02763 0.860664 
SHE Q5VZ18 IRS1 Y465 P35568 0.868732 
SHE Q5VZ18 IRS2 Y675 Q9Y4H2 0.66999 
SHE Q5VZ18 GAB1 Y406 Q13480 0.779488 
SLA2 Q9H6Q3 EPHB1 Y600 P54762 0.92209 
SLA2 Q9H6Q3 EPHB2 Y602 P29323 0.92209 
SLA2 Q9H6Q3 FLT3 Y591 P36888 0.782272 
SLA2 Q9H6Q3 FLT3 Y599 P36888 0.546351 
SLA2 Q9H6Q3 INSR Y1011 P06213 0.918463 
SLA2 Q9H6Q3 FLT4 Y1063 P35916 0.996178 
SLA2 Q9H6Q3 KDR Y1054 P35968 0.996178 
SLA2 Q9H6Q3 KIT Y570 P10721 0.8511 
SLA2 Q9H6Q3 KIT Y900 P10721 0.71062 
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SLA2 Q9H6Q3 NTRK3 Y516 Q16288 0.642477 
SLA2 Q9H6Q3 PDGFRB Y1021 P09619 0.925795 
SLA2 Q9H6Q3 ABL1 Y276 P00519 0.922494 
SLA2 Q9H6Q3 ABL1 Y412 P00519 0.228597 
SLA2 Q9H6Q3 PLCG1 Y775 P19174 0.96763 
SLA2 Q9H6Q3 PLCG1 Y783 P19174 0.933353 
SLA2 Q9H6Q3 DAB1 Y198 O75553 0.805459 
SLA2 Q9H6Q3 DOK1 Y146 Q99704 0.987742 
SHD Q96IW2 ERBB4 Y1150 Q15303 0.627641 
SH3BP2 P78314 MST1R Y1360 Q04912 0.479254 
SH3BP2 P78314 ERBB2 Y1139 P04626 0.638327 
SH3BP2 P78314 ABL1 Y412 P00519 0.445064 
SH3BP2 P78314 BLNK Y72 Q8WV28 0.301613 
SH3BP2 P78314 VAV2 Y172 P52735 0.96058 
SH3BP2 P78314 PTPN6 Y564 P29350 0.296235 
SH3BP2 P78314 CBL Y368 P22681 0.618432 
SH3BP2 P78314 IRS1 Y732 P35568 0.760589 
SH3BP2 P78314 KIT Y553 P10721 0.795158 
SH3BP2 P78314 CSK Y263 P41240 0.846633 
SH3BP2 P78314 PTK2 Y1007 Q05397 0.971083 
SH3BP2 P78314 CTNNB1 Y64 P35222 0.973008 
TXK P42681 FGFR3 Y724 P22607 0.636714 
TXK P42681 FLT3 Y599 P36888 0.652799 
TXK P42681 MET Y1313 P08581 0.565677 
TXK P42681 MST1R Y1317 Q04912 0.41949 
TXK P42681 PDGFRB Y740 P09619 0.907376 
TXK P42681 RET Y981 P07949 0.910854 
BLNK Q8WV28 DOK1 Y315 Q99704 0.953814 
JAK2 O60674 PDGFRB Y740 P09619 0.98565 
HCK P08631 FLT1 Y1327 P17948 0.918355 
HCK P08631 INSR Y1011 P06213 0.854272 
HCK P08631 KIT Y936 P10721 0.771467 
HCK P08631 MET Y1313 P08581 0.697985 
HCK P08631 NTRK3 Y516 Q16288 0.764975 
HCK P08631 ROS1 Y2274 P08922 0.901643 
HCK P08631 EPHA2 Y735 P29317 0.857514 
HCK P08631 EPHA2 Y772 P29317 0.777762 
HCK P08631 ABL1 Y276 P00519 0.839866 
HCK P08631 ABL1 Y412 P00519 0.184251 
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HCK P08631 FES Y811 P07332 0.525171 
HCK P08631 PLCG1 Y472 P19174 0.759282 
HCK P08631 PLCG1 Y775 P19174 0.943007 
HCK P08631 PLCG2 Y1217 P16885 0.617216 
HCK P08631 GRAP2 Y45 O75791 0.629852 
HCK P08631 SH3BP2 Y183 P78314 0.889483 
HCK P08631 SH2D2A Y290 Q9NP31 0.750748 
HCK P08631 VAV1 Y174 P15498 0.97876 
HCK P08631 CBL Y368 P22681 0.834459 
HCK P08631 DAB1 Y198 O75553 0.982772 
HCK P08631 DOK1 Y146 Q99704 0.752051 
HCK P08631 DOK1 Y315 Q99704 0.704688 
HCK P08631 DOK1 Y398 Q99704 0.21887 
HCK P08631 EPHA3 Y937 P29320 0.969613 
HCK P08631 EPHA5 Y656 P54756 0.909587 
HCK P08631 ERBB2 Y1005 P04626 0.841927 
HCK P08631 ERBB2 Y1127 P04626 0.518496 
HCK P08631 FLT1 Y1048 P17948 0.933053 
HCK P08631 FLT3 Y969 P36888 0.895423 
HCK P08631 IRS1 Y662 P35568 0.995321 
HCK P08631 PDGFRB Y934 P09619 0.803922 
HCK P08631 PIK3R1 Y607 P27986 0.97921 
HCK P08631 VAV3 Y173 Q9UKW4 0.812208 
HCK P08631 TNS1 Y1144 Q9HBL0 0.597145 
HCK P08631 DOK4 Y255 Q8TEW6 0.518617 
HCK P08631 ANKS1A Y454 Q92625 0.453355 
PTK6 Q13882 FGFR3 Y724 P22607 0.481767 
PTK6 Q13882 FLT3 Y599 P36888 0.615964 
PTK6 Q13882 MET Y1313 P08581 0.581419 
PTK6 Q13882 MST1R Y1317 Q04912 0.656706 
PTK6 Q13882 ERBB2 Y1139 P04626 0.596626 
PTK6 Q13882 AXL Y702 P30530 0.340438 
PTK6 Q13882 FES Y811 P07332 0.695225 
PTK6 Q13882 PLCG2 Y1217 P16885 0.82153 
PTK6 Q13882 JAK3 Y785 P52333 0.770936 
PTK6 Q13882 VAV2 Y159 P52735 0.558588 
PTK6 Q13882 CBL Y368 P22681 0.856633 
PTK6 Q13882 IRS2 Y823 Q9Y4H2 0.748847 
PTK6 Q13882 PIK3R1 Y607 P27986 0.918981 
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PTK6 Q13882 VAV3 Y173 Q9UKW4 0.672018 
PTK6 Q13882 SHB Y336 Q15464 0.208212 
PTK6 Q13882 TNS1 Y339 Q9HBL0 0.961328 
PTK6 Q13882 CBL Y731 P22681 0.688723 
PTK6 Q13882 CBLB Y889 Q13191 0.489144 
PTK6 Q13882 CTNNB1 Y64 P35222 0.934059 
BMX P51813 MET Y1313 P08581 0.720563 
BMX P51813 NTRK3 Y516 Q16288 0.605955 
BMX P51813 RET Y1096 P07949 0.858643 
BMX P51813 EGFR Y1172 P00533 0.722513 
BMX P51813 EPHA7 Y614 Q15375 0.542996 
BMX P51813 IRS2 Y675 Q9Y4H2 0.859645 
BMX P51813 PDGFRA Y613 P16234 0.339029 
BMX P51813 PIK3CB Y772 P42338 0.857509 
BMX P51813 PIK3CB Y962 P42338 0.999141 
BMX P51813 PIK3CD Y440 O00329 0.74516 
BMX P51813 ABL2 Y683 P42684 0.715014 
BMX P51813 SYK Y203 P43405 0.634323 
BMX P51813 VAV3 Y173 Q9UKW4 0.636309 
BMX P51813 PTPN6 Y377 P29350 0.508892 
BMX P51813 PTPN6 Y390 P29350 0.824666 
JAK3 P52333 FGFR1 Y463 P11362 0.525197 
JAK3 P52333 FLT1 Y1333 P17948 0.36201 
JAK3 P52333 PDGFRB Y1021 P09619 0.916916 
JAK3 P52333 VAV3 Y173 Q9UKW4 0.225368 
SUPT6H Q7KZ85 FGFR1 Y585 P11362 0.864715 
SUPT6H Q7KZ85 MET Y1356 P08581 0.559482 
SUPT6H Q7KZ85 RET Y1062 P07949 0.760979 
SUPT6H Q7KZ85 PLCG2 Y1245 P16885 0.686971 
SUPT6H Q7KZ85 IRS1 Y465 P35568 0.754652 
SUPT6H Q7KZ85 IRS2 Y823 Q9Y4H2 0.87079 
GRB10 Q13322 EPHA3 Y596 P29320 0.778055 
GRB10 Q13322 FGFR1 Y463 P11362 0.559947 
GRB10 Q13322 FGFR3 Y724 P22607 0.757221 
GRB10 Q13322 FGFR3 Y760 P22607 0.379215 
GRB10 Q13322 FLT1 Y1213 P17948 0.649781 
GRB10 Q13322 FLT1 Y1327 P17948 0.810267 
GRB10 Q13322 FLT3 Y591 P36888 0.590679 
GRB10 Q13322 FLT3 Y599 P36888 0.597995 
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GRB10 Q13322 KDR Y1214 P35968 0.963463 
GRB10 Q13322 MET Y1313 P08581 0.677635 
GRB10 Q13322 MET Y1356 P08581 0.310468 
GRB10 Q13322 NTRK1 Y676 P04629 0.931614 
GRB10 Q13322 NTRK2 Y706 Q16620 0.899509 
GRB10 Q13322 NTRK3 Y709 Q16288 0.899509 
GRB10 Q13322 PDGFRB Y581 P09619 0.814658 
GRB10 Q13322 PDGFRB Y1009 P09619 0.729117 
GRB10 Q13322 PDGFRB Y1021 P09619 0.907036 
GRB10 Q13322 RET Y1062 P07949 0.928312 
GRB10 Q13322 RET Y1096 P07949 0.636598 
GRB10 Q13322 ROS1 Y2274 P08922 0.635648 
GRB10 Q13322 TEK Y1102 Q02763 0.439297 
GRB10 Q13322 FRS2 Y306 Q8WU20 0.71758 
GRB10 Q13322 ERBB2 Y1023 P04626 0.669002 
GRB10 Q13322 ERBB2 Y1222 P04626 0.238161 
GRB10 Q13322 ERBB3 Y1197 P21860 0.715254 
GRB10 Q13322 RET Y952 P07949 0.868027 
GRB10 Q13322 EPHA2 Y628 P29317 0.69929 
GRB10 Q13322 EPHA7 Y614 Q15375 0.8508 
GRB10 Q13322 ABL2 Y515 P42684 0.909842 
GRB10 Q13322 ABL1 Y412 P00519 0.429343 
GRB10 Q13322 FGR Y412 P09769 0.886526 
GRB10 Q13322 FYN Y420 P06241 0.860677 
GRB10 Q13322 SRC Y419 P12931 0.860677 
GRB10 Q13322 YES1 Y426 P07947 0.860677 
GRB10 Q13322 ZAP70 Y248 P43403 0.612234 
GRB10 Q13322 ZAP70 Y474 P43403 0.716557 
GRB10 Q13322 PLCG1 Y472 P19174 0.920346 
GRB10 Q13322 PLCG1 Y771 P19174 0.84914 
GRB10 Q13322 PLCG2 Y743 P16885 0.882296 
GRB10 Q13322 PLCG2 Y1217 P16885 0.891161 
GRB10 Q13322 JAK3 Y785 P52333 0.868351 
GRB10 Q13322 RASA1 Y460 P20936 0.627014 
GRB10 Q13322 RASA1 Y615 P20936 0.20624 
GRB10 Q13322 SH2D2A Y39 Q9NP31 0.631467 
GRB10 Q13322 VAV1 Y160 P15498 0.801708 
GRB10 Q13322 CBL Y368 P22681 0.807108 
GRB10 Q13322 DAB1 Y198 O75553 0.92431 
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GRB10 Q13322 DOK2 Y299 O60496 0.384779 
GRB10 Q13322 EPHA5 Y656 P54756 0.683118 
GRB10 Q13322 IRS1 Y46 P35568 0.968586 
GRB10 Q13322 IRS1 Y465 P35568 0.998518 
GRB10 Q13322 IRS1 Y732 P35568 0.823034 
GRB10 Q13322 IRS1 Y896 P35568 0.895896 
GRB10 Q13322 IRS2 Y823 Q9Y4H2 0.699428 
GRB10 Q13322 GAB1 Y373 Q13480 0.863045 
GRB10 Q13322 GAB1 Y406 Q13480 0.584951 
GRB10 Q13322 PIK3CB Y962 P42338 0.963318 
GRB10 Q13322 SYK Y203 P43405 0.772257 
GRB10 Q13322 TNS1 Y339 Q9HBL0 0.490715 
FES P07332 FGFR1 Y585 P11362 0.732101 
FES P07332 FYN Y420 P06241 0.733602 
FES P07332 SRC Y419 P12931 0.733602 
FES P07332 YES1 Y426 P07947 0.733602 
FES P07332 SYK Y203 P43405 0.524532 
TNS4 Q8IZW8 EPHB1 Y600 P54762 0.590108 
TNS4 Q8IZW8 EPHB2 Y602 P29323 0.590108 
TNS4 Q8IZW8 FGFR3 Y724 P22607 0.5199 
TNS4 Q8IZW8 FLT1 Y1213 P17948 0.414545 
TNS4 Q8IZW8 KDR Y1214 P35968 0.185156 
TNS4 Q8IZW8 KIT Y936 P10721 0.452862 
TNS4 Q8IZW8 MET Y1356 P08581 0.444885 
TNS4 Q8IZW8 PDGFRB Y771 P09619 0.238891 
TNS4 Q8IZW8 PDGFRB Y775 P09619 0.637354 
TNS4 Q8IZW8 ERBB4 Y1208 Q15303 0.414408 
TNS4 Q8IZW8 ERBB2 Y1139 P04626 0.736658 
TNS4 Q8IZW8 ERBB3 Y1328 P21860 0.853656 
TNS4 Q8IZW8 EPHA2 Y772 P29317 0.652663 
TNS4 Q8IZW8 EPHA7 Y791 Q15375 0.407779 
TNS4 Q8IZW8 PTPN6 Y564 P29350 0.497664 
TNS4 Q8IZW8 CBL Y774 P22681 0.856737 
TNS4 Q8IZW8 DAB1 Y232 O75553 0.639806 
TNS4 Q8IZW8 DOK1 Y315 Q99704 0.843359 
TNS4 Q8IZW8 DOK1 Y398 Q99704 0.930117 
TNS4 Q8IZW8 EPHA5 Y656 P54756 0.685047 
TNS4 Q8IZW8 EPHB3 Y754 P54753 0.458759 
TNS4 Q8IZW8 IRS1 Y46 P35568 0.828215 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
TNS4 Q8IZW8 IRS2 Y823 Q9Y4H2 0.993151 
TNS4 Q8IZW8 SHB Y297 Q15464 0.380368 
TNS4 Q8IZW8 TNS1 Y339 Q9HBL0 0.712314 
TNS4 Q8IZW8 ANKS1A Y454 Q92625 0.551364 
PIK3R3-N Q92569 FGFR1 Y730 P11362 0.500412 
PIK3R3-N Q92569 FGFR3 Y724 P22607 0.224147 
PIK3R3-N Q92569 IGF1R Y1346 P08069 0.72992 
PIK3R3-N Q92569 INSR Y1011 P06213 0.624803 
PIK3R3-N Q92569 INSR Y1361 P06213 0.417651 
PIK3R3-N Q92569 KDR Y1059 P35968 0.587181 
PIK3R3-N Q92569 KIT Y721 P10721 0.148005 
PIK3R3-N Q92569 KIT Y900 P10721 0.16118 
PIK3R3-N Q92569 MET Y1365 P08581 0.644616 
PIK3R3-N Q92569 MST1R Y1317 Q04912 0.306182 
PIK3R3-N Q92569 NTRK1 Y496 P04629 0.877985 
PIK3R3-N Q92569 NTRK3 Y516 Q16288 0.716839 
PIK3R3-N Q92569 PDGFRA Y742 P16234 0.211803 
PIK3R3-N Q92569 PDGFRB Y771 P09619 0.16925 
PIK3R3-N Q92569 ROS1 Y2334 P08922 0.835472 
PIK3R3-N Q92569 ERBB4 Y1056 Q15303 0.912233 
PIK3R3-N Q92569 EGFR Y1016 P00533 0.951999 
PIK3R3-N Q92569 EGFR Y1092 P00533 0.555743 
PIK3R3-N Q92569 EGFR Y1138 P00533 0.78676 
PIK3R3-N Q92569 ERBB3 Y1054 P21860 0.945303 
PIK3R3-N Q92569 ERBB3 Y1197 P21860 0.320616 
PIK3R3-N Q92569 ERBB3 Y1276 P21860 0.607545 
PIK3R3-N Q92569 RET Y952 P07949 0.351387 
PIK3R3-N Q92569 EPHA7 Y597 Q15375 0.749327 
PIK3R3-N Q92569 ABL2 Y515 P42684 0.525211 
PIK3R3-N Q92569 FGR Y412 P09769 0.394922 
PIK3R3-N Q92569 EPHA1 Y605 P21709 0.857363 
PIK3R3-N Q92569 GRB2 Y209 P62993 0.818709 
PIK3R3-N Q92569 NCK1 Y268 P16333 0.461985 
PIK3R3-N Q92569 BLNK Y84 Q8WV28 0.309163 
PIK3R3-N Q92569 VAV2 Y172 P52735 0.957145 
PIK3R3-N Q92569 CBL Y368 P22681 0.541972 
PIK3R3-N Q92569 CBL Y371 P22681 0.348621 
PIK3R3-N Q92569 CBLB Y363 Q13191 0.348621 
PIK3R3-N Q92569 CBL Y700 P22681 0.874884 
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PIK3R3-N Q92569 ERBB2 Y1127 P04626 0.552762 
PIK3R3-N Q92569 IRS1 Y465 P35568 0.254603 
PIK3R3-N Q92569 IRS1 Y612 P35568 0.3301 
PIK3R3-N Q92569 IRS1 Y732 P35568 0.346878 
PIK3R3-N Q92569 IRS1 Y896 P35568 0.745123 
PIK3R3-N Q92569 IRS1 Y941 P35568 0.354162 
PIK3R3-N Q92569 IRS1 Y989 P35568 0.449961 
PIK3R3-N Q92569 IRS2 Y653 Q9Y4H2 0.579357 
PIK3R3-N Q92569 IRS2 Y675 Q9Y4H2 0.442295 
PIK3R3-N Q92569 PDGFRB Y934 P09619 0.187995 
PIK3R3-N Q92569 PIK3CB Y246 P42338 0.467183 
PIK3R3-N Q92569 FGR Y209 P09769 0.600016 
PIK3R3-N Q92569 LYN Y473 P07948 0.834271 
PIK3R3-N Q92569 BTK Y225 Q06187 0.886019 
PIK3R3-N Q92569 SH2D3C Y183 Q8N5H7 0.248673 
PIK3R3-N Q92569 STAT5A Y694 P42229 0.802729 
PIK3R3-N Q92569 CBL Y731 P22681 0.450964 
PIK3R3-N Q92569 ANKS1A Y454 Q92625 0.80046 
PIK3R3-N Q92569 CTNNB1 Y64 P35222 0.7427 
PIK3R3-N Q92569 CTNNB1 Y86 P35222 0.564123 
PIK3R3-C Q92569 FGFR1 Y605 P11362 0.756545 
PIK3R3-C Q92569 FGFR3 Y724 P22607 0.235694 
PIK3R3-C Q92569 FGFR3 Y770 P22607 0.461049 
PIK3R3-C Q92569 FLT3 Y589 P36888 0.461049 
PIK3R3-C Q92569 FLT1 Y1333 P17948 0.785137 
PIK3R3-C Q92569 KIT Y721 P10721 0.997247 
PIK3R3-C Q92569 NTRK3 Y516 Q16288 0.94605 
PIK3R3-C Q92569 PDGFRB Y740 P09619 0.179778 
PIK3R3-C Q92569 CSF1R Y923 P07333 0.898656 
PIK3R3-C Q92569 PLCG2 Y1245 P16885 0.87787 
PIK3R3-C Q92569 NCK1 Y268 P16333 0.471766 
PIK3R3-C Q92569 SH2D3A Y231 Q9BRG2 0.607423 
PIK3R3-C Q92569 CBL Y368 P22681 0.953896 
PIK3R3-C Q92569 CBL Y371 P22681 0.668943 
PIK3R3-C Q92569 CBLB Y363 Q13191 0.668943 
PIK3R3-C Q92569 IRS1 Y465 P35568 0.559534 
PIK3R3-C Q92569 IRS1 Y989 P35568 0.728693 
PIK3R3-C Q92569 IRS2 Y675 Q9Y4H2 0.846564 
PIK3R3-C Q92569 IRS2 Y823 Q9Y4H2 0.790033 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PIK3R3-C Q92569 IRS4 Y921 O14654 0.737564 
PIK3R2-N O00459 AXL Y821 P30530 0.255535 
PIK3R2-N O00459 CSF1R Y723 P07333 0.623378 
PIK3R2-N O00459 FGFR1 Y605 P11362 0.83266 
PIK3R2-N O00459 FGFR1 Y730 P11362 0.550045 
PIK3R2-N O00459 FGFR3 Y724 P22607 0.187271 
PIK3R2-N O00459 IGF1R Y1346 P08069 0.599752 
PIK3R2-N O00459 INSR Y1011 P06213 0.451329 
PIK3R2-N O00459 INSR Y1361 P06213 0.21691 
PIK3R2-N O00459 KDR Y1059 P35968 0.460323 
PIK3R2-N O00459 KIT Y900 P10721 0.158886 
PIK3R2-N O00459 MET Y1313 P08581 0.27235 
PIK3R2-N O00459 MET Y1356 P08581 0.48317 
PIK3R2-N O00459 MST1R Y1317 Q04912 0.311527 
PIK3R2-N O00459 MST1R Y1360 Q04912 0.538928 
PIK3R2-N O00459 NTRK3 Y516 Q16288 0.926999 
PIK3R2-N O00459 PDGFRA Y742 P16234 0.144509 
PIK3R2-N O00459 PDGFRB Y740 P09619 0.255318 
PIK3R2-N O00459 PDGFRB Y775 P09619 0.585683 
PIK3R2-N O00459 ROS1 Y2274 P08922 0.706561 
PIK3R2-N O00459 TEK Y1048 Q02763 0.962066 
PIK3R2-N O00459 ERBB4 Y1056 Q15303 0.885027 
PIK3R2-N O00459 EGFR Y1092 P00533 0.445087 
PIK3R2-N O00459 EGFR Y1138 P00533 0.610805 
PIK3R2-N O00459 ERBB2 Y1023 P04626 0.32545 
PIK3R2-N O00459 ERBB2 Y1139 P04626 0.819383 
PIK3R2-N O00459 ERBB3 Y1054 P21860 0.464131 
PIK3R2-N O00459 ERBB3 Y1197 P21860 0.279326 
PIK3R2-N O00459 ERBB3 Y1199 P21860 0.547884 
PIK3R2-N O00459 ABL2 Y515 P42684 0.211589 
PIK3R2-N O00459 FGR Y523 P09769 0.504471 
PIK3R2-N O00459 TXK Y420 P42681 0.368572 
PIK3R2-N O00459 PLCG1 Y783 P19174 0.486987 
PIK3R2-N O00459 GRB2 Y209 P62993 0.804746 
PIK3R2-N O00459 NCK1 Y268 P16333 0.43131 
PIK3R2-N O00459 SH3BP2 Y183 P78314 0.715898 
PIK3R2-N O00459 JAK3 Y785 P52333 0.63162 
PIK3R2-N O00459 BLNK Y72 Q8WV28 0.382587 
PIK3R2-N O00459 BLNK Y84 Q8WV28 0.427679 
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PIK3R2-N O00459 VAV2 Y172 P52735 0.518707 
PIK3R2-N O00459 CBL Y337 P22681 0.96038 
PIK3R2-N O00459 CBL Y368 P22681 0.555761 
PIK3R2-N O00459 CBL Y371 P22681 0.527177 
PIK3R2-N O00459 CBLB Y363 Q13191 0.527177 
PIK3R2-N O00459 CBL Y700 P22681 0.487285 
PIK3R2-N O00459 DOK1 Y146 Q99704 0.715066 
PIK3R2-N O00459 ERBB2 Y1127 P04626 0.579233 
PIK3R2-N O00459 IRS1 Y465 P35568 0.1754 
PIK3R2-N O00459 IRS1 Y612 P35568 0.286453 
PIK3R2-N O00459 IRS1 Y632 P35568 0.623725 
PIK3R2-N O00459 IRS1 Y896 P35568 0.593692 
PIK3R2-N O00459 IRS1 Y989 P35568 0.360433 
PIK3R2-N O00459 IRS2 Y653 Q9Y4H2 0.509648 
PIK3R2-N O00459 IRS2 Y675 Q9Y4H2 0.32933 
PIK3R2-N O00459 PDGFRB Y934 P09619 0.252797 
PIK3R2-N O00459 PIK3R2 Y365 O00459 0.781059 
PIK3R2-N O00459 SHC3 Y424 Q92529 0.781059 
PIK3R2-N O00459 PIK3R2 Y605 O00459 0.874755 
PIK3R2-N O00459 PIK3CB Y246 P42338 0.742448 
PIK3R2-N O00459 SYK Y203 P43405 0.707288 
PIK3R2-N O00459 PTK6 Y114 Q13882 0.99134 
PIK3R2-N O00459 JAK3 Y981 P52333 0.566404 
PIK3R2-N O00459 STAT5A Y694 P42229 0.711786 
PIK3R2-N O00459 CBL Y731 P22681 0.235796 
PIK3R2-N O00459 IRS4 Y921 O14654 0.259791 
PIK3R2-N O00459 ANKS1A Y454 Q92625 0.805612 
PIK3R2-N O00459 PTK2B Y849 Q14289 0.938913 
DAB1 O75553 MST1R Y1317 Q04912 0.54767 
DAB1 O75553 IRS1 Y465 P35568 0.996483 
DAB1 O75553 IRS2 Y675 Q9Y4H2 0.923732 
DAB2 P98082 DOK1 Y315 Q99704 0.953693 
NUMBL Q9Y6R0 FGFR1 Y585 P11362 0.870022 
NUMBL Q9Y6R0 MET Y1356 P08581 0.446074 
NUMBL Q9Y6R0 NTRK1 Y496 P04629 0.871145 
NUMBL Q9Y6R0 RET Y1062 P07949 0.549413 
NUMBL Q9Y6R0 ROS1 Y2334 P08922 0.831127 
NUMBL Q9Y6R0 NCK1 Y268 P16333 0.935082 
NUMBL Q9Y6R0 IRS1 Y465 P35568 0.769519 
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NUMB P49757 ERBB3 Y1289 P21860 0.688588 
SHC2 P98077 FGFR3 Y724 P22607 0.536382 
SHC2 P98077 FLT3 Y591 P36888 0.714134 
SHC2 P98077 INSR Y1011 P06213 0.573644 
SHC2 P98077 KDR Y996 P35968 0.635291 
SHC2 P98077 MET Y1230 P08581 0.698177 
SHC2 P98077 MET Y1313 P08581 0.90214 
SHC2 P98077 MET Y1356 P08581 0.561741 
SHC2 P98077 MST1R Y1317 Q04912 0.646097 
SHC2 P98077 NTRK3 Y516 Q16288 0.622085 
SHC2 P98077 PDGFRB Y562 P09619 0.902254 
SHC2 P98077 PDGFRB Y579 P09619 0.796316 
SHC2 P98077 PDGFRB Y740 P09619 0.508218 
SHC2 P98077 PDGFRB Y1021 P09619 0.697985 
SHC2 P98077 RET Y1029 P07949 0.695054 
SHC2 P98077 RET Y1096 P07949 0.771903 
SHC2 P98077 EGFR Y1172 P00533 0.824948 
SHC2 P98077 ABL1 Y412 P00519 0.448718 
SHC2 P98077 PLCG2 Y1245 P16885 0.799926 
SHC2 P98077 DOK1 Y402 Q99704 0.801563 
SHC2 P98077 ABL2 Y231 P42684 0.955135 
SHC1-PTB P29353 ALK Y1092 Q9UM73 0.701593 
SHC1-PTB P29353 ALK Y1096 Q9UM73 0.612222 
SHC1-PTB P29353 ALK Y1507 Q9UM73 0.322462 
SHC1-PTB P29353 FGFR1 Y653 P11362 0.702376 
SHC1-PTB P29353 FGFR1 Y730 P11362 0.323243 
SHC1-PTB P29353 FLT4 Y1337 P35916 0.335467 
SHC1-PTB P29353 IGF1R Y980 P08069 0.956031 
SHC1-PTB P29353 INSR Y999 P06213 0.854868 
SHC1-PTB P29353 INSR Y1011 P06213 0.947498 
SHC1-PTB P29353 KIT Y900 P10721 0.3917 
SHC1-PTB P29353 MET Y1313 P08581 0.696655 
SHC1-PTB P29353 MET Y1356 P08581 0.570236 
SHC1-PTB P29353 NTRK1 Y496 P04629 0.576407 
SHC1-PTB P29353 NTRK1 Y676 P04629 0.723206 
SHC1-PTB P29353 NTRK2 Y516 Q16620 0.41416 
SHC1-PTB P29353 PDGFRA Y574 P16234 0.300106 
SHC1-PTB P29353 ERBB4 Y1242 Q15303 0.713939 
SHC1-PTB P29353 ERBB4 Y1284 Q15303 0.53015 
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SHC1-PTB P29353 ERBB2 Y1023 P04626 0.877826 
SHC1-PTB P29353 ERBB2 Y1196 P04626 0.571858 
SHC1-PTB P29353 ERBB2 Y1221 P04626 0.583772 
SHC1-PTB P29353 EPHA2 Y735 P29317 0.689082 
SHC1-PTB P29353 ABL1 Y276 P00519 0.953334 
SHC1-PTB P29353 FGR Y412 P09769 0.629607 
SHC1-PTB P29353 FGR Y523 P09769 0.945145 
SHC1-PTB P29353 SRC Y216 P12931 0.508687 
SHC1-PTB P29353 PLCG1 Y775 P19174 0.963615 
SHC1-PTB P29353 JAK3 Y785 P52333 0.805383 
SHC1-PTB P29353 INPPL1 Y986 O15357 0.312206 
SHC1-PTB P29353 DOK1 Y146 Q99704 0.546272 
SHC1-PTB P29353 IRS1 Y732 P35568 0.802505 
SHC1-PTB P29353 IRS1 Y989 P35568 0.773927 
SHC1-PTB P29353 SYK Y203 P43405 0.778369 
SHC1-PTB P29353 ANKS1A Y833 Q92625 0.637643 
DOK1 Q99704 ALK Y1096 Q9UM73 0.728568 
DOK1 Q99704 AXL Y821 P30530 0.568248 
DOK1 Q99704 AXL Y866 P30530 0.916121 
DOK1 Q99704 EPHB2 Y912 P29323 0.872626 
DOK1 Q99704 FGFR1 Y463 P11362 0.558966 
DOK1 Q99704 FLT3 Y591 P36888 0.724501 
DOK1 Q99704 FLT3 Y597 P36888 0.357462 
DOK1 Q99704 FLT3 Y599 P36888 0.26234 
DOK1 Q99704 INSR Y1011 P06213 0.569571 
DOK1 Q99704 KIT Y900 P10721 0.182644 
DOK1 Q99704 MET Y1003 P08581 0.863337 
DOK1 Q99704 MET Y1230 P08581 0.761542 
DOK1 Q99704 MET Y1313 P08581 0.173679 
DOK1 Q99704 MET Y1356 P08581 0.491896 
DOK1 Q99704 PDGFRA Y572 P16234 0.73293 
DOK1 Q99704 PDGFRB Y740 P09619 0.92818 
DOK1 Q99704 PDGFRB Y751 P09619 0.590363 
DOK1 Q99704 PDGFRB Y1009 P09619 0.728491 
DOK1 Q99704 PDGFRB Y1021 P09619 0.952081 
DOK1 Q99704 RET Y1096 P07949 0.545897 
DOK1 Q99704 ROS1 Y2274 P08922 0.365737 
DOK1 Q99704 ROS1 Y2334 P08922 0.730627 
DOK1 Q99704 ERBB2 Y1023 P04626 0.582152 
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DOK1 Q99704 INSR Y1149 P06213 0.934878 
DOK1 Q99704 CSK Y263 P41240 0.925293 
DOK2 O60496 FGFR3 Y724 P22607 0.737005 
DOK2 O60496 NTRK1 Y496 P04629 0.942248 
DOK2 O60496 RET Y1062 P07949 0.862249 
DOK2 O60496 ABL2 Y515 P42684 0.831347 
DOK2 O60496 ABL1 Y276 P00519 0.650633 
DOK2 O60496 VAV2 Y159 P52735 0.897972 
DOK2 O60496 CBL Y368 P22681 0.94491 
DOK2 O60496 CSK Y263 P41240 0.992938 
DOK4 Q8TEW6 FGFR1 Y463 P11362 0.948323 
DOK4 Q8TEW6 MET Y1356 P08581 0.742546 
DOK4 Q8TEW6 IRS1 Y465 P35568 0.620847 
DOK4 Q8TEW6 IRS2 Y823 Q9Y4H2 0.762194 
DOK4 Q8TEW6 GAB1 Y242 Q13480 0.358118 
DOK4 Q8TEW6 GAB1 Y259 Q13480 0.365096 
DOK5 Q9P104 PDGFRB Y1021 P09619 0.808282 
DOK5 Q9P104 PLCG2 Y1245 P16885 0.761905 
IRS1 P35568 PDGFRB Y1021 P09619 0.841574 
IRS4 O14654 PLCG2 Y1245 P16885 0.630501 
FRS3 O43559 NTRK1 Y496 P04629 0.688318 
FRS3 O43559 RET Y1062 P07949 0.696125 
FRS3 O43559 ABL1 Y488 P00519 0.84047 
FRS3 O43559 IRS2 Y675 Q9Y4H2 0.761283 
ANKS1A Q92625 FGFR1 Y463 P11362 0.452842 
ANKS1A Q92625 FGFR3 Y770 P22607 0.853093 
ANKS1A Q92625 FLT3 Y589 P36888 0.853093 
ANKS1A Q92625 PDGFRB Y1021 P09619 0.832722 
ANKS1A Q92625 RET Y1062 P07949 0.988126 
ANKS1A Q92625 FRS2 Y436 Q8WU20 0.32211 
ANKS1A Q92625 EGFR Y1172 P00533 0.817516 
ANKS1A Q92625 ERBB2 Y1139 P04626 0.903046 
APPL1 Q9UKG1 MET Y1313 P08581 0.648983 
APPL1 Q9UKG1 ZAP70 Y126 P43403 0.32182 
GULP1 Q9UBP9 AXL Y821 P30530 0.501512 
GULP1 Q9UBP9 EPHB1 Y600 P54762 0.57623 
GULP1 Q9UBP9 EPHB2 Y602 P29323 0.57623 
GULP1 Q9UBP9 FLT3 Y591 P36888 0.845127 
GULP1 Q9UBP9 FLT3 Y597 P36888 0.592763 
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GULP1 Q9UBP9 INSR Y1011 P06213 0.593207 
GULP1 Q9UBP9 KIT Y936 P10721 0.921791 
GULP1 Q9UBP9 MET Y1003 P08581 0.454465 
GULP1 Q9UBP9 MET Y1230 P08581 0.906948 
GULP1 Q9UBP9 MET Y1234 P08581 0.63235 
GULP1 Q9UBP9 MET Y1313 P08581 0.607378 
GULP1 Q9UBP9 MET Y1356 P08581 0.532448 
GULP1 Q9UBP9 MST1R Y1360 Q04912 0.995928 
GULP1 Q9UBP9 PDGFRA Y572 P16234 0.597337 
GULP1 Q9UBP9 PDGFRB Y579 P09619 0.863653 
GULP1 Q9UBP9 PDGFRB Y740 P09619 0.66385 
GULP1 Q9UBP9 PDGFRB Y751 P09619 0.453731 
GULP1 Q9UBP9 PDGFRB Y775 P09619 0.95902 
GULP1 Q9UBP9 PDGFRB Y1021 P09619 0.703334 
GULP1 Q9UBP9 RET Y981 P07949 0.424132 
GULP1 Q9UBP9 RET Y1029 P07949 0.982662 
GULP1 Q9UBP9 RET Y1062 P07949 0.64938 
GULP1 Q9UBP9 RET Y1096 P07949 0.822959 
GULP1 Q9UBP9 EGFR Y1125 P00533 0.702493 
GULP1 Q9UBP9 IRS1 Y732 P35568 0.849669 
GULP1 Q9UBP9 IRS1 Y896 P35568 0.699241 
GULP1 Q9UBP9 ROS1 Y2110 P08922 0.634215 
TNS1-PTB Q9HBL0 EPHA7 Y791 Q15375 0.680334 
TENC1-PTB Q63HR2 ERBB3 Y1054 P21860 0.34174 
TENC1-PTB Q63HR2 EPHA7 Y791 Q15375 0.832303 
TENC1-PTB Q63HR2 FGR Y523 P09769 0.145152 
TENC1-PTB Q63HR2 EPHA1 Y599 P21709 0.99187 
TENC1-PTB Q63HR2 LCK Y192 P06239 0.295724 
TENC1-PTB Q63HR2 DOK1 Y315 Q99704 0.938282 
TENC1-PTB Q63HR2 ROS1 Y2110 P08922 0.393144 
TENC1-PTB Q63HR2 ABL1 Y191 P00519 0.92347 
TENC1-PTB Q63HR2 SYK Y203 P43405 0.395918 
TENC1-PTB Q63HR2 FYN Y531 P06241 0.773591 
TENC1-PTB Q63HR2 YES1 Y537 P07947 0.773591 
CCM2 Q9BSQ5 PLCG2 Y1245 P16885 0.881716 
ANKS1B Q7Z6G8 MET Y1313 P08581 0.644095 
ANKS1B Q7Z6G8 PDGFRB Y1021 P09619 0.884444 
ANKS1B Q7Z6G8 ABL1 Y412 P00519 0.894799 
ANKS1B Q7Z6G8 ZAP70 Y292 P43403 0.76104 
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ANKS1B Q7Z6G8 ZAP70 Y474 P43403 0.747184 
ANKS1B Q7Z6G8 CBL Y368 P22681 0.994338 
ANKS1B Q7Z6G8 IRS2 Y823 Q9Y4H2 0.918242 
DOK6 Q6PKX4 FLT1 Y1333 P17948 0.365173 
DOK6 Q6PKX4 PDGFRB Y1021 P09619 0.811197 
DOK6 Q6PKX4 ZAP70 Y492 P43403 0.253591 
DOK6 Q6PKX4 LCK Y505 P06239 0.673593 
DOK6 Q6PKX4 DOK1 Y398 Q99704 0.578489 
DOK6 Q6PKX4 GAB1 Y307 Q13480 0.382919 
DOK6 Q6PKX4 GAB1 Y472 Q13480 0.535772 
APBB1-NC O00213 FGFR1 Y463 P11362 0.893491 
APBB1-NC O00213 FGFR3 Y724 P22607 0.781596 
APBB1-NC O00213 FGFR3 Y760 P22607 0.284467 
APBB1-NC O00213 KIT Y900 P10721 0.921657 
APBB1-NC O00213 MET Y1313 P08581 0.609947 
APBB1-NC O00213 MET Y1356 P08581 0.567844 
APBB1-NC O00213 MST1R Y1317 Q04912 0.48237 
APBB1-NC O00213 NTRK1 Y496 P04629 0.897435 
APBB1-NC O00213 NTRK3 Y516 Q16288 0.96863 
APBB1-NC O00213 RET Y1062 P07949 0.54266 
APBB1-NC O00213 ABL1 Y412 P00519 0.750048 
APBB1-NC O00213 IRS1 Y896 P35568 0.553994 
APBB1-NC O00213 IRS1 Y1179 P35568 0.970284 
APBB1-NC O00213 IRS2 Y823 Q9Y4H2 0.807003 
APBB2-NC Q92870 NTRK3 Y516 Q16288 0.749227 
APBB2-NC Q92870 DOK1 Y315 Q99704 0.87709 
APBB2-NC Q92870 ABL1 Y191 P00519 0.933695 
APBB3-NC O95704 PLCG2 Y1245 P16885 0.946783 
APBB3-NC O95704 CBL Y368 P22681 0.912086 
APBB3-NC O95704 EPHB3 Y924 P54753 0.385251 
APBB3-NC O95704 IRS1 Y989 P35568 0.813134 
CBL P22681 AXL Y821 P30530 0.877172 
CBL P22681 AXL Y866 P30530 0.936307 
CBL P22681 EPHB1 Y778 P54762 0.914351 
CBL P22681 FGFR1 Y605 P11362 0.800067 
CBL P22681 FGFR3 Y724 P22607 0.921497 
CBL P22681 FLT1 Y1327 P17948 0.390255 
CBL P22681 FLT3 Y599 P36888 0.263014 
CBL P22681 FLT4 Y1337 P35916 0.806653 
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CBL P22681 INSR Y1011 P06213 0.838048 
CBL P22681 KIT Y900 P10721 0.439409 
CBL P22681 KIT Y936 P10721 0.852357 
CBL P22681 MET Y1234 P08581 0.884883 
CBL P22681 MET Y1313 P08581 0.43049 
CBL P22681 MET Y1365 P08581 0.91234 
CBL P22681 MST1R Y1317 Q04912 0.391109 
CBL P22681 MST1R Y1360 Q04912 0.943777 
CBL P22681 NTRK3 Y516 Q16288 0.586438 
CBL P22681 PDGFRB Y1021 P09619 0.728491 
CBL P22681 ROS1 Y2274 P08922 0.827528 
CBL P22681 TEK Y1102 Q02763 0.656324 
CBL P22681 ERBB4 Y1150 Q15303 0.539476 
CBL P22681 ERBB2 Y877 P04626 0.917709 
CBL P22681 ERBB2 Y1023 P04626 0.932632 
CBL P22681 ERBB2 Y1112 P04626 0.988212 
CBL P22681 ERBB2 Y1221 P04626 0.55019 
CBL P22681 ERBB2 Y1222 P04626 0.308569 
CBL P22681 PLCG2 Y753 P16885 0.756607 
CBL P22681 CBL Y368 P22681 0.864434 
CBL P22681 INSR Y1149 P06213 0.860252 
CBL P22681 GAB1 Y285 Q13480 0.934788 
CBL P22681 TNS1 Y339 Q9HBL0 0.528601 
PIK3R2-C O00459 RET Y1096 P07949 0.719235 
PIK3R2-C O00459 DOK1 Y146 Q99704 0.623798 
PIK3R2-C O00459 DOK2 Y139 O60496 0.888514 
PIK3R2-C O00459 FLT1 Y1053 P17948 0.140497 
PIK3R2-C O00459 IRS1 Y662 P35568 0.828726 
PIK3R2-C O00459 PTPN6 Y301 P29350 0.627026 
PIK3R3-NC Q92569 AXL Y821 P30530 0.657743 
PIK3R3-NC Q92569 FGFR1 Y730 P11362 0.474357 
PIK3R3-NC Q92569 FGFR3 Y724 P22607 0.267028 
PIK3R3-NC Q92569 IGF1R Y1161 P08069 0.625473 
PIK3R3-NC Q92569 INSR Y1185 P06213 0.625473 
PIK3R3-NC Q92569 IGF1R Y1280 P08069 0.929501 
PIK3R3-NC Q92569 IGF1R Y1346 P08069 0.586984 
PIK3R3-NC Q92569 INSR Y1011 P06213 0.313409 
PIK3R3-NC Q92569 INSR Y1361 P06213 0.243616 
PIK3R3-NC Q92569 KDR Y1059 P35968 0.762151 
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PIK3R3-NC Q92569 MET Y1313 P08581 0.300051 
PIK3R3-NC Q92569 MST1R Y1317 Q04912 0.265298 
PIK3R3-NC Q92569 PDGFRA Y742 P16234 0.162098 
PIK3R3-NC Q92569 PDGFRB Y740 P09619 0.397489 
PIK3R3-NC Q92569 PDGFRB Y775 P09619 0.721229 
PIK3R3-NC Q92569 PDGFRB Y1021 P09619 0.609036 
PIK3R3-NC Q92569 RET Y981 P07949 0.368778 
PIK3R3-NC Q92569 ERBB4 Y1056 Q15303 0.845634 
PIK3R3-NC Q92569 FRS2 Y196 Q8WU20 0.963482 
PIK3R3-NC Q92569 FRS2 Y306 Q8WU20 0.621464 
PIK3R3-NC Q92569 FRS2 Y349 Q8WU20 0.87593 
PIK3R3-NC Q92569 EGFR Y1092 P00533 0.761228 
PIK3R3-NC Q92569 EGFR Y1138 P00533 0.943412 
PIK3R3-NC Q92569 EGFR Y1172 P00533 0.723479 
PIK3R3-NC Q92569 ERBB2 Y1196 P04626 0.875449 
PIK3R3-NC Q92569 ERBB2 Y1221 P04626 0.556073 
PIK3R3-NC Q92569 ERBB3 Y1199 P21860 0.646337 
PIK3R3-NC Q92569 FYN Y420 P06241 0.254837 
PIK3R3-NC Q92569 SRC Y419 P12931 0.254837 
PIK3R3-NC Q92569 YES1 Y426 P07947 0.254837 
PIK3R3-NC Q92569 ZAP70 Y315 P43403 0.911487 
PIK3R3-NC Q92569 LCP2 Y128 Q13094 0.95075 
PIK3R3-NC Q92569 SH2D2A Y39 Q9NP31 0.564425 
PIK3R3-NC Q92569 VAV1 Y174 P15498 0.430338 
PIK3R3-NC Q92569 CBL Y371 P22681 0.346544 
PIK3R3-NC Q92569 CBLB Y363 Q13191 0.346544 
PIK3R3-NC Q92569 DOK1 Y315 Q99704 0.772111 
PIK3R3-NC Q92569 IRS1 Y989 P35568 0.204048 
PIK3R3-NC Q92569 IRS2 Y653 Q9Y4H2 0.583628 
PIK3R3-NC Q92569 GAB1 Y259 Q13480 0.78733 
PIK3R3-NC Q92569 PDGFRA Y613 P16234 0.169158 
PIK3R3-NC Q92569 NCK2 Y50 O43639 0.616749 
PIK3R3-NC Q92569 VAV3 Y173 Q9UKW4 0.66962 
PIK3R3-NC Q92569 PTPN6 Y301 P29350 0.928051 
PIK3R3-NC Q92569 CBL Y731 P22681 0.251014 
PIK3R3-NC Q92569 CBLB Y709 Q13191 0.305185 
PIK3R2-NC O00459 FGFR1 Y730 P11362 0.558408 
PIK3R2-NC O00459 FGFR3 Y724 P22607 0.229568 
PIK3R2-NC O00459 FLT1 Y1213 P17948 0.628015 
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PIK3R2-NC O00459 KIT Y721 P10721 0.158754 
PIK3R2-NC O00459 MST1R Y1317 Q04912 0.292133 
PIK3R2-NC O00459 NTRK3 Y516 Q16288 0.613315 
PIK3R2-NC O00459 ERBB4 Y1056 Q15303 0.772274 
PIK3R2-NC O00459 EGFR Y1138 P00533 0.717774 
PIK3R2-NC O00459 ERBB3 Y1276 P21860 0.341317 
PIK3R2-NC O00459 ERBB3 Y1289 P21860 0.516252 
PIK3R2-NC O00459 NCK1 Y268 P16333 0.771296 
PIK3R2-NC O00459 VAV2 Y172 P52735 0.862663 
PIK3R2-NC O00459 CBL Y371 P22681 0.617489 
PIK3R2-NC O00459 CBLB Y363 Q13191 0.617489 
PIK3R2-NC O00459 IRS1 Y896 P35568 0.408697 
PIK3R2-NC O00459 IRS1 Y989 P35568 0.228816 
PIK3R2-NC O00459 IRS2 Y653 Q9Y4H2 0.505608 
LCK P06239 EPHA3 Y779 P29320 0.893664 
LCK P06239 EPHA4 Y779 P54764 0.893664 
LCK P06239 EPHA5 Y833 P54756 0.893664 
LCK P06239 FGFR3 Y724 P22607 0.71417 
LCK P06239 FLT1 Y1327 P17948 0.795837 
LCK P06239 INSR Y1011 P06213 0.731166 
LCK P06239 KIT Y721 P10721 0.519325 
LCK P06239 KIT Y900 P10721 0.599839 
LCK P06239 KIT Y936 P10721 0.870901 
LCK P06239 MET Y1313 P08581 0.33765 
LCK P06239 MET Y1356 P08581 0.95673 
LCK P06239 ERBB3 Y1289 P21860 0.416355 
LCK P06239 EPHA7 Y614 Q15375 0.856101 
LCK P06239 EPHA1 Y599 P21709 0.562484 
LCK P06239 EPHA1 Y605 P21709 0.723717 
LCK P06239 PLCG2 Y1217 P16885 0.795307 
LCK P06239 VAV1 Y174 P15498 0.78843 
LCK P06239 CBL Y368 P22681 0.996805 
LCK P06239 DOK1 Y315 Q99704 0.561315 
LCK P06239 EPHA3 Y937 P29320 0.646067 
LCK P06239 EPHA5 Y656 P54756 0.521736 
LCK P06239 ERBB2 Y1127 P04626 0.723004 
LCK P06239 FLT1 Y1048 P17948 0.717697 
LCK P06239 FLT3 Y969 P36888 0.920208 
LCK P06239 KIT Y553 P10721 0.674019 
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LCK P06239 PIK3R1 Y528 P27986 0.970238 
LCK P06239 PIK3C2B Y685 O00750 0.964672 
LCK P06239 PIK3R1 Y699 P27986 0.964672 
LCK P06239 ABL1 Y191 P00519 0.793807 
LCK P06239 FGR Y180 P09769 0.567284 
LCK P06239 FYN Y185 P06241 0.567284 
LCK P06239 YES1 Y194 P07947 0.567284 
LCK P06239 SYK Y203 P43405 0.862977 
LCK P06239 PLCG1 Y1253 P19174 0.792398 
LCK P06239 CHN2 Y21 P52757 0.797007 
LCK P06239 PTPN6 Y301 P29350 0.527871 
LCK P06239 TNS4 Y150 Q8IZW8 0.562618 
LCK P06239 SHB Y297 Q15464 0.735368 
LCK P06239 TNS1 Y366 Q9HBL0 0.76999 
LCK P06239 CBL Y731 P22681 0.901779 
LCK P06239 CBLB Y889 Q13191 0.835729 
LCK P06239 APBB3 Y291 O95704 0.49301 
LCK P06239 IRS4 Y921 O14654 0.791007 
LCK P06239 ANKS1A Y833 Q92625 0.791877 
LCK P06239 CSK Y263 P41240 0.969775 
LCK P06239 PTK2 Y397 Q05397 0.783774 
LCK P06239 PTK2 Y407 Q05397 0.953714 
LCK P06239 PTK2 Y861 Q05397 0.663407 
LCK P06239 PTK2 Y925 Q05397 0.499888 
SH2D2A Q9NP31 PDGFRB Y771 P09619 0.607596 
SH2D2A Q9NP31 ERBB2 Y1139 P04626 0.654339 
SH2D2A Q9NP31 PLCG2 Y1245 P16885 0.922343 
SH2D2A Q9NP31 CBL Y700 P22681 0.972193 
SH2D2A Q9NP31 DAB1 Y198 O75553 0.495338 
SH2D2A Q9NP31 IRS1 Y465 P35568 0.900128 
SH2D2A Q9NP31 IRS1 Y732 P35568 0.949546 
SH2D2A Q9NP31 IRS1 Y989 P35568 0.802336 
SH2D2A Q9NP31 CSK Y263 P41240 0.898666 
SH2D3C Q8N5H7 ALK Y1092 Q9UM73 0.381734 
SH2D3C Q8N5H7 ALK Y1096 Q9UM73 0.549853 
SH2D3C Q8N5H7 EPHB1 Y600 P54762 0.962653 
SH2D3C Q8N5H7 EPHB2 Y602 P29323 0.962653 
SH2D3C Q8N5H7 EPHB2 Y596 P29323 0.739096 
SH2D3C Q8N5H7 FGFR1 Y463 P11362 0.864898 
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SH2D3C Q8N5H7 FGFR3 Y724 P22607 0.298312 
SH2D3C Q8N5H7 FLT1 Y1327 P17948 0.316663 
SH2D3C Q8N5H7 FLT3 Y591 P36888 0.836358 
SH2D3C Q8N5H7 FLT3 Y597 P36888 0.378353 
SH2D3C Q8N5H7 FLT3 Y599 P36888 0.286201 
SH2D3C Q8N5H7 FLT4 Y1337 P35916 0.7077 
SH2D3C Q8N5H7 IGF1R Y1280 P08069 0.524607 
SH2D3C Q8N5H7 IGF1R Y1281 P08069 0.316681 
SH2D3C Q8N5H7 INSR Y1011 P06213 0.628714 
SH2D3C Q8N5H7 KIT Y900 P10721 0.405702 
SH2D3C Q8N5H7 KIT Y936 P10721 0.681898 
SH2D3C Q8N5H7 MET Y1313 P08581 0.341611 
SH2D3C Q8N5H7 MST1R Y1317 Q04912 0.235489 
SH2D3C Q8N5H7 MST1R Y1360 Q04912 0.885484 
SH2D3C Q8N5H7 NTRK1 Y496 P04629 0.495529 
SH2D3C Q8N5H7 NTRK1 Y676 P04629 0.979604 
SH2D3C Q8N5H7 NTRK3 Y516 Q16288 0.537946 
SH2D3C Q8N5H7 PDGFRB Y1021 P09619 0.908834 
SH2D3C Q8N5H7 RET Y791 P07949 0.496501 
SH2D3C Q8N5H7 RET Y1062 P07949 0.976337 
SH2D3C Q8N5H7 RET Y1096 P07949 0.53939 
SH2D3C Q8N5H7 ROS1 Y2274 P08922 0.796667 
SH2D3C Q8N5H7 TEK Y1048 Q02763 0.31579 
SH2D3C Q8N5H7 TEK Y1102 Q02763 0.649007 
SH2D3C Q8N5H7 ERBB2 Y1023 P04626 0.948881 
SH2D3C Q8N5H7 ERBB2 Y1222 P04626 0.315431 
SH2D3C Q8N5H7 ABL2 Y515 P42684 0.475032 
SH2D3C Q8N5H7 DAB1 Y198 O75553 0.699674 
SH2D3C Q8N5H7 DOK1 Y203 Q99704 0.979938 
SH2D3C Q8N5H7 IRS1 Y465 P35568 0.904383 
SH2D3C Q8N5H7 IRS1 Y896 P35568 0.535081 
SH2D3C Q8N5H7 IRS1 Y1179 P35568 0.80332 
SH2D3C Q8N5H7 IRS2 Y675 Q9Y4H2 0.71887 
SH2D3C Q8N5H7 IRS2 Y823 Q9Y4H2 0.979542 
SH2D3C Q8N5H7 GAB1 Y373 Q13480 0.63155 
SH2D3C Q8N5H7 SRC Y521 P12931 0.90118 
SH2D3C Q8N5H7 SYK Y203 P43405 0.629236 
SH2B1 Q9NRF2 PDGFRB Y1021 P09619 0.879998 
SH2B1 Q9NRF2 GRB2 Y209 P62993 0.788918 
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RASA1-NC P20936 ALK Y1092 Q9UM73 0.626474 
RASA1-NC P20936 ALK Y1096 Q9UM73 0.68284 
RASA1-NC P20936 AXL Y866 P30530 0.909161 
RASA1-NC P20936 FGFR1 Y766 P11362 0.92155 
RASA1-NC P20936 FGFR3 Y724 P22607 0.34659 
RASA1-NC P20936 FLT1 Y1327 P17948 0.463713 
RASA1-NC P20936 FLT4 Y1337 P35916 0.545616 
RASA1-NC P20936 IGF1R Y1280 P08069 0.91097 
RASA1-NC P20936 IGF1R Y1346 P08069 0.490879 
RASA1-NC P20936 INSR Y1011 P06213 0.780154 
RASA1-NC P20936 FLT4 Y1063 P35916 0.699334 
RASA1-NC P20936 KDR Y1054 P35968 0.699334 
RASA1-NC P20936 KIT Y570 P10721 0.51353 
RASA1-NC P20936 KIT Y900 P10721 0.498773 
RASA1-NC P20936 MET Y1313 P08581 0.419338 
RASA1-NC P20936 MET Y1356 P08581 0.342958 
RASA1-NC P20936 MST1R Y1317 Q04912 0.519472 
RASA1-NC P20936 NTRK1 Y496 P04629 0.697821 
RASA1-NC P20936 NTRK2 Y706 Q16620 0.91031 
RASA1-NC P20936 NTRK3 Y709 Q16288 0.91031 
RASA1-NC P20936 NTRK3 Y516 Q16288 0.50186 
RASA1-NC P20936 PDGFRB Y1009 P09619 0.761799 
RASA1-NC P20936 RET Y791 P07949 0.515646 
RASA1-NC P20936 RET Y806 P07949 0.520195 
RASA1-NC P20936 RET Y1096 P07949 0.785543 
RASA1-NC P20936 TEK Y1102 Q02763 0.514791 
RASA1-NC P20936 ERBB4 Y1221 Q15303 0.781575 
RASA1-NC P20936 ERBB2 Y1023 P04626 0.899355 
RASA1-NC P20936 ERBB2 Y1222 P04626 0.300823 
RASA1-NC P20936 ERBB3 Y1276 P21860 0.942986 
RASA1-NC P20936 ABL1 Y276 P00519 0.689004 
RASA1-NC P20936 ABL1 Y412 P00519 0.139186 
RASA1-NC P20936 RASA1 Y615 P20936 0.307835 
RASA1-NC P20936 VAV1 Y174 P15498 0.684902 
RASA1-NC P20936 VAV2 Y159 P52735 0.956125 
RASA1-NC P20936 CBL Y371 P22681 0.704434 
RASA1-NC P20936 CBLB Y363 Q13191 0.704434 
RASA1-NC P20936 DOK2 Y139 O60496 0.8378 
RASA1-NC P20936 IRS1 Y941 P35568 0.695478 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
RASA1-NC P20936 PIK3R2 Y365 O00459 0.878477 
RASA1-NC P20936 SHC3 Y424 Q92529 0.878477 
RASA1-NC P20936 SRC Y521 P12931 0.672195 
RASA1-NC P20936 SYK Y203 P43405 0.986425 
RASA1-NC P20936 IRS4 Y921 O14654 0.622386 
RASA1-NC P20936 CSK Y263 P41240 0.904032 
PLCG2-C P16885 FLT3 Y597 P36888 0.825676 
PLCG2-C P16885 RET Y981 P07949 0.562782 
PLCG2-C P16885 ABL1 Y204 P00519 0.987962 
PLCG2-NC P16885 ALK Y1092 Q9UM73 0.543996 
PLCG2-NC P16885 ALK Y1096 Q9UM73 0.938776 
PLCG2-NC P16885 ALK Y1131 Q9UM73 0.60643 
PLCG2-NC P16885 FGFR1 Y463 P11362 0.81399 
PLCG2-NC P16885 FGFR1 Y730 P11362 0.683063 
PLCG2-NC P16885 FGFR3 Y724 P22607 0.252343 
PLCG2-NC P16885 FLT1 Y1327 P17948 0.514331 
PLCG2-NC P16885 IGF1R Y1280 P08069 0.56637 
PLCG2-NC P16885 IGF1R Y1281 P08069 0.824529 
PLCG2-NC P16885 IGF1R Y1346 P08069 0.662383 
PLCG2-NC P16885 INSR Y1011 P06213 0.511922 
PLCG2-NC P16885 FLT4 Y1063 P35916 0.873841 
PLCG2-NC P16885 KDR Y1054 P35968 0.873841 
PLCG2-NC P16885 KIT Y721 P10721 0.83522 
PLCG2-NC P16885 KIT Y900 P10721 0.325984 
PLCG2-NC P16885 MET Y1356 P08581 0.404987 
PLCG2-NC P16885 MST1R Y1317 Q04912 0.479559 
PLCG2-NC P16885 NTRK1 Y496 P04629 0.672929 
PLCG2-NC P16885 NTRK1 Y676 P04629 0.974187 
PLCG2-NC P16885 NTRK3 Y516 Q16288 0.488847 
PLCG2-NC P16885 PDGFRA Y574 P16234 0.888509 
PLCG2-NC P16885 PDGFRB Y771 P09619 0.923141 
PLCG2-NC P16885 PDGFRB Y1021 P09619 0.829302 
PLCG2-NC P16885 RET Y1029 P07949 0.46012 
PLCG2-NC P16885 EGFR Y1092 P00533 0.939561 
PLCG2-NC P16885 ERBB2 Y877 P04626 0.852092 
PLCG2-NC P16885 ERBB2 Y1023 P04626 0.592124 
PLCG2-NC P16885 ERBB2 Y1196 P04626 0.968809 
PLCG2-NC P16885 ERBB2 Y1221 P04626 0.44514 
PLCG2-NC P16885 ERBB3 Y1276 P21860 0.826813 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
PLCG2-NC P16885 FGR Y523 P09769 0.957014 
PLCG2-NC P16885 EPHA1 Y599 P21709 0.866723 
PLCG2-NC P16885 EPHB4 Y581 P54760 0.456748 
PLCG2-NC P16885 IRS1 Y732 P35568 0.984798 
PLCG2-NC P16885 VAV3 Y173 Q9UKW4 0.585296 
PLCG2-NC P16885 SHB Y336 Q15464 0.810495 
PTPN6-N P29350 PDGFRB Y740 P09619 0.9752 
PTPN6-N P29350 RET Y1029 P07949 0.980756 
PTPN6-N P29350 VAV2 Y159 P52735 0.438642 
PTPN6-N P29350 FLT1 Y1053 P17948 0.322372 
PTPN6-N P29350 IRS1 Y896 P35568 0.446783 
PTPN6-NC P29350 TEK Y1048 Q02763 0.552983 
SYK-N P43405 ALK Y1092 Q9UM73 0.811594 
SYK-N P43405 EPHB1 Y600 P54762 0.959097 
SYK-N P43405 EPHB2 Y602 P29323 0.959097 
SYK-N P43405 FGFR1 Y730 P11362 0.79148 
SYK-N P43405 FLT1 Y1327 P17948 0.730361 
SYK-N P43405 FLT3 Y597 P36888 0.580203 
SYK-N P43405 FLT4 Y1337 P35916 0.601583 
SYK-N P43405 MET Y1313 P08581 0.579525 
SYK-N P43405 MET Y1365 P08581 0.775436 
SYK-N P43405 MST1R Y1317 Q04912 0.822837 
SYK-N P43405 NTRK3 Y516 Q16288 0.684779 
SYK-N P43405 PDGFRA Y731 P16234 0.562725 
SYK-N P43405 PDGFRB Y775 P09619 0.938515 
SYK-N P43405 RET Y791 P07949 0.756238 
SYK-N P43405 RET Y900 P07949 0.308295 
SYK-N P43405 RET Y981 P07949 0.365889 
SYK-N P43405 TEK Y1048 Q02763 0.728166 
SYK-N P43405 TEK Y1102 Q02763 0.996068 
SYK-N P43405 ERBB2 Y1221 P04626 0.621918 
SYK-N P43405 ERBB2 Y1222 P04626 0.38546 
SYK-N P43405 ERBB3 Y1276 P21860 0.835128 
SYK-N P43405 RET Y952 P07949 0.989995 
SYK-N P43405 ABL1 Y412 P00519 0.384715 
SYK-N P43405 FYN Y420 P06241 0.726417 
SYK-N P43405 SRC Y419 P12931 0.726417 
SYK-N P43405 YES1 Y426 P07947 0.726417 
SYK-N P43405 RASA1 Y460 P20936 0.85097 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SYK-N P43405 SH2D2A Y39 Q9NP31 0.792051 
SYK-N P43405 DOK2 Y345 O60496 0.363701 
SYK-N P43405 EPHA5 Y967 P54756 0.981014 
SYK-N P43405 IRS1 Y896 P35568 0.762976 
SYK-N P43405 TYRO3 Y681 Q06418 0.872891 
SYK-N P43405 PIK3R1 Y467 P27986 0.723379 
SYK-N P43405 PIK3CB Y772 P42338 0.779417 
SYK-N P43405 ZAP70 Y69 P43403 0.588645 
SYK-N P43405 SRC Y338 P12931 0.659999 
SYK-N P43405 JAK2 Y119 O60674 0.209591 
SYK-N P43405 SHB Y272 Q15464 0.412757 
SYK-N P43405 TNS1 Y339 Q9HBL0 0.674441 
SYK-N P43405 IRS4 Y921 O14654 0.577975 
SYK-N P43405 INPPL1 Y1135 O15357 0.92321 
SYK-NC P43405 ALK Y1092 Q9UM73 0.447309 
SYK-NC P43405 ALK Y1096 Q9UM73 0.819903 
SYK-NC P43405 EPHA4 Y602 P54764 0.965445 
SYK-NC P43405 EPHB1 Y600 P54762 0.810192 
SYK-NC P43405 EPHB2 Y602 P29323 0.810192 
SYK-NC P43405 EPHB1 Y778 P54762 0.670969 
SYK-NC P43405 FGFR1 Y463 P11362 0.364204 
SYK-NC P43405 FGFR1 Y653 P11362 0.462512 
SYK-NC P43405 FGFR3 Y724 P22607 0.735469 
SYK-NC P43405 FGFR3 Y760 P22607 0.444274 
SYK-NC P43405 FLT1 Y1213 P17948 0.775183 
SYK-NC P43405 FLT1 Y1327 P17948 0.904181 
SYK-NC P43405 FLT3 Y591 P36888 0.523166 
SYK-NC P43405 FLT3 Y599 P36888 0.363407 
SYK-NC P43405 INSR Y1011 P06213 0.937644 
SYK-NC P43405 KDR Y1214 P35968 0.514659 
SYK-NC P43405 KIT Y721 P10721 0.59525 
SYK-NC P43405 KIT Y900 P10721 0.298658 
SYK-NC P43405 KIT Y936 P10721 0.385503 
SYK-NC P43405 MET Y1313 P08581 0.817337 
SYK-NC P43405 MET Y1356 P08581 0.785316 
SYK-NC P43405 MST1R Y1317 Q04912 0.257265 
SYK-NC P43405 NTRK1 Y676 P04629 0.327239 
SYK-NC P43405 NTRK2 Y702 Q16620 0.924976 
SYK-NC P43405 NTRK3 Y705 Q16288 0.924976 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SYK-NC P43405 NTRK3 Y709 Q16288 0.930604 
SYK-NC P43405 PDGFRA Y574 P16234 0.378253 
SYK-NC P43405 PDGFRB Y562 P09619 0.655582 
SYK-NC P43405 PDGFRB Y579 P09619 0.931748 
SYK-NC P43405 PDGFRB Y771 P09619 0.976826 
SYK-NC P43405 PDGFRB Y775 P09619 0.440792 
SYK-NC P43405 RET Y900 P07949 0.607624 
SYK-NC P43405 RET Y981 P07949 0.339786 
SYK-NC P43405 RET Y1096 P07949 0.748231 
SYK-NC P43405 ROS1 Y2274 P08922 0.978553 
SYK-NC P43405 TEK Y1102 Q02763 0.705143 
SYK-NC P43405 ERBB4 Y1150 Q15303 0.595647 
SYK-NC P43405 EGFR Y1172 P00533 0.571332 
SYK-NC P43405 ERBB2 Y1023 P04626 0.670592 
SYK-NC P43405 ERBB2 Y1221 P04626 0.365035 
SYK-NC P43405 ERBB3 Y1197 P21860 0.613176 
SYK-NC P43405 ERBB3 Y1276 P21860 0.573242 
SYK-NC P43405 RET Y952 P07949 0.807682 
SYK-NC P43405 EPHA2 Y628 P29317 0.659309 
SYK-NC P43405 EPHA2 Y960 P29317 0.307696 
SYK-NC P43405 ABL2 Y515 P42684 0.822875 
SYK-NC P43405 ABL1 Y276 P00519 0.864362 
SYK-NC P43405 ABL1 Y412 P00519 0.430713 
SYK-NC P43405 FGR Y412 P09769 0.852834 
SYK-NC P43405 ZAP70 Y248 P43403 0.955232 
SYK-NC P43405 ZAP70 Y474 P43403 0.72578 
SYK-NC P43405 TXK Y91 P42681 0.811066 
SYK-NC P43405 BLNK Y189 Q8WV28 0.667216 
SYK-NC P43405 RASA1 Y615 P20936 0.309195 
SYK-NC P43405 PTPN6 Y564 P29350 0.931509 
SYK-NC P43405 CBL Y368 P22681 0.933607 
SYK-NC P43405 CBL Y371 P22681 0.748832 
SYK-NC P43405 CBLB Y363 Q13191 0.748832 
SYK-NC P43405 CBL Y774 P22681 0.861974 
SYK-NC P43405 DAB1 Y198 O75553 0.953851 
SYK-NC P43405 DAB1 Y220 O75553 0.443868 
SYK-NC P43405 DOK1 Y146 Q99704 0.826895 
SYK-NC P43405 DOK2 Y345 O60496 0.700307 
SYK-NC P43405 IRS1 Y896 P35568 0.616144 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SYK-NC P43405 IRS2 Y675 Q9Y4H2 0.91288 
SYK-NC P43405 SRC Y521 P12931 0.784728 
SYK-NC P43405 SYK Y203 P43405 0.715826 
SYK-NC P43405 VAV1 Y826 P15498 0.901898 
SYK-NC P43405 SHB Y272 Q15464 0.734447 
SYK-NC P43405 TNS1 Y903 Q9HBL0 0.903128 
SYK-NC P43405 IRS4 Y921 O14654 0.677963 
INPPL1 O15357 KIT Y900 P10721 0.344976 
INPPL1 O15357 MST1R Y1317 Q04912 0.676942 
INPPL1 O15357 TNS1 Y366 Q9HBL0 0.746222 
INPPL1 O15357 TNS1 Y796 Q9HBL0 0.387599 
INPPL1 O15357 CBLB Y889 Q13191 0.713757 
ZAP70-N P43403 NTRK3 Y516 Q16288 0.867725 
ZAP70-N P43403 FRS2 Y196 Q8WU20 0.652037 
ZAP70-N P43403 FYN Y420 P06241 0.438844 
ZAP70-N P43403 SRC Y419 P12931 0.438844 
ZAP70-N P43403 YES1 Y426 P07947 0.438844 
ZAP70-N P43403 PLCG2 Y1217 P16885 0.297265 
ZAP70-N P43403 DOK1 Y315 Q99704 0.992807 
ZAP70-N P43403 FLT1 Y1053 P17948 0.590569 
ZAP70-N P43403 IRS1 Y896 P35568 0.498934 
ZAP70-N P43403 GAB1 Y406 Q13480 0.803257 
ZAP70-N P43403 PIK3R3 Y341 Q92569 0.94236 
ZAP70-N P43403 ABL2 Y683 P42684 0.513786 
ZAP70-N P43403 FGR Y180 P09769 0.681028 
ZAP70-N P43403 FYN Y185 P06241 0.681028 
ZAP70-N P43403 YES1 Y194 P07947 0.681028 
ZAP70-N P43403 SYK Y203 P43405 0.572743 
ZAP70-N P43403 TNS1 Y366 Q9HBL0 0.852759 
ZAP70-NC P43403 ALK Y1092 Q9UM73 0.462672 
ZAP70-NC P43403 ALK Y1096 Q9UM73 0.4824 
ZAP70-NC P43403 AXL Y866 P30530 0.960221 
ZAP70-NC P43403 FGFR1 Y653 P11362 0.887557 
ZAP70-NC P43403 FGFR1 Y730 P11362 0.45763 
ZAP70-NC P43403 FGFR3 Y724 P22607 0.995236 
ZAP70-NC P43403 FLT1 Y1327 P17948 0.893576 
ZAP70-NC P43403 FLT3 Y597 P36888 0.537925 
ZAP70-NC P43403 FLT3 Y599 P36888 0.498379 
ZAP70-NC P43403 MET Y1313 P08581 0.837078 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
ZAP70-NC P43403 NTRK3 Y516 Q16288 0.476746 
ZAP70-NC P43403 PDGFRA Y731 P16234 0.587634 
ZAP70-NC P43403 RET Y900 P07949 0.367413 
ZAP70-NC P43403 RET Y981 P07949 0.87992 
ZAP70-NC P43403 TEK Y1048 Q02763 0.762477 
ZAP70-NC P43403 NCK1 Y268 P16333 0.822284 
ZAP70-NC P43403 RASA1 Y615 P20936 0.374943 
ZAP70-NC P43403 CBL Y700 P22681 0.613807 
ZAP70-NC P43403 DOK1 Y315 Q99704 0.976211 
ZAP70-NC P43403 IRS1 Y465 P35568 0.94864 
ZAP70-NC P43403 GAB1 Y373 Q13480 0.740566 
ZAP70-NC P43403 SYK Y203 P43405 0.820327 
ZAP70-NC P43403 TNS1 Y339 Q9HBL0 0.408614 
SHB Q15464 EPHB1 Y600 P54762 0.488475 
SHB Q15464 EPHB2 Y602 P29323 0.488475 
SHB Q15464 FGFR1 Y463 P11362 0.515537 
SHB Q15464 FLT3 Y591 P36888 0.582967 
SHB Q15464 INSR Y992 P06213 0.799455 
SHB Q15464 INSR Y1011 P06213 0.646292 
SHB Q15464 KDR Y996 P35968 0.697336 
SHB Q15464 FLT4 Y1063 P35916 0.840804 
SHB Q15464 KDR Y1054 P35968 0.840804 
SHB Q15464 KDR Y1214 P35968 0.885113 
SHB Q15464 MET Y1003 P08581 0.704016 
SHB Q15464 MET Y1230 P08581 0.689469 
SHB Q15464 MET Y1234 P08581 0.862347 
SHB Q15464 MET Y1313 P08581 0.343401 
SHB Q15464 MST1R Y1317 Q04912 0.864931 
SHB Q15464 PDGFRB Y562 P09619 0.733825 
SHB Q15464 PDGFRB Y581 P09619 0.799038 
SHB Q15464 PDGFRB Y740 P09619 0.453919 
SHB Q15464 PDGFRB Y751 P09619 0.356384 
SHB Q15464 PDGFRB Y1009 P09619 0.568205 
SHB Q15464 PDGFRB Y1021 P09619 0.811647 
SHB Q15464 RET Y1062 P07949 0.465949 
SHB Q15464 RET Y1096 P07949 0.823944 
SHB Q15464 EGFR Y1069 P00533 0.875899 
SHB Q15464 EGFR Y1125 P00533 0.920206 
SHB Q15464 ERBB2 Y1023 P04626 0.535646 






Table 6.2: Sub micromolar interactions identified in these studies  (Continued) 
 
SHB Q15464 CSF1R Y923 P07333 0.847531 
SHB Q15464 TEC Y206 P42680 0.708688 
SHB Q15464 PLCG2 Y753 P16885 0.827631 
SHB Q15464 PLCG2 Y1245 P16885 0.75859 
SHB Q15464 CRKL Y207 P46109 0.258296 
SHB Q15464 INPPL1 Y986 O15357 0.933448 
SHB Q15464 CBL Y368 P22681 0.908981 
SHB Q15464 IRS1 Y896 P35568 0.628243 
SHB Q15464 SYK Y203 P43405 0.487639 
SHB Q15464 SYK Y244 P43405 0.660686 
SHB Q15464 VAV3 Y173 Q9UKW4 0.40617 
SHB Q15464 ANKS1A Y454 Q92625 0.440588 
 
